Performance Characteristics of Centrifugal Pump Impeller for Heart Failure Therapy: Numerical and In-vitro Approach by Hincapie, Paula Andrea Ruiz
Performance Characteristics of Centrifugal
Pump Impeller for Heart Failure Therapy:
Numerical and In-vitro Approach
Paula Andrea Ruiz Hincapié
A thesis submitted in fulfilment of the requirements of
The Degree of Doctor of Philosophy
at the University of London
October 2015
Declaration
I hereby declare that this thesis titled
Performance Characteristics of Centrifugal Pump Impeller
for Heart Failure Therapy: Numerical and In-vitro
Approach
and the work reported herein was composed by and originated entirely from
me. Information derived from the published and unpublished work of others
has been acknowledged in the text and references are given in the list of
sources. This work has not been submitted for any other qualification.
London – 2015 —————————————–
(signature)
To Balazs, Tina and Alexis.
Acknowledgements
Firstly, I would like to thank my supervisor, Professor Theodosios Korakiani-
tis, for allowing me to take on research studies in the field of cardiovascular
technologies. Also, to my sponsor the Westfield Trust for supporting my PhD
studies.
I also would like to give a special thank you to Dr. Akbar Rahideh for his
unconditional support throughout my PhD studies. Also, thanks to Mr Mike
Collins and Mr Dennis Ife for the technical guidance and excellent manufac-
turing skills.
Above all, I am most grateful to my husband, Balazs, whose never ending
patience and continuous support kept me going. And, to my parents and
sister for their patience and moral support.
Abstract
Heart failure (HF) is a common cause of hospitalisation and mortality across
industrialised countries. The number of hospitalisations and deaths attributed
to heart failure is increasing, and this trend is predicted to continue. Numeri-
cal and in-vitro simulations of the human cardiovascular system constitute the
basic tools for enhancing diagnostic and therapeutic technologies for HF and
this would in turn, have significant effects on morbidity, mortality, and health-
care expenditure. Mechanical Circulatory Support (MCS) as a destination
therapy for HF is rising significantly as it provides a cost-effective alterna-
tive to long-term treatment and cardiac transplantation. However, long-term
versatility is far from ideal and incidence of transient and permanent neuro-
logical events is still high. To this end, evolution of MCS devices calls for
more sophisticated design and evaluation methods.
The purpose of this work is to develop a numerical model and to implemented
a novel in-vitro model of the cardiovascular system with the intention of
evaluating the performance characteristics of a purposely selected centrifugal
pump impeller for the treatment of both Class III and IV HF conditions when
placed in series with the heart at two different anatomic locations: Ascending
Aorta and Descending Aorta.
An existing lumped-parameter model of the CV system, that included models
for the heart, the pulmonary and the systemic circulatory loops by adapting
a modified version of the fourth-element Windkessel model was enhanced
by dividing the systemic circulation into six parallel vascular beds, and by
including an autoregulatory system to control both pressures and volumes
throughout the system. As part of the novelty of the present work, a volume
reflex loop was included with the purpose of simulating volume overload con-
ditions, as commonly found in HF conditions, and obtaining a more realistic
analysis of volume displacement, while using a MCS device.
The in-vitro model implemented in this work adopted most of the features
included in the mathematical counterpart with the purpose of validating the
numerical results. As a result of the combination of models and proper opti-
misation of the system parameters, predictions of pathophysiological trends
and MCS usage are satisfactorily obtained.
The models implemented in this work offer a valuable tool for the selection
and performance evaluation of MCS devices for the treatment of HF condi-
tions.
Thesis Supervisor: Prof. Theodosios Korakianitis
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Heart failure (HF) is a common cause of hospitalisation and mortality across industrialised
countries. The number of hospitalisations and deaths attributed to heart failure is increas-
ing, and this trend is predicted to continue [1]. Numerical and in-vitro simulations of the
human cardiovascular system constitute the basic tools for enhancing diagnostic and ther-
apeutic technologies for HF and this would, in turn, have significant effects on morbidity,
mortality, and healthcare expenditure, which in the United Kingdom alone were estimated
to be £715.7 millions in 1995 [2]. According to the Heart Disease and Stroke Statistics
2012 Update conducted in the United States (US) [3], an estimated 5.7 million Americans
over the age of 20 have HF. It was also reported that in 2010, approximately 6.6 million
US adults over 18 years of age had HF, and that by 2030, approximately 3 million people
will suffer the condition. The incidence of HF is about 10 per 1000 population beyond 65
years of age, and according to the Framingham study, the most prevalent etiologic precur-
sor is hypertension in 75% of the cases [4]. In both Europe and North America, there are
over 7 million HF patients, 60% of whom have systolic dysfunction; 1.2% of whom are
younger than 65 years of age amounting to over 200 thousand potential transplant-eligible
patients between the two continents.
The present work focuses on enhancing an existing grey-box model of the human car-
diovascular (CV) system, developed by Prof. Korakianitis, by including cardiovascular
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control elements that represent the autonomic nervous system with the purpose of study-
ing the effect of a centrifugal pump connected in-series with the heart while the system
was set to mimic a HF condition. It was also the intention of this study to select a cen-
trifugal pump impeller, with a pressure rise of 70 mmHg against a flow of 5 lt/min for
an existing centrifugal pump volute and to analyse its effect in a cardiovascular system
simulator while concurrently mimicking HF.
This chapter starts by briefly describing the human cardiovascular system and its main
functions. It then focuses on the vascular and neuroendocrine mechanisms that influence
changes in regional blood flow and sodium/water retention commonly found in HF. Next,
it briefly looks into a historical review of heart failure device management and describes
some of the available mechanical circulatory support (MCS) devices and their operating
conditions. Finally, the chapter presents the motivation of the present study, its aims and
objectives, and an outline of the thesis.
1.1 Human cardiovascular physiology
The CV system is composed of three main elements, namely, the heart, vasculature and
blood. Its main functions are: to distribute oxygen and nutrients to all body tissues;
to unburden the same tissues from carbon dioxide and waste products; to control body
temperature [5]. These functions are primordially achieved by the circulation of blood to
and from the body tissues.
1.1.1 The heart as a pump
In the average 70-kg man, there are about 5.5 litres of blood composed of plasma and
blood cells. Blood is pumped through the vasculature by means of a pulsating motion
generated by the heart muscle. The heart muscle or myocardium is composed of striated,
multinucleated, slow-rate contracting cells that are linked by intercalated disks forming
the muscle mass that makes up the heart [6, 7]. In turn, the heart is made up of two
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pumps: left- and right-sided pumps, and each of these pumps are in turn composed of
two chambers: one atrium and one ventricle. On arrival to the right-sided pump, via the
inferior and superior vena cava, blood enters the right atrium (whose main function is to
fill or prime the right ventricle) and then flows through the atrio-ventricular valve into the
right ventricle, where it is ejected to the lungs for oxygenation. Oxygenated blood returns
to the left-sided pump via the pulmonary veins. Once on the left pump, blood is finally
ejected to the systemic circulation to supply oxygen to all body tissues. Unidirectional
flow through each heart chamber is achieved by four one-way heart (check) valves; these
are: mitral, tricuspid, pulmonary, and aortic. The mitral and tricuspid valves are placed at
the atrio-ventricular interface, whereas the pulmonary and aortic valves are located at the
arterio-ventricular coupling. Fig.1.1 shows the four chambers of the heart and illustrates
the pathway of blood flow through the heart.
Figure 1.1. The pathway of blood flow through the heart. The arrows and numbers indicate the




The native heart chambers have a very complex functioning and can be widely viewed
as having two main phases: systolic and diastolic. Over the duration of a single cardiac
cycle, the cardiac chambers have changes in volume and pressure according to the phase
in which they are. In broad terms, a systolic phase would be one where contraction of the
heart muscle takes place, which translates into an increase in pressure and a decrease of
a chamber’s volume. A diastolic phase, by contrast, allows for the blood return to take
place by increasing the chamber’s size; this can be thought of as a suctioning mechanism
that draws blood back in. This suctioning event in turn, lowers the chamber’s pressure.
Considering a cardiac cycle with a period of 0.9 s and starting from a resting position,
the ventricular diastolic phase can be arbitrarily selected as the precursor of the cycli-
cal process. The ventricular diastole starts at the concurrent closing of inlet and outlet
heart valves (see point c in Fig.1.2), allowing the ventricles to become close chambers
and to become ready to initiate the filling process. This event, in which inlet and outlet
valves are closed, is known as the isovolumetric relaxation of the ventricles, where vol-
ume remains constant and lasts for approximately 0.08 s; this can be viewed in Fig.1.2
being depicted by a light blue band. Once the isovolumetric relaxation has taken place,
the atrioventricular valves open (see point d in Fig.1.2), initiating the filling process; the
atria empty rapidly into the ventricles, producing a sharp fall in pressure denominated as
the Y descent. The ventricular filling commonly lasts for 0.5 s and is initially fast-paced
up to the point where the ventricular natural relaxed volume is achieved; thereafter, the
filling slows down and terminates with an extra blood volume injected by means of the
atrial contraction (see the A wave in Fig.1.2) commonly known as the atrial kick or boost.
The blood volume at the end of the filling process is known as the End Diastolic Volume
(EDV), which is about 110-120 ml on the average 70-kg man; the corresponding End
Diastolic Pressure (EDP) is about 9 mmHg in the Left Ventricle (LV) and 4 mmHg in the
Right Ventricle (RV). Following the atrial boost, the ventricular contraction takes place.
The ventricular systole typically lasts for 0.35 s and is divided into two further phases:
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a short isovolumetric contraction phase of about 0.05 s (see light green band in Fig.1.2)
and a long ejection phase lasting for approximately 0.3 s. The former is characterised by
a simultaneous closure of the inlet and outlet heart valves (see point a in Fig.1.2) and and
can be identified by the C wave in the atria pressure, allowing for the blood volume to
remain constant while increasing the chamber’s pressure. The latter is characterised by
the opening of the outlet valves (see point b in Fig.1.2), by means of the steep increment
in pressure in the ventricles with respect to that of the central arteries, creating a rapid
ejection; in the atria this can be seen as a sharp fall in pressure denominated as the X
descent. Three-quarters of the stroke volume (SV) are displaced into the elastic vessels
during this rapid ejection phase. Once the pressure in the ventricle falls below that of the
central arteries, the outlet valves close allowing the ventricles to become closed chambers
again. In the meantime, the atria have been refilling during the ventricular ejection and
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Figure 1.2. Schematic diagram of the human cardiac cycle. Top: Changes in pressure in the aorta
artery, the left ventricle, and the left atrium. Bottom: Changes in volume in the left ventricle where
EDV, end-diastolic volume; ESV, end-systolic volume; and SV is the stroke volume as given by the dif-
ference between EDV and ESV. The electrocardiogram (ECG) signal is shown to provide an indication
of the cardiac cycle timings. Adapted from Levick, JR [5]
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1.1.3 Cardiac Output Regulation
Cardiac output (CO) is adopted throughout this work as the main haemodynamic variable
and measure of cardiac functionality. In general, CO is defined as the amount of blood
ejected from the left ventricle into the aorta artery per minute and is modulated by two
complex regulatory systems namely, the autonomic nervous system (ANS) and the in-
trinsic regulation of the heart [6]. The former responds to the local blood flow demands;
whereas, the latter responds to the summation of all the local blood flows that converge
into the heart, a process that is better known as the venous return. In the 70-kg man,
CO is about 5− 5.6 lt/min during resting condition and can increase up to 4 times this
amount during exercise, in which oxygen consumption and tissue metabolic rates are in-
creased. In disease conditions such as HF, CO is commonly found to be reduced at about
3.5 lt/min.
1.1.3.1 Autonomic regulation
Regulation of the cardiovascular (CV) system is brought about by a combination of sev-
eral feedback control mechanisms that are continuously determining the difference be-
tween a reference value and an actual one obtained via sensor sites [8]. The mechanical
sensors, or mechanoreceptors, responsible for blood pressure regulation are of two types:
pressure sensors and volume sensors. The former, better known as baroreceptors, respond
to changes in arterial pressure and are located in the left ventricle and central arteries,
specially in the carotid sinus and in the renal juxtaglomerular apparatus. The latter are
mainly associated with the renal perfusion and the sodium-water homeostasis [9]. Both
of these types of sensors are tightly linked to the peripheral resistance that essentially
regulates CO; this relationship is an inversely proportional one, that is, at greater levels
of peripheral resistance, CO decreases; conversely, at lower peripheral resistance, CO
increases. The information gathered at the sensor sites is both conveyed to the central
nervous system (CNS), via the afferent pathways, and locally interpreted by the renal
juxtaglomerular apparatus. The result is an autonomic reflex that is converged to the CV
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system via efferent pathways, either parasympathetic or sympathetic, and the activation
of the renin-angiotensin-aldosterone (RAA) system according to the required action. In
general, locally synthesised angiotensin II regulates vascular function by contracting the
arterioles and promoting sympathetic nervous transmission; a sympathetic signal would
increase heart rate and contractility as well as modulate the resistance and capacitance of
the blood vessels, while a parasympathetic one will oppose the effect of a sympathetic
stimulus [6, 10].
The heart is greatly innervated by sympathetic fibres, but scarcely innervated by parasym-
pathetic ones. The latter are mainly found in the atria, where the heart rate modulation
centre or sinus node is located, and has as major effect to decrease heart rate as supposed
to decreasing contractility.
1.1.3.2 Intrinsic regulation of the heart
In addition to the autonomic regulation, the heart has an intrinsic regulation system, com-
monly known as the Frank-Startling mechanism, which determines the stroke volume
generated per cardiac cycle. This mechanism is entirely controlled by the amount of
blood flowing into the heart from the vein reservoir, and holds a linear relationship be-
tween the lengthening of the heart muscle due to the amount of returned blood volume
and the force of contraction generated by the heart. In other words, the greater the re-
turning blood volume or heart muscle stretch is, the greater the force of contraction is
[5, 6, 11]. In a similar linear fashion, increased stretch of the right atrial wall is related
to the modulation of heart rate, with the objective of displacing the extra amount of blood
entering the heart. Nevertheless, it is worth noting that the intrinsic regulation of the heart




HF can be described as a combination of several symptoms including: shortness of breath,
fatigue, and congestion that are brought about by inadequate tissue perfusion, water re-
tention, and elevated ventricular filling pressure [12]. To sustain life, the heart must pump
enough blood to supply nutrients for all tissues. In providing this perfusion, the ventricles
must generate enough force to overcome the resistance imposed by the systemic and pul-
monary circulations; this function can be cleverly described with an electrical analogy by
using Ohm’s law, in which voltage is equal to the current by the resistance of the circuit,
where the voltage is analogue to pressure and current to flow; this relationship can be
expressed with the following equation
P(t) = Q(t)×R (1.1)
where P(t) is the instantaneous pressure, R is the resistance, and Q(t) is the flow which
is commonly known as the cardiac output. Succinctly, HF can be defined as a disability
of the left ventricle to fill or empty adequately. This results in decreased cardiac output,
initially during exercise and eventually at rest. The neuroendocrine systems respond to
this lack of perfusion with regional blood flow vasoconstriction in both the pulmonary
and systemic circulations, renal retention of sodium, and pulmonary congestion; this in
turn, increases the load required by the heart to eject blood, thereby creating further heart
failure [12, 13]
HF patients are commonly classified into 4 categories (I, II, III, IV) with higher class
suggesting more severe symptoms, physical activity limitation, and poorer prognosis. In
1928, the New York Heart Association (NYHA) developed this classification system to
aid clinicians categorise HF patients based on symptoms as reported by the patient, med-
ical history and cardiac performance tests [14]. Table 1.1 summarises the NYHA func-
tional classification system.
In advanced HF or NYHA class IV the typical clinical findings include: severe congestion
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Table 1.1. Functional classification system by The New York Heart Association [15]
Class functional classification
I
Patients have cardiac disease, but without the resulting limitations of physical
activity. Ordinary physical activity does not cause undue fatigue, palpitation,
dyspnoea or anginal pain
II
Patients have cardiac disease resulting in slight limitation of physical activity.
They are comfortable at rest. Ordinary physical activity results in fatigue,
palpitation, dyspnoea, or anginal pain
III
Patients have cardiac disease resulting in marked limitation of physical activity.
They are comfortable at rest. Less than ordinary physical activity causes fatigue,
palpitation, dyspnoea, or anginal pain
IV
Patients have cardiac disease resulting in inability to carry out any physical
activity without discomfort. Symptoms of cardiac insufficiency or anginal
syndrome may be present even at rest. If any physical activity is undertaken,
discomfort is increased
associated with reduced left ventricular ejection fraction (EF) and pulmonary hyperten-
sion in addition to unresponsive pharmacotherapy [13]. A further subcategory is applied
to NYHA class IV patients according to their systolic function as having a reduced or
preserved systolic function. In the work by Dauterman et al. [16], a reduced systolic
function is defined by an ejection fraction that is lower than 40%, where ejection fraction






where EDV is the end diastolic volume and ESV is the end systolic volume.
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1.3 Autoregulation in HF
Patients with HF have raised blood levels of neurohormonal factors, including: nore-
pinephrine, angiotensin, aldosterone that are detrimental in the progression of HF. These
factors have direct and indirect effects on the heart. Indirectly, they alter the structure and
function of the heart in response to sodium retention and peripheral vasoconstriction; and
directly, they alter the myocytes performance and phenotype [17]. Important changes take
place in the cardiovascular system in response to HF. These changes are brought about by
activation of the neurohormonal systems that regulate fluid volume and vascular tone. The
activation of these systems may be attributable to abnormal baroreceptor function which
is a feature commonly found in HF patients [13]. Blunted baroreceptor sensitivity in HF
is associated with, increased circulating catecholamines and renal sympathetic activity in
addition to parasympathetic withdrawal [9, 18]. In patients with congestive heart failure
(CHF), the increased sympathetic activity is reflected on high plasma concentrations of
norepinephrine; moreover, greater the concentration, more severe the disease [19]. In
general, a decrease in myocardial contractiliy leads to a decrease in cardiac output and
blood pooling; concurrently, the fractional CO distribution to renal, limb and splachnic
systems decreases [20]. Disrupted renal hemodynamics, particularly low renal perfusion
contributes to sodium and water retention in response to the release of strong vasoactive
substances such as renin [21–23]. By contrast, blood flow to the brain and heart is pre-
served; nevertheless, in patients with low ejection fraction (EF), cerebral autoregulation
may be impaired by high levels of circulating catecholamines [18, 24].
The kidneys play a very important role in the control of systemic blood pressure. This
control is mediated by either regulating the extracellular fluid volume or modifying the
vascular tone. In low perfusion conditions such as CHF, arterial pressure is controlled
by increasing contraction of systemic arterioles [10, 25]. This vasoconstriction is the
result of the activation the renin-angiotensin system, which in turn acts on the kidneys
to cause sodium (Na+) and water retention. Angiotensin plays another crucial role in
the development of HF; it causes the adrenal glands to secrete aldosterone and this in turn
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increases salt and water reabsorption by the kidney’s tubules, thus increasing extracellular
Na+ [18]. From this point onwards, a negative feedback loop is initiated in an attempt
to maintaining extracellular Na+ homeostasis; the resulting effect is the increased in total
blood volume leading to further congestion; see the flowchart presented in Fig.1.3 for
a summary of the effect of the RAA system in response to hypoperfusion in CHF. In
patients with CHF, increased activity of the RAA system is known to directly correlate
with mortality [26].
Similar to the kidneys, the heart produces a family of vasoactive peptides that have im-
portant effects on cardiovascular and renal functions. Two main types of peptides are
produced by the heart; these are: atrial natriuretic peptide (ANP) and brain natriuretic
peptide (BNP). ANP is chiefly synthesised by atrial myocytes whereas BNP is primarily
produced in ventricular tissue, although a small proportion of BNP is produced by the
atrial myocytes [27].
ANP is released in a prompt response to atrial wall stretch or mechanical strain from
increased blood volume, whereas BNP is released within an hour from the initial wall
stretch [28]. In normal conditions, the natriuretic peptides have a vasodilator effect on
blood vessels; however, in HF patients, this effect is markedly blunted; what is more,
ANP and BNP plasma levels are increased in HF patients and this is directly related with
the severity of HF [27]. Other functions of the natriuretic peptides include: myocardial
and vascular remodelling, regulation of myocardial perfusion [28].
1.3.1 Body Fluid Volume Regulation
Sodium and water retention are hallmarks of HF [18]. Regulation of sodium and wa-
ter excretion, hence total body fluid volume, is mainly attributed to the arterial-tree fluid
compartment, which is responsible for the perfusion of vital organs. In the average 70-
kg man, the total body fluid volume is about 42 lt, 1.7% of which resides in the arterial
compartment whereas over 60% is found in the veins. This can only imply that body























Figure 1.3. The Heart failure vicious cycle. Decreased baroreceptor sensitivity in HF patients pro-
motes further cardiac failure by triggering the RAA system and sympathetic activity; concurrently,
raised aldosterone level promotes a negative feedback loop for the extracellular Na+ homeostasis; this
in turn, results in fluid retention and blunted response to natriuretic peptides. Adapted from Schrier et
al. [18].
ing that the system is over sensitive to small changes in fluid volume [26]. Increased fluid
volume can increase cardiac pre-load, and ultimately create cardiac dilation and myocar-
dial remodelling, heart valve insufficiency, especially of the mitral valve, and promote
pulmonary hypertension [18]. Until recently, it was uncertain whether renal dysfunction
promotes the progression of HF or whether it reflected the severity of the condition. The
data published by Dries et al [29], suggested that impaired renal function is independently
associated with all-cause mortality in patients with mild to moderate heart failure. How-
ever, other studies suggested that worsening renal function occurs often among elderly
patients admitted with heart failure and this was in turn associated with higher mortality,
increased length of stay, and higher costs [30]. It is now recognized that renal dysfunction
is an important predictor of morbidity and mortality in HF [18, 30, 31].
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The kidneys play a major role in the regulation of blood pressure, both via pressure and
body fluid volume control mediated by pressure sensors. High-pressure receptors, lo-
cated in the juxtaglomerular apparatus within the kidney’s afferent arterioles, respond to
decreased renal perfusion commonly found in CHF by activating the sympathetic and
RAA systems in an attempt to increase the arterial pressure by promoting further sodium
and water retention [21–23, 32, 33]. In addition to the regulating factor brought about by
the kidneys, stretch receptors in the left atrium and pulmonary veins respond to intravas-
cular volume expansion by releasing ANP [9, 34, 35]. These two regulating systems are
commonly known as the atrial-renal sympathetic reflex and have been found to have a
direct correlation between left atrial pressure and renal sodium excretion in the dog [34];
however, this reflex is blunted in CHF [36, 37]. The experiments carried out by Volpe et
al., citeVolpe1991, showed that cardiorenal and hormonal regulation, in response to acute
volume expansion, are critically diminished in patients with dilated cardiomyopathy and
mild heart failure; particularly, the inability to increase plasma ANP levels in response to
an acute rise of cardiac preload. While plasma ANP levels were almost doublefold in nor-
mal subjects, in those with dilated cardiomyopathy there was no increase, thus confirming
previous observations of impaired ANP activity obtained in animal models of acute and
chronic congestive heart failure [37]
Table 1.2. Body Fluid Volume Distribution [26].
Compartment Amount Volumes in 70-kg Man
Total body fluid 60% of body weight 42 lt
Intracellular fluid 40% of body weight 28 lt
Extracellular fluid (ECF) 20% of body weight 14 lt
Interstitial fluid (ISF) 2/3 of ECF 9.4 lt
Plasma fluid 1/3 of ECF 4.6 lt
Venous fluid 85% of plasma fluid 3.9 lt
Arterial fluid 15% of plasma fluid 0.7 lt
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1.4 Mechanical Circulatory Support
The two main therapeutic modalities for managing advanced HF are pharmacotheraphy
and cardiac transplantation. Cardiac transplantation remains the gold standard therapy for
class-IV patients; however, the great immunosuppression hurdle and the organ donation
not meeting the high demand make this therapy the most limited of them all [38]. Current
pharmacotherapy can alleviate HF symptoms [12] and can even be successful in terms
of life expectancy [39]; however, in many cases, HF remains refractory to pharmacother-
apy, especially in advanced cases. In these cases, MCS therapy could prove beneficial.
Over the last three decades, MCS therapy has evolved enormously and is currently con-
sidered as a standard one in many industrialised countries [40]. The MCS therapy goals
span from relief of circulatory congestion symptoms and increasing tissue perfusion to
prolonging life by slowing or even reversing both structural damage and blunted neuro-
hormonal mechanisms [12, 38]. Nowadays, there is a wide selection of MCS devices
allowing for an adequate selection of treatment according to duration and level of sup-
port. In general, short-term devices may be used to support patients during heart surgery
or even to reverse mild HF brought about by myocardial infarction, while long-term de-
vices are mainly used in advanced HF stages as a bridge to cardiac transplantation and
even as destination therapy [41].
1.4.1 Heart Failure Device Management: brief historical review
The first clinical usage of MCS therapy was done in 1953 during a cardiopulmonary by-
pass by implementing a heart-lung machine. From this point onwards, several therapies
were developed for different cardiac disorders; however, special interest was focused in
enhancing circulatory support technologies [42]. The starting point for today’s MCS de-
vices was led by several researchers including Dr John H. Gibbon Jr., who pioneered the
extracorporeal circulation machine usage in open heart surgery [43].
In 1960, counterpulsation techniques were studied and developed by Masopuolos et al.
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[44]; they mainly consisted of inflating an elongated balloon inserted in the aorta via a
small calibre catheter during diastole and deflating it during systole. This technique is still
the most widely used, mainly because it is minimally invasive and operates in-series with
the native heart. Although this technique does not cause haemolysis, it cannot be used
in patients with aortic dissection, aortic valve regurgition, amongst other conditions. The
most noteworthy limitation of the Intra-Aortic Balloon Counterpulsation (IABC) tech-
nique is that it is not beneficial when systolic aortic pressure is lower than 60 mmHg
[44].
In 1963, BeBakey et al. [43] implanted a pulsatile ventricular assist device (VAD) consist-
ing of a double-lumen silicon elastomer tube reinforced with polyethylene terephthalate
fibre (Dacron), with a compressible silicone elatomer blood chamber actuated by pres-
surised air and ball valves at inlet and outlet ports to ensure unidirectional flow.
In 1969, the first clinical bridge to transplant (BTT) was performed swhen a critically ill
47-year old man was implanted with a total artificial heart (TAH). The device consisted
of two diaphragm pumps pneumatically driven by an extracorporeal control console. The
patient was successfully supported for a period of 64 hours while waiting for a donor heart
to be transplanted [45].
In 1978, a patient with acute bacterial endocarditis was implanted with an intracorporeal
partial artificial heart for almost 6 days while waiting for a donor heart. The device was
implanted in the abdominal region [46, 47].
In 1979, utilization of a nonpulsatile biventricular bypass research on animals was re-
ported by Nosé et al. at the Cleveland Clinic Foundation [48]. However, for the next 20
years, mechanical cardiac assistance development remained focused on pulsatile perfu-
sion devices. In 1982, the implantation of a permanent total artificial heart (TAH) was
performed by William DeVries. The implanted TAH was the Jarvik-7 designed by Robert
Jarvik. During implantation time, the incidence of infection and embolic events were
36% and 9%, respectively; moreover, the 1-year survival rate for all patients receiving the
Jarvik-7 was only 37% [49].
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In 1990s, the axial-flow-device generation emerged increasing versatility and reliability
over their pneumatic counterpart. In the same decade, the European and US regulatory
bodies approved the use of the first BTT device. A decade later, the US Food and Drug
Administration (FDA) approved the first device for destination therapy (DT) as a result
of the Randomised Evaluation of Mechanical Assistance for the Treatment of Conges-
tive Heart Failure (REMATCH) trial, which compared optimal medical management with
long-term use of LVADs for patients with NYHA class IV HF who were ineligible for
orthotopic heart transplantation [38, 50].
1.4.2 Continuous vs. Pulsatile Flow Circulatory Support
Over the last three decades, MCS devices have significantly varied in both type and num-
ber; in general, they can be subdivided into two categories: pulsatile-flow and continuous-
flow devices. The former are mainly pneumatic devices with several moving parts while
the latter are mainly rotary devices, either axial or centrifugal pumps, with a single moving
component. The continuous-flow devices offer several advantages over the pulsatile ones
including: minimisation of thrombus formation and bacterial growth due to lack of blood
pooling; shorter implantation periods and less invasive surgical procedures; greater dura-
bility and reliability [51]. Table 1.3 summarises the main pulsatile-flow and continuous-
flow devices.
1.4.2.1 HearMate XVE
The HeartMate XVE is an FDA-approved pulsatile Left Ventricular Assist Device (LVAD)
device indicated to NYHA class IV patients use as a BTT or DT [52]. It consists of a flex-
ible polyurethane diaphragm bonded to a pusher plate, which is actuated by compressed
air. The inflow and outflow conduits are both made out of woven Dacron with a 25-mm
diameter porcine xenograft heart valve in each of them for adequate unidirectional flow
[53]. Implantation is performed with the patient under total cardiopulmonary bypass.
The pump housing is placed inside or outside the peritoneal cavity, just bellow the left
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diaphragm, in a left ventricular apex to ascending aorta (LV-AAo) bypass configuration;
see Fig.1.4. The maximum stroke volume is 83 ml corresponding to a pressure rise of
100 mmHg [53].
Figure 1.4. Schematic of the HearMate XVE placement in the human body. From [52]
1.4.2.2 Novacor LVAS
Novacor (Baxter Healthcare Corp) is a pulsatile Left Ventricular Assist System (LAVS)
that completely takes over the LV workload. The pump consist of a polyurethane di-
aphragm, actuated by compressed air via two pusher plates, and a 21-mm diameter bio-
prosthetic heart valve to ensure unidirectional flow [42]. The drive unit is implanted in
the abdominal wall just below the diaphragm. The system is connected in parallel to
the native system in a LV-AAo configuration, see Fig.1.5, while the patient is under car-
diopulmonary bypass [54]. The drive-line exits through the abdominal wall and it is then
connected to the external control unit.




Thoratec is a paracorporeal Ventricular Assist System (VAS) that can be used for univen-
tricular or biventricular support. It consists of a pneumatically driven polyurethane sac
within a polycarbonate housing. The inflow and outflow cannula have tilting-disk valves
to achieve unidirectional flow. It has a maximum stroke volume of 65 ml and can be op-
erated at a maximum flow of 6.5 lt/min with a corresponding pressure rise of 100 mmHg
[42, 56]. The implantation technique is via median sternotomy with cardiopulmonry by-
pass in most cases. For LV support, the system is implanted in a LV-AAo or left atrium
appendage to ascending aorta (LA-AAo) bypass configuration. For RV support, a right
atrium appendage to the main pulmonary artery (RV-Pa) bypass configuration is imple-
mented. The inflow and outflow conduits exit below the rib cage (subcostally) to be
attached to the pump(s) [42], see Fig. 1.6.
a) b) c) d)
Figure 1.6. Thoratec VAS: a) Univentricular leaft heart support; b) and c) biventricular support. From
[56]; d) Schematic of the Thoratec VAS placement in the human body. From [42]
1.4.2.4 MEDOS VAD
The MEDOS VAD is a paracorporeal pneumatically driven MCS device for children. The
system is available in three different sizes of 10, 25, and 60 ml maximum LV stroke
volume. It is made of polyurethane and allows visualisation of the filling and empty-
ing processes while observing for any unwanted air during installation or clot formation
while in prolonged usage; see Fig.1.7. The inflow and outflow conduits are fitted with
trileaflet valves to ensure unidirectional flow [57]. The pump can generate pressures be-
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tween 300 mmHg and −80 mmHg at a maximum rate of 180 beats/min [57]. The implan-
tation technique is via median sternotomy with cardiopulmonry bypass. For LV support,
the inflow conduit is sewn to the right superior pulmonary vein and exits through the supe-
rior abdominal wall (right epigastrium), while the outflow conduit is internalised through
the left epigastrium and sewn to the aorta.
Figure 1.7. 60-ml sized MEDOS VAD for left ventricular support. From [57]
1.4.2.5 CardioWest TAH
The CardioWest Total Artificial Heart (TAH) is a pulsatile biventricular heart replacement
system. It consists of a polyurethane membrane actuated pneumatically, the outlets of
each chamber house a Medtronic-Hall mechanical heart valve to ensure unidirectional
flow. After removal of both native ventricles, the CardioWest is implanted within the
mediastinal space [42, 58]; see Fig.1.8. It weighs 160 g and displaces 400 ml of volume.
It has a maximum stroke volume of 70 ml and can deliver up to 9 lt/min.
a) b)
Figure 1.8. The Incor (Berlin Heart) axial flow pump: a) Actual device displaying the pump cradled
between inlet and outlet elbow connectors; b) Schematic of the CardioWest TAH placement in the
human body. From [58]
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1.4.2.6 HeartMate II LVAS
The HeartMate II LVAS (ThermoCardiosystems, Inc, Woburn, MA) is an axial flow rotary
VAD composed of a blood pump, percutaneous lead, and external power and system driver
designed for long-term use. It is implanted in the abdominal wall or preperitoneally in a
LV-AAo bypass configuration; see Fig.1.9. The pump features a single moving part, a
3-bladed rotor that spins on two ball-and-cup bearings. It operates at rates of 8,000−
9,000 rpm with pressure differentials of 80− 100 mmHg with corresponding flows of
3−4 lt/min [59].
a) b) 
Figure 1.9. The HeartMate II VAD axial flow pump: a) Actual device displaying the pump cradled
between inlet and outlet elbow connectors; b) Schematic of the CardioWest TAH placement in the
human body. From [59]
1.4.2.7 MicroMed DeBakey VAD
The MicroMed DeBakey is an electromagnetically actuated, implantable axial flow pump.
It consists of a titanium inflow conduit, a housing containing the rotor and a motor, and a
vascular graft outflow; all internal components have a total weight of 93 g. The pump is
designed to operate at a flow of 5 lt/min corresponding to a pressure rise of 100 mmHg
at a speed of 10,000 rpm. The implantation technique is via median sternotomy and car-
diopulmonary bypass; the pump is housed in a small preperitoneal pocket and is attached
to the native circulation in a LV-AAo bypass configuration; see Fig.1.10. The drive-line
exits the abdominal wall at the left lower quadrant to be connected to the controller [60].
Ongoing improvement and optimisation of the MicroMed DeBakey VAD resulted in the




Figure 1.10. DeBakey VAD axial flow pump: a) Schematic of the essential components of DeBakey/-
NASA axial flow pump; b) Schematic of the CardioWest TAH placement in the human body. From
[62]
1.4.2.8 Jarvik 2000 VAS
The Jarvik 2000 is an electromagnetically actuated, implantable axial flow pump with a
single rotating part held in position by two ceramic bearings, designed for either DT or
BTT [63, 64]. It consist of a 16-mm outflow graft, a blood pump, a speed controller, a
percutaneous power cable, and a direct-current power supply. It can operate at 8,000−
12,000 rpm generating an average flow rate of 3−6 lt/min. The implantation technique
is via left thoracotomy or sternotomy with partial cardiopulmonary bypass. The pump is
placed within the LV through the apex while the outflow conduit may be placed in either
the ascending or descending aorta [63], see Fig.1.11.




The Incor (Berlin Heart AG, Berlin) is an axial flow pump that weights about 200 g,
30 mm in diameter and can rotate at speeds of up to 10,000 rpm, which corresponds to
a blood flow of 7 lt/min against a pressure rise of 150 mmHg. The impeller is held by
a magnetic bearing and has no physical contact with any other parts of the system. The
implantation technique is via median sternotomy supported with extracorporeal circula-
tion and is placed in a LV-AAo bypass configuration, see Fig.1.12. The inflow conduit,
made out of silicone, is inserted and fixed via a Dacron ring to the left ventricular apex.
The pump housing is placed in the pericardial cavity, while its drive-line exits through the
abdominal wall. The outflow conduit, made out of silicone, is sutured to the ascending
aorta [65].
a) b)
Figure 1.12. The Incor (Berlin Heart) axial flow pump: a) Actual device displaying the pump cradled
between inlet and outlet elbow connectors. From [66]; b) Intraoperative view of the inserted device.
From [65]
1.4.2.10 HeartWare (HVAD)
The HeartWare VAS is designed to support a dysfunctional LV. It consists of a 21-mm
diameter inflow conduit, a centrifugal blood pump (registered as the HVAD® pump), an
outflow graft, a percutaneous drive-line and an external controller; the implantable parts
weigh a total of 160 g. The drive-line cable features a tissue in-growth polyester fabric.
The impeller is the only moving component suspended by magnetic and hydrodynamic
forces; it rotates at about 1,800−4,000 and can generate flow rates up to 10 lt/min. The
small size of the inflow conduit and pump housing allow for pericardial placement without
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the need for abdominal pockets. The HeartWare® is implanted via median sternotomy
and cardiopulmonary bypass. The device is placed in a LV-AAo or a LV-DAo bypass
configuration, see Fig.1.13. The driveline is externalised through the right upper quadrant
of the abdomen [67, 68].
a) b)
Figure 1.13. The HeartWare® VAS: a) Actual device displaying the inflow conduit and housing; b)
Schematic of the placement in the native heart. From [68]
1.4.2.11 DuraHeart LVAS
The DuraHeart (Terumo Heart, Inc., Ann Arbor, Michigan, USA) is the first approved
magnetically supported LVAS for long-term circulatory support. It consists of an inflow
conduit, a centrifugal pump, an outflow conduit and an external controller. The impeller is
the only moving part and is suspended by three electromagnets; hence it neither requires
a rotating shaft or shaft seals. The DuraHeart™ can generate flows up to 8 lt/min corre-
sponding to a pressure rise of 120 mmHg. It can operate in a wide pressure range from
50 mmHg at 1,200 rpm to 180 mmHg at 2,400 rpm. The DuraHeart™ benefits from drug-
eluting blood contacting surfaces to reduce the risk of thrombus formation. The device
is implanted via median sternotomy and cardiopulmonary bypass in a LV-AAo bypass
configuration; see Fig.1.14.
1.4.2.12 VentrAssits LVAD
VentrAssist is a third-generation implantable rotary LVAD designed for long-term cir-
culatory support. It consists of inflow and outflow conduits, a centrifugal pump, a per-




Figure 1.14. The DuraHeart™ LVAS: a) Actual device displaying the pump cradled between inlet and
outlet elbow connectors; b) Schematic of the DuraHeart™ placement in the human body. From [69]
four blades with embedded permanent magnets, which are suspended by hydrodynamic
bearings; it rotates at 1,800− 3,000 rpm in the normal setting [70, 71]. The device is
implanted via median sternotomy and cardiopulmonary bypass in a LV-AAo bypass con-
figuration; see Fig.1.15. The pump is placed in a pocket bellow the diaphragm. The
VentrAssits features a diamond-like carbon coating in the blood contacting surfaces to
reduce the risk of platelet activation and hence thrombus formation [71].
a) b)
Figure 1.15. The VentrAssits™ LVAS: a) Actual device displaying the pump titanium housing and
silicone percutaneous lead; b) Schematic of the VentrAssist™ placement in the human body. From
[71]
1.4.2.13 Levacor LVAD
The Levacor LVAD, formerly ‘HeartQuest’, is a third generation implantable radial flow
pump. It is designed for long-term circulatory support in BTT and DT applications. The
impeller is magnetically suspended reducing wear. The device can generate flows ranging




The EVAHEART is a third generation implantable LVAS designed for long-term circu-
latory support. The impeller rotates on a shaft supported with hydrodynamic journal
bearings that are lubricated with water. The device is implanted in a LV-AAo bypass
configuration. Flows over 12 lt/min with a corresponding pressure rise of 100 mmHg are
achieved at 2,600 rpm [73, 74].
1.4.2.15 Synergy Pocket Micro-pump
Synergy Pocket Micro-pump (CircuLite®) is an axial implantable micro blood pump de-
signed to partially support the ventricles in patients with advanced heart failure who are
not eligible for implantation with a contemporary full support LVAD. It consists of a niti-
nol reinforced silicone inflow cannula, a pump, an 8-mm polytetrafluoroethylene outflow
graft, a driveline and a controller. The device is implanted via mini-thoracotomy; the dis-
tal end of inflow cannula is guidewired into the left atrium (LA), while the proximal end
of the inflow cannula exits through the second intercostal space to meet the main body
of the pump already placed in a small subcutaneous pocket. The outflow graft is anasto-
mosed to the subclavian artery. The driveline exits through the upper right quadrant of
the abdomen. The pump operates at speeds as high as 22,000−24,000 corresponding to
a flow of approximately 3 lt/min [75, 76].
a) b)
Figure 1.16. The Synergy Pocket Micro-pump LVAS: a) Actual device being compared in size to an




























HeartMate XVE Electromechanically driven;
Opposing pusher plates
NA 2-10 100 LV-AAo; external
drive
LVAD CE Mark BTT, DT [52, 53, 78]
Novacor Electromechanically driven;
Opposing pusher plates pneu-
matically actuated




LVAD CE Mark BTT, DT [42, 54]





CE Mark PC, BTT [42, 56]
MEDOS VAD Pneumatic (diaphragm pump) NA LV: 10, 25 &
60 ml; RV: 9,
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3 - 4 80 - 100 LV-AAo LVAD CE Mark BTT DT [42, 59, 78, 80]
MicroMed De-
Bakey
Axial pump 10,000 5 100 LV-AAo LVAD CE Mark BTT DT [60, 62]
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Levacor LVAD Centrifugal pump; bearingless
magnetically levitate impeller
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AAo, ascending aorta; LA-AAo, Left atrium to ascending aorta bypass configuration; BiVAD, biventricular assist device; BTT, bridge to transplant;
CE Mark, conformity mark in European Economic Area; DT, destination therapy; FDA, Food and Drug Administration; IDE, investigational device
exemption; LA-SA, Left atrium to subclavian artery bypass configuration; LV-AAo, Left Ventricle apex to Aorta bypass configuration; LVAD, left
ventricular assist device; LV-DAo, Left Ventricular apex to descending aorta bypass configuration; PC, post-cardiotomy; PMDA, Pharmaceutical and





The use of MCS devices as a DT for HF treatment is rising significantly as it provides
a cost-effective alternative to long-term treatment and cardiac transplantation. The most
significant result of the REMATCH trial has been its role in proving the utility of MCS
devices as DT. However, long-term versatility is far from ideal and incidence of transient
and permanent neurological events is still high [86]. More recently, it has been reported
that at low-flow low-pressure CV support, there is lower incidence of neurologic dysfunc-
tion [87]. To this end, evolution of MCS devices calls for more sophisticated design and
evaluation methods.
1.6 Objective
The objective of this work is to develop a method to identify the effect of performance
characteristics, pressure and flow rate, of mechanical circulatory support (MCS) devices
on the human cardiovascular system. The evaluation will be carried out both numerically
and experimentally.
1.7 Specific Aims
The research outlined in this thesis has the following specific aims:
1. To enhance an existing computational model of the human cardiovascular system
that is capable of simulating normal and diseased conditions.
2. To implement a purposely built multi-chamber cardiovascular test rig to evaluate
haemodynamic variables at several sites of the system while connected to a MCS
device .
3. To modify an off-the-shelf centrifugal pump impeller with the purpose of unloading




4. To evaluate the capabilities of a new centrifugal pump impeller as an alternative
NYHA Class III and IV HF therapy.
1.8 Thesis Outline
Chapter 2 will describe the mathematical formulation used to simulate Class III and IV HF
conditions. In Chapter 3, a local sensitivity analysis of the mathematical formulation is
performed. In Chapter 4, transient simulations are run with the objective of identifying the
centrifugal pump operating condition adequate for optimal perfusion in Class III and IV
HF conditions. Chapter 5 starts by describing the method for centrifugal pump impeller
blade generation and concludes by providing performance results from both numerical
and experimental procedures. In Chapter 6, the numerical results are compared against
those from a novel cardiovascular test rig. Lastly, Chapter 7 gives a brief conclusion and
provides a suggestion for future research.
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Chapter 2
Mathematical Model of The Human
Cardiovascular System
2.1 Justification of the 0-D Model
In general, there are many models of the human cardiovascular system including those
that emphasize on the mechanics of the left ventricle [88–92], or the arterial tree [93–
96], the ones that include both the systemic and pulmonary circulations [97–101], those
that are coupled to mechanical circulatory devices (MCD) [102–105], and the latest ap-
proach the multidomain models [91, 106–110]. The great majority of them make use of
the 0-D Windkessel model given its simplicity, its good estimation of essential central
hemodynamic variables (particularly CO [111]) and its potential estimation of hemody-
namic variables that takes as input a patient’s specific variables including age, gender,
etc., [112].
The present cardiovascular model includes: systemic and pulmonary circulations; instan-
taneous pressure-volume (PV) relation of the four chambers of the heart; a modified valve
model; and adapts a modified version of the fourth-element Windkessel model, by includ-
ing resistance, capacitance and inductance (RCL) elements for each of the vessel segments
in the model.
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A very important issue in cardiovascular modelling is the accurate analysis of the PV
relation of the heart chambers. Many cardiovascular models [88, 92, 100] have used the
time-varying elastance model introduced by Suga et al. [88], in which the PV relation is
formulated as
P(t) = E(t)[V(t)−V0] (2.1)
where P(t) and V (t) are the LV pressure and volume respectively, E(t) is the variable elas-
tance, and V0 is a fixed volume-axis intercept. This equation assumes that all isochrones
(curves that connect PV data points occurring at the same time) are linear and have a
common volume intercept in the PV graph. This is problematic because for a similar left
ventricular end-systolic pressure (LVESP) and volume ratio, the volume intercept varies
depending on the cardiac abnormality [113]. It has been shown that the left-ventricle
has a non-linear PV relation [114–117]. Claessens et al. [116] found that the shape of
the isochrones, was best simulated by a quadratic or logarithmic function with a variable
volume intercept as a function of time. Langewouters et al. [114] formulated an arctan-
gent model for the pressure-area plot of the aorta; this translates into tangentially curved
isochrones when formulated as a PV relation [118]. Shroff et al. [115] developed a PV
relation model that includes ventricular resistive behaviour; however, this model is iden-
tical to the work of Suga et al. [88] when the aortic flow is equal to zero [118]. Campbell
et al. [117] suggested that to improve time-varying elastance models, it is necessary to
include the dynamic effects of volume variation over pressure variation. In their model,
the dynamic left ventricular elastance was determined by integrating the dynamic rela-
tions between muscle-fiber force and fibre length into PV relationships. In the present
model, Campbell’s concept is adopted, in a modified manner, by including an elastance
function generator and its rate of change with respect to time to represent muscle-fiber
action, since the normalized time-varying elastance waveform does not change in either
normal condition or various cardiovascular diseases [119–121].
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Many of the previous numerical studies have described heart valve models by: forward
flow as depicted by the orifice flow model [122, 123]; effective orifice area [124]; Boolean
values to decide whether blood flows through the valves [112]; the diode analogue with
finite resistance [125, 126]. Others, have used more sophisticated and realistic models,
which simulate both the forward flow and the reverse flow phases [92, 100, 127, 128].
However, an easier to tune valve model, is generally more preferable. In this work a model
in terms of electrical analogies is implemented. This is achieved by representing the heart
valves as modified diodes, with decaying leakage current (flow) to model physiological
reverse flow.
2.2 Hemodynamic Model
Components of the whole circulation system are modelled in three main parts: heart,
systemic, and pulmonary circulation loops. The heart is modelled as a four-chamber pump
with variable elastance, and four heart valves that control the blood flow direction. The
circulation loops, are modelled as modified Windkessel model with repetitive RCL units
arranged in a similar fashion to [100, 101, 129–131] to represent the different vascular
compartments. The vascular compartments are in turn divided into 9 groups according to
their size and function.
2.2.1 Heart model
The concept of a variable capacitor is used as an electrical analogue of the heart chambers;
see Fig. 2.1. In this figure each chamber is represented by a time-varying capacitor, and
the heart valves are modified diodes. Compliance is analogous to capacitance, which is
generally expressed as the volume over pressure [6]. The inverse of compliance, known
as elastance, represents the contractile property of the heart chambers. The heart model
parameters are listed in Table 2.1.
A modified PV relation is proposed in this model in which the instantaneous pressure in
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Figure 2.1. Schematic representation of the electrical analogy of the heart chambers and heart valves.
Table 2.1. List of parameters for heart chambers.
Left Heart Value Ref. Right Heart Value Ref. Unit
Elv, max 3.20 [132–137] Erv, max 1.0 [132–137] mmHg/ml
Elv, min 0.10 [132–137] Erv, min 0.1 [132–137] mmHg/ml
Ela, max 1.00 [132–137] Era, max 0.3 [132–137] mmHg/ml
Ela, min 0.10 [132–137] Era, min 0.1 [132–137] mmHg/ml
Vlv,0 90.00 [132–137] Vrv,0 64.0 [132–137] ml
Vla,0 23.00 [132–137] Vra,0 23.0 [132–137] ml
Plv,0 0.00 [132–137] Prv,0 4.0 [132–137] mmHg
Pla,0 0.00 [132–137] Pra,0 4.0 [132–137] mmHg
any heart chamber is governed by the contractile property of the chamber, E(t), and the





and its time derivative is calculated as the flow difference between the inlet and the outlet
of the chamber. In the left ventricle, it is given by the mitral and aortic flow difference
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Figure 2.2. Varying elastance waveforms for the four cardiac chambers during one heart cycle, where
Tc is the time to reach maximum contraction, Tf is the time to initiate chamber filling, Emax and Emin
are the maximum and minimum elastances for each chamber accordingly.
therefore, the dynamic relations between elastance variation and volume variation to gen-
erate the instantaneous pressure change in the left ventricle can be obtained by applying










where Elv(t) represents the time-varying elastance as a function of the maximum and
minimum elastances of the chamber (Emax and Emin) as used by [132–137].




and, e(t), describes the muscle contraction and the relaxation phases in the heart chamber
as seen in Fig. 2.2 for which the following functions are proposed.



















: Tvc ≤ t < Tvf
0 : Tvf ≤ t < T
(2.6)
37
2. MATHEMATICAL MODEL OF THE HUMAN CARDIOVASCULAR SYSTEM
where Tvc and Tvf are related to the time to reach the maximum contraction and that to
initiate chamber filling of the ventricle respectively.












: Tac ≤ t < Taf
0 : Taf ≤ t < T
(2.7)
where Tac and Taf are related to the time to reach the maximum contraction and that to
initiate chamber filling of the atrium respectively. The time parameters are listed in Table
2.2.








2.2.2 Valve flow model
Accurate modelling of the dynamic flow characteristics of the heart valves plays a cru-
cial role in modelling the atrium-to-ventricle and ventricle-to-artery interactions. She et
al. [138] described the instantaneous Q(t)−∆P(t) relation for different prosthetic heart
valves in pulsatile flow as having a deformed 8-shape trace during a whole cardiac cycle.
In this model we adopt this dynamic characteristic by implementing a modified diode
with decaying leakage current (flow) which models physiological reverse flow; for this
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where kmax and kmin are constants that control maximum and minimum flows, ∆P(t) is the
pressure difference across the valve as a function of time, and w(t) is the valve opening,










where kse and k are constants that control the speed of ejection and the dynamic charac-
teristic, respectively. The valve flow model parameters are listed in Table 2.3.
Table 2.3. List of parameters for valve flow model.
Left Heart Value Ref. Right Heart Value Ref. Unit
kmax, MiV 400.00 † kmax, TiV 200.0 † mmHg
−1
kmin, MiV 0.15 † kmin, TiV 0.18 † mmHg
−1
kse, MiV 2.50 † kse, TiV 2.0 † mmHg
−1
kmax, AoV 400.00 † kmax, PoV 300.0 † mmHg
−1
kmin, AoV 0.28 † kmin, PoV 1.5 † mmHg
−1
kse, AoV 2.50 † kse, PoV 2.5 † mmHg
−1
k 0.01 ‡ k 0.01 ‡ s
† Selected values are similar to those found in [132–137] but have different units as the valve
mechanism is different in this work;
‡ Assumed value.
Fig. 2.3 shows a diagrammatic representation of the ∆P(t)−Q(t) relation of the present
model. As previously described in She et al., [138] the following phases are identified.
Starting from a closed position at a; see Fig. 2.3b, the curve quickly rises into the positive
∆P(t) axis constituting the isovolumetric contraction of the muscle. Once the valve has
opened, a rapid ejection phase initiates at b until the maximum flow is reached at c. From
this point, a slow ejection phase takes place up to the point where the curve turns into
the negative flow axis (reverse flow phase) at d. The curve quickly turns into the negative
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Figure 2.3. Illustration of Pressure difference, ∆P(t), and flow relation of the aortic valve during a
cardiac cycle: a) Shockley diode model and b) proposed modified diode with variable inflow-outflow
characteristics and reverse flow.
∆P(t) axis to finally go back to the close position at e and allow chamber filling. When
comparing a normal diode to present valve model, is clearly noticed that the model results
in a good prediction of valve flow dynamics; such as decaying leakage current (shown in
Fig. 2.3).
2.2.3 Blood Circulation Loops
The various components of both the systemic and pulmonary circulation loops are rep-
resented by a lumped parameter model (shown in Fig. 2.5). In this work, the systemic
circulation was divided into six-parallel vascular beds representing head, coronary, up-
per limb, splanchnic, renal and lower limbs circulations with the intention of properly
distributing the total blood volume; see Fig. 2.5. Each vascular bed is divided into nine
segments: central artery; large arteries; terminal arteries; arterioles; capillaries; venules;
small veins; large veins; and central vein. Each Local resistance to flow, compliance, and
inertance of each of these segments are modelled as resistance, compliance, and inertance
effects respectively. An illustration of two RCL segments in series is shown in Fig. 2.4.

















Figure 2.4. Illustration of two RCL units in series.







where Ri is the segment’s resistance to flow, Li is the flow inertance of each segment, Ci





The pulmonary loop model is similar to that of the systemic loop with different values for
system parameters.
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Figure 2.5. Schematic of the pulmonary and systemic circulation loops. Each loop is composed of
nine RCL units in series (shown in Fig. 2.4). The solid lines represent the arterial tree originating
from the aorta (vessel in red) while the broken lines represent the venous tree which converges into the
inferior vena cava and superior vena cava (vessel in blue)
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2.3 Autoregulation model
In this work, the cardiovascular control model includes three main systems representing



























Figure 2.6. Diagrammatic representation of the cardiovascular control model where the broken lines
represent the effector stimulus and the solid lines represent the afferent signals. The heart’s contrac-
tility is assumed to be modulated solely by the sympathetic nerve control; resistance is assumed to
be controlled only at the arterioles as these are the main resistive vessels [5]; vascular compliance is
only controlled at the veins as they are the main capacitive vessels in the whole circulation [140]. This
figure is a modification of the works undertaken by Heldt et al. [141] and Shim et al. [142]
Regulation of pressure is controlled by the sympathetic and parasympathetic innervation
throughout the cardiovascular system. They are the efferent subdivisions of the ANS. The
sympathetic fibres richly innervate: the cardiac chambers; the heart pacemaker; vascular
smooth muscle, whereas the parasympathetic innervation mainly focuses on the heart’s
pacemaker [5, 143]. In general, sympathetic stimulation increases cardiac contractility
and HR, and produces vasoconstriction in the arterioles mainly; whereas parasympathetic
stimulation reduces HR and induces vasodilation on the peripheral vasculature. In Fig.
2.7, it is shown that for changing levels of atrial pressure the amount of blood pumped per
minute can be increased or decreased according to the levels of sympathetic and parasym-
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pathetic stimulus, respectively [144]. Sympathetic stimulus can increase HR, up to 200
beats per minute (bpm), and double the force of contraction, therefore increasing CO and
mean arterial pressure (MAP). By contrast, parasympathetic stimulation can decrease HR
and CO to as low as zero.





















Figure 2.7. Changes in CO in response to nerve stimulation. The figure shows three different condi-
tions: zero stimulation (solid line) where optimal condition is found around the middle of the curve;
parasympathetic stimulation (dotted line); normal sympathetic stimulation (broken line). (The data in
this figure was extrated from Guyton [144])
The baroreflex and volume reflex are responsible for the regulation of pressure and volume
respectively, and are model as reference-point controllers that aim at minimizing an error
signal. In the pressure control reflex loop the error signal, Perror(t), is the difference
between the mean arterial pressure, P̄cs(t), over a full sample of carotid pressures in a
cardiac cycle, τ , and a pre-defined reference pressure Prefcs ; see Fig. 2.8 for a diagrammatic
representation. This difference is then scaled by a sigmoid transform to represent the
experimentally-observed sigmoidicity of the stimulus-response curves as shown in Fig.
2.7. The sigmoid transform is given as follows









where SF is the scaling factor. The carotid sinus is used in this work as the main barore-
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ceptor site as this is how it is found in the human body [145]. The pulmonary baroreflex












Figure 2.8. Arterial baroreflex model where Pcs(t) is the instantaneous carotid pressure, P̄cs(t) is
the arithmetic mean of the carotid pressure in a cardiac cycle, Prefsys is the reference systemic arterial
pressure, Perror(t) is the scaled error signal and τ is the period of the cardiac cycle
The volume reflex is model by simulating the stretch of the atria caused by sensing in-
creased returning blood volume and consequent dilation of the afferent arterioles in the
kidneys brought about by ANS activity [146]. In general, a decreased arteriolar resis-
tance in the kidneys causes the glomerular capillary pressure to rise resulting in increased
glomerular filtration rate (GFR). Simultaneously, the CNS reduces the reabsorption of
water from the kidney tubules, thus increasing the fluid loss and consequently reducing
the increased blood volume back to normal. This feedback mechanism, intrinsic to the
kidneys, normally keeps the renal blood flow and GFR relatively constant even in the
presence of significant changes in arterial blood pressure. In Fig. 2.9 it is noted that the
stimulus curve appears similar to that of the baroreflex system (see Fig. 2.7) with this in
mind, an error signal for the RA volume, Vra, is produced in a similarly manner to that
for the baroreflex model and scaled by a sigmoid transform in order to regulate MAP
as function of the extracellular volume. In previous cardiovascular models that included
automatic pressure control [107, 141, 142, 147, 148], the volume reflex loop has been
neglected as these studies mainly concentrated in acute pressure control, particularly in
hypotensive conditions. As this study requires the simulation of chronic conditions, such
as hypertension and congestive heart failure, kidney autoregulation becomes an important
mechanism to maintain constant CO and adequate MAP [6, 33, 149–152].
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Mean renal artery pressure (mmHg)
Figure 2.9. Autoregulation of the renal blood flow and glomerular filtration rate during changes in
renal mean arterial pressure where the solid line shows the renal blood flow and the broken line GFR.
(Data extracted from [6])
The summation of the error signal from the baroreflex loop and the volume reflex loop
constitutes the effector variable Y (t). This variable represents the ANS response sig-
nal, either a sympathetic or a parasympathetic signal, that ultimately governs the effec-
tor mechanisms, namely: the variation of heart elastance; arteriolar resistance variation;
glomerular filtration rate; venous compliance of the systemic circulation and the pul-
monary circulation. The response signal, Y (t), is scaled by static gain values, GX , where
X denotes any of the effector mechanisms as illustrated in Fig. 2.6. The static gain pa-
rameters implemented in this model are listed in Table 2.4.
Table 2.4. List of static gain values for a normal condition.
Effector Value Unit Reference








2. MATHEMATICAL MODEL OF THE HUMAN CARDIOVASCULAR SYSTEM
2.3.1 Heart Rate
HR variability is simulated by an integral pulse frequency modulator (IPFM) model of
the sino-atrial node (also known as the heart’s pace maker). In this model an input signal,
consisting of the mean HR, m0, and the modulating signal, m(τ), which describes the
variations in HR according to the autonomic activity, is integrated until a threshold, R,
is reached at which time an action potential is triggered off; the integrator is then reset
to zero and the procedure is repeated. The threshold, R, defines the mean interval length
between successive events [153]. The resulting signal can be viewed as the charging of
the membrane potential of the sino-atrial node. The following mathematical expression
represents the IPFM model,
∫ tn
tn−1
(m0 +m(τ))dτ = R, n = 1, ...,N (2.14)
where n is an integer that indexes the nth heart beat.




Parameter Estimation and Sensitivity
Analyses
3.1 Parameter Estimation Model
The cardiovascular model described in Chapter 2 was developed with the intention of fol-
lowing the main physical properties encountered in the native system. Particular attention
was given to the optimisation of the venous compliance values, representing the capaci-
tance of the venous tree, and the volume reflex, which are commonly neglected in most
models. In addition to modelling the physical properties of the vasculature in the various
loops, representing the perfusion to the internal organs and limbs, the CV model also in-
cluded the reflex system. However, the present model has as main downside that it has a
very large number of parameters. With this in mind, a method to estimate the majority of
the model parameters is presented in this chapter.
System parameters for resistances, compliances and inertances were identified in a 4-stage
process. The first three stages implemented a simpler model of the CV system which
consisted of two main circulatory loops, namely pulmonary and systemic loops; see Fig.
3.1 for an illustration of this simplified model. Each circulatory loop is composed of nine
vascular compartments or RCL units that included: central artery; large arteries; terminal
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arteries; arterioles; capillaries; venules; small veins; large veins; and central vein. In the
last stage, the full CV model, as described in Chapter 2, was implemented. The final
optimised system parameters are provided in Appendix A.
Figure 3.1. Schematic of the pulmonary and systemic circulation loops. Each loop is built of nine
RCL units in series (shown in Fig. 2.4)
In the first stage, the majority of parameters were assigned values as found in the literature
[100, 127, 141, 147, 154–158]. These values served as stepping stones to proceed with
the overall optimisation. However, whenever the parameters from the literature where












where µ is the blood viscosity taken as 4 mPa s, ρ is the blood density taken as 1060 kg/m3,
l is the vessel length, r is the vessel radius, and n is the number of vessels, considered in
a parallel configuration in relation to the aorta, per compartment or vascular bed (all nu-
merical data necessary to implement Eq. 3.1 and 3.2 was extracted from J.R Levick;
Appendix 1 [5]).
Table 3.1. List of RCL parameters for the systemic loop.
Segment R(mmHg.s/ml) C(ml/mmHg) L(mmHg.s2/ml)
Central artery 0.003 0.0800 6.20e-05
Large arteries 0.050‡ 1.6000 6.20e-04‡
Terminal arteries 0.283‡ 0.0017 1.70e-05‡
Arterioles 0.630 0.2000 1.07e-06
Capillaries 0.283 0.0100 2.75e-08‡
Venules 0.0179‡ 18.620 5.62e-07‡
Small veins 0.001‡ 66.600 6.75e-05‡
Large veins 0.001‡ 20.500 6.32e-04‡
Central vein 0.075 1.5000 1.97e-04‡
‡ Denotes the parameters calculated using Eq. 3.1 and 3.2
Table 3.2. List of RCL parameters for the pulmonary loop.
Segment R(mmHg.s/ml) C(ml/mmHg) L(mmHg.s2/ml)
Central artery 0.002 0.180 5.20e-05
Large arteries 0.003 ‡ 3.800 9.23e-04‡
Terminal arteries 0.092‡ 0.017 1.7e-05 ‡
Arterioles 0.050 0.200 1.6e-07
Capillaries 0.025 0.100 4.13e-09‡
Venules 0.00179‡ 5.000 8.43e-08‡
Small veins 0.001‡ 66.60 1.01e-05‡
Large veins 0.001‡ 20.50 9.45e-05‡
Central vein 0.006 1.500 2.97e-05‡
‡ Denotes the parameters calculated using Eq. 3.1 and 3.2
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Initial
population





















Figure 3.2. Genetic algorithm flow chart where the solid lines represent the control flow and the
broken lines the data flow. Adapted from Rahided et al., [159].
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In the second stage, a meta-heuristic optimisation technique, called the genetic algorithm
(GA), was employed to optimally identify the systemic and pulmonary compliances given
that many local optima exist in this particular problem.
GAs are mathematical optimisation algorithms that are inspired in nature’s survival-of-
fittest selection mechanism, in particular the one found in the field of genetics. The search
process is initialised with a population of guesses that are processed by operators with the
intention of directing the initial population towards an ultimate goal or global optimum.
These operators are selection, crossover and mutation. Selection, evaluates the best per-
forming individuals and push them forward as mating individuals. Crossover, is charac-
terised by an exchange of information amongst the fitter individuals, thus, creating a new
offspring. Mutation, randomly changes information in the offspring with the intention of
improving the individuals’ performance. After the three operators have been applied, a
new generation is created. The process is continued until either a number of generations
have been reached or the criterion for convergence has been met [160]. Fig. 3.2 shows
a schematic representation of the GA. In this work, an existing GA model, developed by
Dr A. Rahideh, was implemented; the reader is then referred to the work by Rahideh et
al. [159], for further information.
The vascular compliances are the most challenging parameters to be identified and are the
driving characteristics to correctly simulate the different elements of the cardiovascular
system [157, 161–163]. The resistance values were made to adopt a normal distribution
(being highest at the arterioles and lowest at the central arteries and central veins), and
the inertance values were made to adopt an inverted normal distribution (being highest at
the central arteries and central veins and lowest at the arterioles, capillaries and venules),
with the purpose of optimising the compliances values according to them.
The objective of the optimisation problem is to minimize the error between clinically
measured and numerically calculated LV volumes, shown in Fig. 3.4c. Semiautomated
software (CMRtools; Cardiovascular Imaging Solutions, London, UK) was used to derive
LVEDV and LVESV of a control subject using a previously described technique [164]. A
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comparison between the CMR measurement and the numerical data is shown in Fig. 3.4.








where ȳ is the measured data (in this case LV volume over one cardiac cycle), y is the
predicted value, and n is the number of data points. The method calculates the sum
squared of the vertical distance between the measured LV volume and the one predicted
by the CV model. The objective function will be at a minimum when the difference
between measured and predicted data approaches zero [160].
The initial population of the GA consists of the compliance parameters found in the first
stage and some randomly generated individuals [165]. The parameters for the GA are
listed in Table 3.3.
Table 3.3. List of parameters for the genetic algorithms [159].
Parameter Value
Number of individuals 200
Number of elite individuals 5
Number of generations 50
Crossover rate 0.9
Mutation rate 0.025
The values for the systemic and pulmonary vessel compliances obtained in the second
stage were found to continue to display a bell-shaped distribution as initially imposed at
that stage of the optimisation process. In the third stage, non-linear regression analysis
was implemented (MATLAB’s nlinfit model for non-linear regression was used) to fit
a Gaussian distribution model to the compliance values obtained in the second stage.
The estimated regression coefficients aimed at minimising the sum of squared differences
between predicted and actual values.
This fitting was aimed at facilitating parameter estimation while maintaining common
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Figure 3.3. Illustration of the parameters for blood vessels as described in Tables 3.1 and 3.2: a) sys-
temic resistance, b) pulmonary resistance, c) systemic compliance , d) pulmonary compliance (show-
ing within brackets the percent change of the paremeter from stage 1 to stage 2), e) systemic inertance
and f) pulmonary inertance.
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physiological trends, namely: stroke volume within the 70-80 ml range; CO in the 4-
7 l/min range; central systemic blood pressure close to 120/80 mmHg; and pulmonary












where β , gc, σ , gh and dl are coefficients (generated by the nonlinear regression analysis)
which govern the characteristics of the bell-shaped curve, xi is the value of the indepen-
dent parameter, in this case the location, where i takes values from 1 to 9 representing the
vascular tree distribution from central arteries (1) to central veins (9). The coefficients
β , σ and gh control the peak value and dilation factor of the curve, respectively, and can
therefore be regarded as the variance; gc shifts the curve sideways whereas gl controls
the lowest value of the bell-shaped curve. As these two parameters cause no modification
to the shape of the curve they can be constrained as the location of highest vessel com-
pliance and the lowest compliance value as found in stage 2, respectively. All Gaussian
coefficients are summarised in Table 3.4
Table 3.4. Gaussian fitting coefficients.
Coefficient Cs Cp Ls Lp Rs Rp
β 42.04 33.45 50 30 53.18 52.78
gl (constrained) 0.43 0.18 17782 118550 0.01 5.80e-4
gc (constrained) 8.00 8.00 4 4 4.00 4.00
σ 4.65 3.91 9 10 5.18 5.20
gh 553.00 137.44 28535 19023 1.29 0.20
The choice of values for the model’s parameters, as presented in Fig. 3.3a-f, show the
highest systemic resistance occurring at the arteriole vessels and the lowest in the central
vessels; this is consistent with the small diameters found towards the periphery as resis-
tance is inversely proportional to the radius raised to the fourth power, r4, as described
by Eq. 3.1. Conversely, inertance is mainly influential in the central vessels and very
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insignificant at the periphery as inertance is inversely proportional to the squared of the
radius, r2, as described by Eq. 3.2; hence, it plays a significant role in large diameter
vessels. The pulmonary loop parameter values for both resistance and inertance were cal-
culated as being 15% of their systemic counterpart. Vascular compliance or the ability
of the vessels to store blood per pressure change is significantly higher in the veins when
compared to the corresponding arteries with about 64% of the total blood volume stored
in the systemic venules, small veins and vena cava [6]; Fig. 3.3 (c) and (d) show that the
results from the third optimisation stage approximate this fact, with the peak compliance
value occurring at the large veins.
In the fourth and final optimisation stage, the systemic loop, as implemented in stages 1
to 3, was divided into six parallel loops representing coronary, head, upper limb, splanch-
nic, renal and lower limb circulations (see Fig. 2.5); each of which having nine vascular
compartments or RCL units, and connected to the heart by a lumped-parameter repre-
sentation of the aorta and the vena cava, as described in Chapter 2. The fitted Gaussian
coefficients gh and gl, as identified in the third stage, were divided into the mentioned
vascular beds according to CO distribution percentage as follows: coronary 3.0%, head
13%, upper limb 11%, splanchnic 32%, renal 28% and lower limb 13%. The remaining
Gaussian coefficients were not changed for any of the vascular beds given that each of
the loops has the same amount of vascular compartments, but most importantly because
the haemodynamic properties of all vascular beds behave in the same fashion. GA op-
timisation was once again employed to identify the maximum and minimun values for
TPR, total vascular compliance and total vascular inertance that would in turn control the
Gaussian coefficients gh and gl for all vascular beds as a function of CO distribution. The
objective function of this optimisation problem was the same as in the second stage, that
is, to minimise the error between the clinically measured LV volume and the numerically
calculated LV volume. The Gaussian coefficients obtained in stage 4 are summarised in
Table 3.5
Table 3.6 gives a quantitative representation of the changes that took place from stages 1
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Table 3.5. Gaussian parameters for all systemic vascular beds
Vacular bed R C L
gh gl gh gl gh gl
Coronary 10.00 1.00 12 0.0112 0.0021 3.514e-4
Head 3.33 0.28 90.00 0.0120 0.0113 1.933e-6
Upper limb 8.89 0.89 48.00 0.0120 0.0103 1.757e-5
Splanchnic 1.60 0.22 180.00 0.0120 0.0247 4.217e-6
Renal 2.00 0.28 144.00 0.0029 0.0196 3.338e-6
Lower limb 11.11 1.11 60.00 0.0012 0.0082 1.757e-5
Table 3.6. Output measures from stages 1 to 4 of the optimisation process.
Variable Control Stage 1 Stage 2 Stage 3 Stage 4 Unit
CO 4-7 6.0 5.7 (-8.1%) 5.6 (-1.8%) 5.6 (0%) l/min
MSAP 70-100 101.7 98.5 (-3.1%) 97.5 (-1.0%) 102.7 (5.3%) mmHg
MPAP 9-18 19.6 17.6 (-10.2%) 18.4 (4.5%) 18.8 (2.2%) mmHg
CVP 3-8 8.0 8.1 (1.3%) 8.4 (3.7%) 3.7 (-55.9%) mmHg
Quantitative information about the changes in output measures from stage 1 to stage 2 to stage
3 to stage 4 of the optimisation process is given within the brackets.
to 4 of the optimisation process. From Table 3.6 it can be seen that the parameters used
in stage 1 resulted in a relatively good fit when compared to the control values therefore
making of them a good estimate for stage 2 of the optimisation process; the Gaussian fit-
ting performed in stage 3 did not vary greatly the output measures with respect to stage 2
as identified with the GA tool; lastly, the comparison of the output measures from stages
3 and 4, although presented with greater variation than for the other stages, proves that
the Gaussian fit for estimation of the model’s parameters works well for both the sim-
ple and the complex CV model. However, as the output measures listed in Table 3.6 are
cycle-averaged values no time histories of the simulation details can be assessed. When
comparing the clinical LV volume with the calculated LV volume at stage 1 as found in
Fig. 3.4a it can be seen that the there are many inaccuracies throughout the cardiac cycle
as depicted by the error bars. When comparing the numerical LV volume obtained at stage
4 to that of stage 3 (see Fig. 3.4c and d), it can be appreciated that very small changes
occur making the implementation of the Gaussian fit for estimation of the model’s param-
eters a useful tool.
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Numerical Output stage 2
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Numerical Output stage 3
(c)




















Numerical Output stage 4
(d)
Figure 3.4. Comparison of calculated left ventricular volume vs normal clinical measurement through-
out the 4-stage optimisation process. (a) stage 1, (b) stage 2, (c) stage 3 and (d) stage 4.
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3.2 Sensitivity Analyses
The present model, although has as main intention to produce a heart failure model, is
intended to be robust enough to simulate normal and diseased cardiovascular conditions.
The intention of this sensitivity analysis is therefore, to find the main influencing param-
eters of the CV model over a set of output variables. A deterministic method, requiring
as many model evaluations as there are parameters in the model, is used in this work to
carry out a local sensitivity analysis or derivative based analysis in which the sensitivity
of the cost function is evaluated with respect to each of the model’s parameters. The sen-
sitivity analysis is performed in two separate parts: 1. Analysis of the sensitivities of the
uncontrolled CV model in steady state; 2. Analysis of the sensitivities of the CV model
with automated regulation.
In this work, particular interest was given to finding the most significant parameters that
affect CO as a derived feature of the aortic valve outflow, MAP, MPAP and central ve-
nous pressure (CVP) on a beat-by-beat basis. These four cost functions are chosen here
because these are the gold standards of cardiac condition assessment [111]. Investigation
of parametric sensitivities is achieved by assessing the difference between the nominal
response (output y) and perturbed values ∆y brought about by imposing small changes,
∆α , in the model’s parameters, α . The output, y, consists of the cycle-averaged values
of cost function over one cycle. The local sensitivity of a cost function with respect to a
given parameter, αi, is equal to the partial derivative of the cost function with respect to










where n is the number of independent parameters in the model, the superscript 0 denotes
the nominal value and ∂CO/∂α is the local sensitivity of the cost function CO with respect
to small variations in the model’s parameters. A forward difference approximation was
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, (i = 1, ...,n) (3.6)
where ∆αi is the parameter variation with step sizes of 10% and 25% in increment from
the nominal parameter values. Tables 3.7, 3.9, 3.10 and 3.8 present numerical results for
the relative sensitivities of CO, MSAP, MPAP and CVP, respectively, to the top 15 most
significant parameters out of the total 492 model parameters for the uncontrolled CV
model. The parameters are ordered from high to low according to their absolute values.
Tables 3.11, 3.13, 3.14 and 3.12 present the results for the autoregulated CV model.
3.2.1 Results and Discussion
From Tables 3.7, 3.9, 3.10, 3.8 it can be appreciated that 8 parameters repeatedly appear to
have a significant influence over the output variables for the uncontrolled analysis, these
are: heart period, T, total blood volume, Vtotal,0, onset of atria filling Taf, right ventric-
ular volume, Vrv,0, right ventricular minimum elastance, Erv, min, venous compliance of
the splanchnic vascular bed, Csvn,svb, inferior vena cava resistance, Rivc and splanchnic
arteriolar resistance Rsar,svb.
This result is consistent with mechanisms that drive CO, mainly heart rate and stroke
volume. The latter is in turn affected by venous return and onset of atria filling through
the Frank-Starling mechanism.
According to Table 3.7 the main determinants of CO are heart period, T, total blood vol-
ume, Vtotal,0, right ventricular diastolic elastance, Erv, min, splanchnic arteriolar resistance
Rsar,svb and right ventricular volume, Vrv,0. This result is consistent with mechanisms that
drive CO, mainly heart rate and stroke volume. Stroke volume, in turn, is determined
by the right ventricular end-diastolic volume (RVEDV), which is mainly governed by ve-
nous return, minimum right ventricular elastance, Erv, min, and onset of atria filling,Taf.
Other main factor influencing CO is TPR, the splanchnic vascular bed has the largest CO
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Erv, max 0.097 0.122
Taf 0.275 0.107





distribution hence, splanchnic arteriolar resistance ranked highest amongst other vascular
beds.
The sensitivity spectrum for CVP; see Table 3.8, displays an expected overlap with some
of the determinants of CO and this in turn being a consistent result with the Frank-Starling
mechanism of the heart. CVP is determined by the addition of all the systemic veins flow
into the right atrium. The sensitivity spectrum is found to be consistent with this fact given
that the most influencing parameters are related to venous return to the heart such as right
ventricular volume, Vrv,0, onset of atria filling,Taf, venous compliance of the splanchnic,
Csvn,svb, and renal, Csvn,rvb, vascular beds since over 50% of the total circulating blood
volume resides within those beds.
The sensitivity spectrum for MSAP; see Table 3.9, displays an overlap with both the CO
and CVP sprectra hence overstating the presence of a strong Frank-Starling mechanism in
the CV model. In the native system, increased arterial pressure is connected to a series of
events starting from an increased circulating blood volume which in turn increases venous
return to the heart ultimately increasing CO and arterial pressure.
The sensitivity spectrum for MPAP; see Table 3.10, displays an expected overlap with
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Erv, min 0.272 0.238
Prv,0 0.269 0.272
Rsar,svb 0.261 0.243
Erv, max 0.239 0.217
Rssv,svb 0.238 0.226
T 0.216 0.217
both CO and CVP sensitivity spectra given that all returning blood first enters the pul-
monary circulation. In addition to these, pulmonary arteriolar resistance, Rpar, ranked top
three amongst the most influencing parameters of MPAP.
The same parameters that rank high in the sensitivity spectra of the uncontrolled system
rank high in the corresponding spectra of the controlled system. However, the heart rate
controller and the pressure and volume reflex reference points were commonly found in
the sensitivity spectra of the autoregulated system. From Tables 3.11, 3.8, 3.13 and 3.14
it can be appreciated that 7 parameters repeatedly appear to have a significant influence
over the output variables for the controlled analysis, these are: CO reference point COref,
onset of ventricular filling Tvf, total blood volume Vtotal,0, systemic arterial baroreflex
gain Gsap, GFR gain Ggfr, right atrium volume reference point Vra,ref and the heart rate
set-point Tref.
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Erv, min 0.104 0.098
Csvn,svb 0.101 0.085
Rsar,cvd 0.099 0.098
Elv, min 0.098 0.093
Erv, max 0.090 0.107
Vsvb,0 0.089 0.081



















Erv, max 0.208 0.187
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Elv, min 1.422 1.733
Gsap 0.565 1.610
Ggfr 9.504 1.293
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Elv, min 1.317 1.237

































Erv, min 0.193 0.159
kGFR 0.154 0.139
Erv, max 0.126 0.110
Elv, min 0.101 0.109
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Chapter 4
Simulations and Selection of
Centrifugal Pump Operating Condition
This Chapter will be concerned with the calculation of the hemodynamic variables in the
healthy or control condition and their comparison with experimental data extracted from
the literature review carried out on this topic. It also considers the simulation of HF Class
III and IV with and without a MCS device.
The model written by Prof. T. Alexander was originally solved explicitly in C language
with a fourth-order Runge-Kutta formulation [100]; this implementation was found to
be computationally costly. To overcome this issue Simulink software (MathWorks®) is
implemented in this work to solve the set of ordinary differential equations (ODE) that
represent the mathematical model of the CV system as presented in Chapter 2. The se-
lected solver is ode15s (stiff/NDF) given that the present CV model becomes unstable if
a large step size is used; in other words, the set of ODEs are stiff. A varible-step solver
is hereby used to obtain satisfactory results. Other important parameters are specified in
Table 4.1.
The simulations reach periodic solution after the forty fourth heart cycles; see Fig. 4.1. In
all simulated cases the converged solution of the 100th second is presented in the figures;
however, to facilitate discussion of results, the time scale is normalised by the time period.
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Figure 4.1. System response with cardiovascular model in normal or control state. Periodic solution
obtained after the forty fourth heart cycle (40th second).
4.1 Modelling Healthy or Control Condition
Fig. 4.2 shows the simulation results for pressure, flow and volume changes in the four
cardiac chambers during normal or control state. In general, the pulmonary artery pres-
sure is 25.7/12.3 mmHg, aortic pressure 124/82 mmHg, total pulmonary resistance of
0.185 mmHg.s/ml, total peripheral resistance (TPR) 1.27 mmHg.s/ml, CO 5.6 lt/min,
LVSV 79 ml, and left ventricular stroke work (LVSW) 1.1 J. Other important commonly
used clinical parameters are summarized in Table 4.2. In this Table a comparison be-
tween calculated and experimental data extracted from the literature review is provided.
In general, it can be appreciated that the model gives a good estimate of cycle-averaged
haemodynamic varibles but when compared with full time pressure histories there are sev-
eral features that are not adequately represented; see Fig. 4.4 (a) and (c). Nevertheless,
the model is adequate enough for the purpose set out in this work.
The combination of the modified PV relation and valve models predicted several impor-
tant features in the pressure, flow and volume calculations of the cardiac chambers. In the
atrial model, the V-wave, Y-descent, and A-wave were evidently seen. They indicate the
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Time (s)


















































































































































Figure 4.2. System response with cardiovascular model in normal or control state: (a) left heart
pressure waveforms; (b) right heart pressure waveforms, (c) left heart volume waveforms, (d) right
heart volume waveforms, (e) aortic and mitral valvular flow and (f) pulmonary and tricuspid valvular
flow.
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Max. step size 0.001
Min. step size auto
Initial step size auto
Relative tolerance 1e-3
Absolute tolerance 1e-6
Solver reset method Fast
Maximum order 3
No. of consecutive min. steps 1
Solver Jacobian method sparse perturbation ‡
‡ Sparse methods are beneficial for models having a large number of states; the run-
time performance is also improved.
changes in pressure according to the filling pressure, the opening of the atrio-ventricular
valves and the actual atrial contraction, respectively as seen in Fig. 4.3. In the ventricular
model, a realistic description of the chamber volume is achieved, the instances of isovol-
umetric contraction, isovolumetric relaxation, rapid-ejection phase, filling phase and the
atrial boost (due to the atrio-ventricular interaction), are clearly identified as seen in Fig.
4.2(c)-(d). The atrio-ventricular valve flow is also realistically modelled, showing two
main peaks better known as the E and A velocities as seen in Fig. 4.2(e)-(f).






























Figure 4.3. Illustration of validation test for calculated PV relation.
To further validate the model’s trends, a test was carried out in a similar way as Smith
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Table 4.2. Comparison of calculated and experimental data in control condition.
Variable Simulation Measurement (range) Unit
Pavs,s 124.0 90−140 [166] mmHg
Pavs,d 82.0 60−90 [166] mmHg
Pavs,mean 96.0 70−105 [166] mmHg
Psvn,mean 3.8 4−13 [143] mmHg
Ppvs,s 25.7 15−30 [166] mmHg
Ppvs,d 12.3 5−15 [166] mmHg
Ppvs,mean 19.0 10−20 [166] mmHg
Ppvn,mean ‡ 2.2 3−15 [166] mmHg
Pra,mean 0.46 −2−2 [143] mmHg
Prv,s 26.0 15−30 [166] mmHg
Prv,d 0.26 0−8 [166] mmHg
Pla,mean 2.1 2−12 [143] mmHg
Plv,s 124.5 90−140 [166] mmHg
Plv,d 2.1 4−12 [166] mmHg
TPR 1.27 0.85−0.13 [166] mmHg.s/ml
SV 79 70−80 [5] ml
LVSW 1.1 1(mean) [5] J
MiV E/A Ratio 1.81 0.98 (mean) [167] -
CO 5.6 4−7 lt/min [5] lt/min
‡ Comparable to Pulmonary capillary wedge pressure
et al. [92]. This test consists of increasing TPR by 50% each time. Four PV loops were
obtained and two representative isochrones were plotted. The non-linear isochrones ob-
tained with the modified PV relation model were found to follow physiological trends
as described by Lankhaar et al, [118] in which the end-systolic pressure-volume relation
(ESPVR) showed a concavity towards the volume axis; see Fig. 4.3. In general it was
found that, the higher the resistance the higher the stroke work and the smaller the CO.
4.2 Modelling Heart Failure
In order to validate the present CV model, a series of cases representing the development
and progression of left ventricular systolic dysfunction (LVSD) were simulated, see Fig.
4.4(a)-(h). The simulations initiate by modelling a healthy condition (see Fig. 4.4(a)-
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(b)), typical of a young healthy subject; then progress to established hypertension (see
Fig. 4.4(c)-(d)) in which LV hypertrophy is commonly found and begins the process of
systolic heart failure [168]; see Fig. 4.4(e)-(f). Finally, a severe heart failure (HF) con-
dition is simulated, see Fig. 4.4(g)-(h). The progression from normal condition to severe
heart failure was achieved by decreasing systemic compliance while concurrently increas-
ing TPR; total volume was also increased with the purpose of mimicking volume overload
as frequently found in hypertensive patients and strongly correlated with progression to
HF [169, 170]. To mimic depressed cardiac contractility, as consistently observed even
in the mildest early stages of heart failure [169, 171], Elv,max was decreased and Elv,min
was increased [172]. Lastly, static gain values, GX , that modify the ANS signal response,
Y (t) (as described in Chapter 2 section 2.3), were reduced to a third of their normal value
to mimic the abnormal function of the baroreflex system given that is a commonly found
feature in patients with HF [13].
From Fig. 4.4(a)-(h), it can be observed that the CV model follows the clinically measured
AoP waveforms (shown in the dotted curves in Fig. 4.4 (a), (c), (e) and (g)); moreover, it
accurately predicts LV volume, in particular, it captures the increase in LVEDV as heart
failure progresses.
The main disadvantage of the present CV model is the lack of a pressure wave propaga-
tion model. This results in a poor representation of the early stages of the systolic AoPW
and an elevated area under the diastolic portion of the AoPW; see Fig. 4.4(a) and (c). In
the native system, the aortic pressure waveform (AoPW) consists of a forward-travelling
wave generated by LV work, and a backward-travelling wave generated by the reflection
of the forward wave from different sites along the arterial tree [168]; see the purple shaded
area in Fig. 4.5. This area under the systolic portion of the reflected wave represents the
required LV effort necessary to overcome the augmented pressure. Nonetheless, when
simulating HF conditions the AoPW appears to be better represented; this can be appreci-
ated in Fig. 4.4(e) and (f). The reason for this false improvement is that wave reflection is
directly affected by the elastic properties of the arterial tree; in HF conditions, the arterial
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Figure 4.4. System response during different simulated cases showcasing changes that occur in the
central aortic pressure waveform (AoPW) and left ventricular volume (LVV) during the development
and progression of LVSD. (a-b) Young normal AoPW; (c-d) established hypertension in the elderly;
(e-f) mild heart failure; (g-h) severe LVSD. Solid curves indicate the calculated AoPW; dotted curves,
clinical AoPW. Clinical data was extracted from Denardo et al. [168].
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Figure 4.5. A central aortic pressure waveform. Pd: diastolic pressure; Ps: systolic pressure; Pi:
inflection point (merging point of the forward and reflected waves); SPA: systolic pressure area; DPA:
diastolic pressure area; ED: ejection duration; Tr: round-trip travel time of the pressure wave to and
from the major reflecting SDR: systolic duration of reflected wave; Ew: LV wasted effort. Adapted
from Denardo et al. [168]
tree is very stiff resulting in faster pulse wave velocities (PWV) and faster arrival of the
backward-travelling wave; see Fig. 4.4 (e) and (g). This can be identified by the variable
Tr in Fig. 4.5 representing the time difference between the occurrence of the diastolic
pressure, Pd, and that of the point of inflection, Pi.
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4.3 Transient Response with MCS device
In this section, a MCS device is installed in series with the left ventricle in two different
locations, AAo and DAo, with the intention of numerically identifying an adequate pump
operating point. This was achieved by heuristically modifying ∆Ppump while the cardio-
vascular system is set up to mimic two diseased conditions; namely, mild HF (NYHA
Class III) and advanced HF (NYHA Class IV). An adequate pump design point was con-
sidered as one that would established a normal CO without compromising cerebral perfu-
sion. The transient haemodynamic responses of MAP, mean pulmonary arterial pressure
(MPAP), HR and CO to MCS support before and after the MCS device is switched on
were evaluated for the above diseased conditions. A summary of these variables is pre-
sented in Tables 4.3 and 4.4.
Table 4.3. Calculated haemodynamic variables in HF Class III condition with MCS device.



















In all modelled transient-response cases the hemodynamic variables CO, renal flow, Qre
and urinary output are normalised 5 seconds after the MCS device is switched on. How-
ever, in the mild HF case; see Fig. 4.6, MPAP increases from 20 mmHg to 23.42 mmHg
indicating that the pulmonary circulation is not coping well with the increased CO.
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Figure 4.6. Comparison of transient responses to MCS device installed at descending aorta (left) and
ascending aorta (right) in Class III HF.
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Figure 4.7. Comparison of transient responses to MCS device installed at descending aorta (left) and
ascending aorta (right)in Class IV HF.
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Table 4.4. Calculated haemodynamic variables in HF Class IV condition with MCS device.



















In Fig. 4.7 the selection of a pressure difference of 70 mmHg corresponding to a flow
of 5 lt/min appears to have a better haemodynamic response when compared to that of a
system with Class III HF; see Fig. 4.6. In particular, placing the MCS device in ascending
aorta accomplishes better perfusion to the head and kidneys as depicted by a Pca,mean of
71.71 mmHg and Pre,mean of 130.2 mmHg. A Pca,mean of 71.71 mmHg is well above the
lower limit of 60 mmHg necessary to maintain an adequate cerebral perfusion [6, 20].
In Fig. 4.6, it can be appreciated that placing a device in the ascending aorta increases
Pca,mean from 94 mmHg to 140 mmHg; however, Pca,mean falls right on the upper limit
for adequate autoregulated cerebral perfusion; it then could be a risky choice with high
possibilities of intra-cranial haemorrhage.
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Chapter 5
Centrifugal Pump: Impeller Selection
and testing
This chapter is concerned with the selection of an adequate impeller blade profile, inlet
and outlet angles, and outer impeller diameter in order to satisfy the design point as math-
ematically found in Chapter 4, that is, a pressure difference, ∆P, equal to 70 mmHg and
a flow rate, Q equal to 5 lt/min. Four different Hozelock pond pumps (Hozelock Ltd.,
Midpoint Park, Birmingham, England) were initially characterised according to head,
flow and rotational speed. The criteria used in selecting an available model was a hy-
draulic performance that was close to the design conditions determined in Chapter 4 and
a rotational speed within 1,200−4,000 rpm as found in literature review made on com-
mercial LVAD devices operating with centrifugal pumps [67–74, 84, 85]. This allows for
a good initial starting point given that the design of a centrifugal blood pump takes into
consideration many geometric parameters which leads to a very large number of cases to
be analysed. The main disadvantages of using off-the-shelf pond pumps is that the speed
cannot be controlled as the motor is sealed (waterproof) and the pump casing cannot be
changed; see Fig. 5.1. However, for the purpose of achieving the set out operating condi-
tion the existing geometric parameters produce a satisfactory result. Table 5.1 summarises
the design constraints and parameters for the pump.
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Table 5.1. List of pump design constraints and parameters
Parameter Value/Assignment
Operating point
Flow rate 5 lt/min
Pressure rise 70 mmHg
Geometric constraints
Maximum wall shear stress < 150 Pa [173]
Impeller diameter (D2) < 33 mm ‡
Suction inlet diameter (D1) 20 mm ‡
Shaft diameter 1.5 mm ‡
Rotational speed (N) 2,800 rpm ‡
Impeller height < 7.5 mm ‡
Minimum blade thickness > 1 mm †
‡ denotes the constraints imposed by the existing Hozelock pump, model 3378-0000.
† manufacturing constraint imposed by the in-house rapid prototyping machine.
Figure 5.1. Pump casing implemented in this work. Hozelock pond pump model 3378-0000.
5.1 Pump Design Theory
5.1.1 Selection of Impeller Blade angles
Velocity triangles are drawn at two places: inlet and outlet of impeller blades. The relative
velocity of flow is considered relative to the impeller. The absolute velocity is equal to the
vectorial sum of the relative velocity and the peripheral velocity of the impeller (U =ωr).
The liquid in this impeller enters with a tangential component and therefore the mathe-
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Figure 5.2. Centrifugal pump impeller with the velocity triangles at inlet and outlet. a) entry velocity
triangle, b) discharge velocity triangle, c)Velocities in an impeller, d) impeller inlet velocity distribu-
tion. Adapted from [174–176]





According to this expression the head is built up gradually as both CU2 and U2 are steadily
increased. It also shows that relative velocity does not contribute to an increase in pressure
[174].
According to the work by Kovas [175] dynamic depression at the impeller eye is highest
at the leading edge of the impeller blades. To achieve the lowest dynamic depression at
the impeller entry, the relation between peripheral velocity U1 and the meridional compo-
nent of the absolute velocity Cm1 must be arranged in such way that the resulting relative
velocity W1 is markedly reduced and the absolute velocity C1 is slightly higher than Cm1 .
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=C2m1 +(1− kU )
2C21 (5.3)
and
W 2 =C2m1 + ku
2 (5.4)
In order to reduce hydraulic losses a slanted leading edge is implemented. This configu-
ration reduces W 21 [175, 177] particularly at the shroud where the curvature of the stream-
lines is smaller when compared to that of the hub. With this in mind a small pre-rotation at
the entrance with a value of 0.1 is implemented [175], that is, (1− kU)U1 = 0.1 therefore
the value of choice for kU is 0.9. The circulating fluid gains rotation as it approaches the
impeller’s flow passages; ideally, as it approaches the impeller, the flow should enter in a
direction that results in the least flow resistance which is dependent on the blade’s inlet





where Cm1, for an oblique leading as seen in Fig. 5.2a, is equal to the sum of the partial













where s is the circumferential spacing at the leading edge, t is the blade thickness mea-
sured along direction of U1, and n is the number of subdivisions of the leading edge. In
this work 4 subdivisions are used.
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In this work, the radius was kept constant along the trailing edge of the blade, therefore
the outlet was kept constant for all blade spans. The following expression was used to





where Cm2, U2 and CuU2 are given as follows
Cm2 = Q/A2 (5.8)





5.1.2 Selection of Impeller Diameter
According to the hydraulic performances of the 4 available pumps, pump No. 3 was
chosen as the starting point with an impeller diameter (D2) of 33 mm, a rotational speed
of 2,800 rpm and an inlet diameter (D1 of 20 mm. The latter dimension represents a good
selection since it approximates to the values found in the human aorta artery, commonly
29 mm at AAo and 20 mm at DAo [158]. Given that many of the geometric parameters
were constrained, this work only pursued to redefine the blade exit width, b2; the blade
angles, β1 and β2, and to achieve smooth curves for the blade profile with the ultimate
goal of achieving the target operating point as specified in Chapter 4.
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Figure 5.3. Pump performance curves for different Hozelock pump models
5.1.3 Selection of Blade Exit Width
The calculation of the blade exit width departs from the operating point found in Chapter
4, the given rotational speed of 2,800 rpm from the existing Hozelock pump, and assum-
ing a target efficiency of 80%, η = 0.8. By implementing the coefficient of flow, φ , and










































Figure 5.4. Head and flow coefficient diagram. Adapted from [176]
5.1.4 Selection of Number of Blade Sets
The selection of number of blades greatly influences a pump performance. A large num-
ber of blade sets reduces recirculation, or slip, given that the impeller passages become
narrower. In low-speed low-flow pumps, flow separation is not a dominant feature conse-
quently viscous effects must dominate the flow [178]. The higher the viscosity of a fluid
the greater the disc friction and hydraulic losses suggesting that a large number of blade
sets could result in a drop in efficiency as a product of a larger surface area [179, 180].
Commonly, the Karl Pfleiderer equation for selection of number of blade sets is used, this
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In section 5.1.1, the inlet and outlet angles were found to be 49.6◦ and 86◦, respectively.
When using Eq. 5.14, it was found that the number of blade was high at thirteen blade
sets. With this in mind, several cases were simulated in which the number of blades
was varied. Table 5.2 summarises the effect of variation of the number of blade sets on
pump efficiency, pressure rise, and wall shear stress. It is worth mentioning that only
a maximum of eleven blade sets was possible to mesh, any higher than eleven blades
resulted in very poor meshes and solver issues.
From Table 5.2, it can be concluded that the impeller with eleven blade sets was the only
one to achieve the set out operating point, however, it can also be appreciated that wall
shear stress increased as the number of blade sets increased. It is also noticeable that the
total efficiency drops as the wall shear stress increases.












6 1.07 60.75 253.25
7 1.06 59.83 267.52
8 1.03 59.33 284.87
9 0.99 58.69 313.32
10 0.94 57.76 403.51
11 0.95 56.63 422.76
5.1.5 Impeller Blade Shape
The meridional coordinate system is used here given its convenience in studying axisym-
metric flow as found in impellers. The coordinate axes are axial, Z, radial, R, and circum-
ferential, θ . The latter is the angle measured about the axis of rotation from a rotating
reference plane. Having selected the inlet diameter, D1, exit diameter, D2, exit width, b2
blade inlet, β1, and outlet angles, β2, a detailed streamwise contour of the blade’s angle
distribution is next on the blade design process. The shape of the blades and the resulting
flow pattern in the impeller determine how energy is transferred to the fluid [176]. In
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general, the blade shapes can be classified as:
• Backward-curved blades (β2 < 90
◦)
• Radial blades (β2 = 90
◦)
• Forward-curved blades (β2 > 90
◦)
According to the exit velocity diagram; see Fig. 5.2(b), high values of β2 leads to very
high values of C2 or high kinetic energy; however, its transformation to static pressure can
only be appropriately achieved if diffusion takes place in a reasonably sized fixed casing
[177]. Since the volute in this work is one of the design constraints, the forward-curved
blades were opted out of the selection process; moreover, the blade’s outlet angle was
found to be lower than 90◦. Radial blades have as main advantages that are relatively
easy to manufacture and produce the highest pressure when compared with the other two
configurations.
5.1.6 Blade Meridional Profile
The calculation of each streamline was achieved by implementing Bezier curves, see
Fig.5.5. In this work, a cubic Bezier curve was implemented as it is simple to control
yet produces smooth profiles. This type of curve can be mathematically expressed by





where P represents a control point and t is the curve’s parameter value.
The inter-displacement of the streamlines is kept equidistant from one another. At the
leading edge, an inclination of 32◦ from axial (Z) was implemented with the purpose
of creating a slanted leading edge; see Fig. 5.5(a). The trailing edge, however, was
kept parallel to the axis rotation, Z. The radius of curvature at the bend, where the flow
direction changes from axial to radial, was made as large as possible from hub to shroud
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Figure 5.5. Graphical representation of: a) blade meridional profiles, and b) blade wrap angles
in order to achieve an adequate performance given that small radius of curvature yields
high flow velocity and possible flow separation after the bend, this in turn reduces the
total efficiency [177].
5.1.7 Pressure and suction sides
Having identified the inlet and outlet blade angles, β1 and β2 respectively, and blade exit
width, the setting of the coordinates of the camber line (m,θ) is next in the design pro-
cess. The angle distribution, β , along the blade was calculated by using a cubic Bezier
curve, see Eq. 5.15. The meridional coordinate, m, is expressed as the relationship be-
















where s is the distance along the meridional curve, S is the normalized distance along
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Figure 5.6. Superposition of thickness distribution (including elliptical profile at LE) on the camber
line. Adapted from Miloş [181].
meridional curve, r is the radial location, and z is the axial location. The normalized



















The thickness distribution, t, of the blade profile was determined by using a cubic Bezier
curve, see Eq. 5.15. The thickness is calculated as gradually increasing from inlet to
outlet in order to to provide an uniform change in area from inlet to outlet of impeller flow
passage [177]. At the leading edge half ellipse is used for shockless entry [177, 181], see
Fig. 5.6. The coordinates of the elliptical leading edge profile (LEP) are determined with
the following equations
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where a and b are the semi-major and semi-minor axes of the ellipse respectively, Xc and
Yc represent the x and y coordinates of the centre of the ellipse, respectively [181].
The next step is to superimpose the thickness distribution on the camber line to create the
pressure and suction sides. These can constructed by using the following equations
xps = ri cosθi (5.21)
yps = ri sin(θi + ti) (5.22)
xss = ri cosθi (5.23)
yss = ri sin(θi − ti) (5.24)
where i specifies the variation of radius, r, thickness, t, and angle, θ , from inlet to outlet,
xps and yps are the x and y coordinates of the pressure side, and xss and yss are the x
and y coordinates of the suction side. The thickness distribution, t, is given as an angle







where m is the meridional coordinate as previously described in Eq. 5.16. Fig. 5.6 shows
a schematic of the superposition method.
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5.1.8 Selection of Impeller Type
Impellers can be classified into opened, semi-opened and closed. An opened impeller has
neither hub nor shroud; a semi-opened impeller has a hub but not shroud; a closed impeller
has both hub and shroud. In general, opened and semi-opened impellers are subjected to
hydraulic friction losses associated with leakage over the clearance between two adjacent
impeller blades and the stationary volute wall [174]. However, high specific speed pumps
favour from opened impellers given that hydraulic friction losses are balanced [174]. By
contrast, in a closed impeller friction losses are associated with flow relative to the inner
side of the shroud [174]. A closed type impeller is then selected in this work given that the








The incompressible flow through the rotating impeller is solved in a moving frame of ref-
erence with constant rotational speed equal the rotational speed of the impeller. The flow
through the stationary parts of the pump is solved in a stationary reference frame. The
governing equations for the impeller are formulated below.
Considering water as a constant density fluid, conservation of mass states that the change
of mass with respect to time is zero, that is, the mass contained in a given volume, V–, must
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ρdV– = 0 (5.28)













dV– = 0 (5.29)
given that the integrand in the bracket must be equal to zero then the continuity equation
for unsteady and compressible may be written as
∂ρ
∂t
+∇ · (ρV) = 0 (5.30)
where ∇ · (ρV) is the divergence of the product of a scalar times a vector and can be
expanded as follows
∇ · (ρV)≡ (ρ∇ ·V)+(V ·∇ρ) (5.31)







+(ρ∇ ·V) = 0 (5.32)
for incompressibility condition the substantial change of density must be equal to zero,






+ρ∇ ·V = 0 (5.33)
substituting Eq. 5.33 into 5.32 the continuity equation for an incompressible flow reduces
to
∇ ·V = 0 (5.34)
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Figure 5.7. Infinitesimally small, moving fluid element. By convention τzx denotes a stress in the x
direction acting on the plane. Adapted from [183]
5.2.2 Equation of Motion
The calculation of the entire flow field through the impeller blade channels requires the
equation of motion in differential form
Applying Newton’s second law of motion to the moving fluid element in Fig. 5.7 and
considering the x component alone the following expression is defined
Fx = max (5.35)
where ax and Fx are the acceleration and force acting on the x-component, respectively.
The force component is equal to the sum of the surface forces acting on the x-component,
including shear and normal stress distributions, and body forces such as the gravitational
force. The net surface force in the x-component, Fx,s, of the element in question can be
written as
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the body force per unit mass in the x-component, Fx,b, acting on the fluid element can be
expressed as
Fx,b = ρ fx(dxdydz) (5.37)
where dxdydz represents the volume of the fluid element. Combining Eq. 5.36 and 5.37,

















given that the mass of the fluid element is fixed it can be expressed as
m = ρdxdydz (5.39)
recalling that the acceleration of the fluid element is the time rate of change of its velocity

























substituting Eq. 5.38, 5.39, 5.40 into 5.35, the x component of the equation of motion for
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the y and z components can be obtained in a similar manner to that of the previously found
x component.





















and ρ∇ ·Vu can be written as
ρ∇ ·Vu = ∇ · (ρuV)−u∇ · (ρV) (5.44)




















+∇ · (ρuV) (5.46)
the term within the square brackets can be recognised as the continuity equation, see Eq.







+∇ · (ρuV) (5.47)
substituting Eq. 5.47 into 5.41 results in the Navier-Stokes equation in the x component
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Figure 5.8. Coordinate system representing a rotating reference frame in the vicinity of a stationary
reference frame. The stationary frame is denoted by the upper case letters X, Y, Z while the rotating
frame is denoted by the lower case letters x, y, z. The rotating reference frame rotates with an angular





























In this work, a rotating frame of reference with angular velocity ω about the z-axis was
considered. From a stationary point of view, a fluid particle passing through a rotating
frame at an arbitrary time, t, has position r and relative velocity W. The inherited rotation
of the frame causes the fluid particle to rotate with velocity ω × r, therefore the velocity
is given by
V = W +ω × r (5.50)
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∂(W+ω × r) · i
∂t
+(W+ω × r) ·∇(W+ω × r) · i (5.51)










× r+W ·∇Wx +[ω × (ω × r)+2W×ω] · i (5.52)
where ∂Wx
∂t
represents the local acceleration of the velocity field within the relative frame of
reference; ∂ωx
∂t
×r the angular acceleration; W ·∇Wx the convective term within the relative
frame of reference; ω × (ω × r) the centripetal acceleration and 2W ×ω the Coriolis
acceleration [185]. The latter two terms appear as a result of the rotational component of
the velocity. The centrifugal acceleration acts in the radial direction whereas the Coriolis
acceleration acts tangentially and in opposite direction to the tangential velocity [176].
Replacing the acceleration in Eq. 5.49 by the expression in Eq. 5.52 and recalling that
for a steady rotating reference frame ∂r
∂t
= 0 and ω = constant the equation of motion in
rotating frame reference is obtained
∂Wx
∂t










In this work, turbulence is simulated with the standard k−ω model. This model utilises
the Reynolds-Averaged Navier-Stokes (RANS) model in which mean flow properties are
calculated by splitting the instantaneous properties into a time-average component and a
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In the k−ω model the turbulence viscosity, µt , is related to the turbulence kinetic energy





where k is the turbulent kinetic energy and ω is the turbulent frequency [186].
In ANSYS CFX, the near-wall treatment for the k −ω model is achieved with an au-
tomatic function that gradually switches from a scalable wall function formulation to a
low-Reynolds number one to capture the details of the boundary layer profile. The scal-
able wall function formulation is useful in that it is less computationally costly as it is
able to model near-wall high gradient shear layers with relatively coarse meshes [186].
By contrast, the low-Reynolds number approach resolves complex details of the bound-
ary layer by using very small mesh length scales in the direction normal to the wall or
inflation layers; for this purpose, the model requires a near-wall mesh resolution of at
least y+ < 2 [186]. With this in mind, ten nodes from the wall were used to resolve the
boundary layer given that in this work it is of great importance to gain an appreciation of
typical wall shear stresses present in the flow passage. This in turn, would have a signif-
icant effect in the preservation of red blood cells. Having reported on the importance of
studying wall shear stress, it is worth noting that in this study water was implemented as
the working fluid, however, if a blood-like working fluid was implemented the resultant
wall shear stresses would have been about 4 times higher than those obtained with water.
5.3 CFD Implementation
Numerical flow analyses were conducted to investigate the flow characteristics the pump
assembly. The commercial software ANSYS-CFX was implemented in all studied cases.
Steady state analyses were performed in all cases studied in this work. Water was se-
lected as the working fluid and was set as being isothermal and having an incompressible
behaviour.
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5.3.1 Computational Domain
The methods used to generate the model of the pump components were of two main
types: 1) x, y and z coordinate data generated with a purposely built MATLAB program
(see Appendix B); 2) typical lofting, surface, and extrusion tools implemented in the
commercial software Autodesk Inventor.
5.3.1.1 Impeller
A MATLAB program was written by implementing the pump theory as reported in section
5.1. This program produces x, y and z coordinate data that can be imported into ANSYS
TurboGrid for impeller mesh generation purposes. Fig. 5.9 displays the blade and the
flow passage obtained with the bespoke program. Table 5.3, summarises the dimensions














































Figure 5.9. 3D geometry definition: a) blade constructed with 5 curves, b) flow passage construction.
5.3.1.2 Volute, suction inlet and outlet pipes
The commercial software Autodesk Inventor was implemented to generate the volute, and
the suction inlet and outlet pipes. Modelling silicone was used to measure the dimensions
of the exiting volute and outlet pipe. The resulting CAD files were saved as IGES files to
be imported into the commercial mesher ANSYS ICEM CFD.
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Table 5.3. List of impeller dimensions.
Parameter Value Unit
Inlet diameter at hub D1,h 11 mm
Inlet diameter at tip D1,t 21 mm
Outlet diameter at hub D2 33 mm
Inlet width b1 6 mm
Outlet width b2 4 mm
Number of blade sets 11 -
Mean blade thickness t 1 mm
Mean Blade inlet angle 39 deg
Blade outlet angle 86 deg
5.3.2 Mesh Generation
5.3.2.1 Mesh Refinement Study
A comparison of the static and total head at the impeller outlet against various grid sizes
was carried out. In Fig. 5.10, it is noticeable that at coarser mesh sizes both the static
and total head are larger. The head starts to plateau at about 400,000 elements, however,
a satisfactory result is achieved with 160,000 elements. The variation in static head from
the last two finest grid sizes is about 0.01% for both the static and total head rise.
(a)


















































Figure 5.10. Comparisson of the effect of grid size on (a) static head and (b) total head.
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5.3.2.2 Impeller
ANSYS TurboGrid was used to generate the computational grid for a single flow pas-
sage. The topology was defined by selecting a placement on curves with control points,
the control points were preserved in all layers to improve the mesh quality. One-to-one
node matching on corresponding periodic surfaces was achieved by imposing a rotational
periodicity, this is of particular importance when generating the full assembly model of
the impeller. The topology method used was a J-Grid type with an embedded O-Grid
that surrounds the blade; this method was implemented with the purpose of resolving the
details of the boundary layer near the blade. Near wall element size specification was
implemented with the Y Plus method by specifying a target y+ = 1 on the passage, hub
and shroud, and the Reynolds number based on the chord length (ReL = 99,600). Next,
the mesh Data Object was modified to adjust the number of nodes; at first the mesh was
generated with a lower density then the mesh was refined. A total of 244,101 elements
were implemented per passage as this was found to produce a satisfactory result for static
and total head; see Fig. 5.10. In all layers a face angle criterion ranging from 15◦ to 165◦
was imposed to achieve a good mesh quality. Fig. 5.11 shows the generated mesh for a
single flow passage.
Figure 5.11. Structured mesh for a single flow passage.
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5.3.2.3 Volute, suction inlet and outlet pipes
ANSYS ICEM CFD was used to generate the computational grid for the volute, suction
inlet and outlet pipes. A blocking technique was implemented to achieve only hexahedral
element and to ensure good mesh quality. In all cases a face angle criteria ranging from
15◦ to 165◦ was imposed to achieve a good mesh quality. Table 5.4 summarises the main
mesh quality parameters for all the components of the pump.
Table 5.4. List of mesh quality parameters.
Parameter Value Unit
Suction inlet
Minimum angle 27 deg
Maximum angle 144 deg
Min. orthogonal qual. 0.55 -
Determinant (3×3×3) 0.6 -
Total elements 261,708 -
Flow passage
Minimum angle 15 deg
Maximum angle 165 deg
Total elements 244,101 -
Volute & Outlet
Minimum angle 18 deg
Maximum angle 162 deg
Min. orthogonal qual. 0.1 -
Determinant (3×3×3) 0.3 -
Total elements 195,950 -
The assembly mesh consists of 3.14 million hexahedral elements. Fig. 5.12 displays the
assembly mesh used for the numerical analyses.
5.3.2.4 Pre-processing
The frozen rotor frame change model was selected for the numerical analyses as it pro-
duces satisfactory solutions and is less computationally costly than a transient study. Do-
main interfaces were created for each of the assembly components. The interface con-
nections between the suction pipe and the impeller’s inlet, and the impeller’s outlet and
the volute’s inlet was achieved by using General Grid Interface (GGI) connection as these
allow to connect two surfaces with non-matching node locations.
For the rotational periodic interfaces, one-to-one connections were implemented as these
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Figure 5.12. Centrifugal pump mesh assembly. Number of elements: 3.14 million
produce the highest accuracy. The rotating frame elements (i.e. the blade, hub and shroud)
were set to a wall type boundary. Finally, the solver control parameters were set to high
resolution for the advection scheme and the turbulence numerics. A physical time step
of 5.95× 10−5 s is used, this is equivalent 360 time steps per one rotor rotation. The
convergence criteria selected was a residual target of 1× 10−4 for the root mean square
(RMS) normalized values of the momentum and mass equations residuals.
5.4 Numerical Results
Fig. 5.13 shows a plane view of the total pressure contours (right column) and velocity
vectors (left column) of the blades and volute for the designed flow rate at different exit
blade widths. The rotational direction of the rotor is the clockwise direction. Secondary
flows (denoted with the letter A) were found in all blade widths at each of the blade-to-
blade flow distributions but they were more predominant as b2 was increased; see Fig.
5.13(g). This can also be appreciated in Fig. 5.13(h) from the negative pressures present
near the suction surface of the blade. The interaction between the blade outlet flow and
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the volute was rather chaotic at b2 = 2 mm with some of the velocity vectors pointing in
the opposite direction of the rotor motion; this is denoted with the letter B. Secondary
flows were also found at the volute throat at all blade widths; this is denoted with the
letter C in Fig. 5.13 (a), (c), (e) and (g). From Table 5.5, the maximum wall shear stress





Figure 5.13. Numerical results at different blade widths, b2, at the design flow rate Q = 5 lt/min. Left
column: velocity vectors; Right column: total pressure distributions.
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1 1.16 48.68 108.1
2 1.09 49.10 213.4
3 1.04 49.95 298.2
4 1.01 50.48 347.2
5 0.95 51.32 422.8
6 0.90 52.02 484.7
7 0.87 52.77 573.1
8 0.83 52.74 617.1
9 0.78 52.31 646.9
10 0.71 50.60 686.2
11 0.63 47.99 711.3
12 0.56 45.78 739.8
5.5 Validation
The hydraulic pump performance of the centrifugal pump was evaluated using a typical
simple loop, by circulating water at room temperature. Flow rate was recorded within
the range of 0 − 12 lt/min with simultaneous recording of the static head. Fig. 5.14
shows the relationship between pump flow rate and static head. In general, it can be
seen that the design point was achieved with the new impeller and that there is agreement
between the experiment and the numerical result for the design point. For flows ranging
from 0− 6 lt/min the numerical static pressure result appears to represent satisfactorily
the experimental results; however, for flows ranging between 7−12 lt/min the numerical
result does not agree with the experimental results.
5.6 Discussion
The main target pump performance of 70 mmHg against 5 lt/min was successfully achieved,
however, the maximum shear wall stress condition was not met. In Table 5.5, it can be
seen that the maximum wall shear stress was 422.8 Pa; this value is well above the thresh-
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Figure 5.14. Numerical and experimental comparison of the new impeller performance.
old level of 150 Pa as found in the work by Leverett et al. [173]. In the latter, two primary
determinants of haemolysis were hypothesised: shear stress and exposure time. Particu-
larly, cells exposed to stress for very short times, can withstand very high stresses without
fragmentation. On the other hand, prolonged exposure at much lower stresses results in
lysis. In the work by Sutera et al.[187], red blood cells fragmentation became appar-
ent at shear stress values of 250 Pa and at exposure time of 4 minutes. From this work,
it was inferred that the presence of turbulence is not adverse by itself provided that the
time-averaged shear stress does not exceed the threshold level. Later works by Paul et
al. [188], suggested that to observe a significant increase in blood damage shear stresses
should be greater than 425 Pa and exposure times greater than 620 ms are required. From
Table 5.5, it can be appreciated that at greater flows the wall shear stress is also higher
suggesting that lower flows should be used to avoid red blood cells rupture (haemolysis).
From a clinical usage stand point, perfusion requirements should be taken into consider-
ation; for instance, excessive flow leads to pulmonary oedema whereas low flow pumps
are prone to thrombus formation due to less vigorous washout; hence the selection of
the right operating condition should be determined by the characteristics of the patient.
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Equally important, is the selection of an appropriate pressure rise as high pressures in-
creases the risk of intracranial bleeding. In the work by Nishida et al. [189], a flow in the
range between 5−5.5 lt/min is considered safe for left ventricular assist devices; higher
flows are specially concerning when considering that in a congestive-heart-failure patient
the right ventricle was operating at flows in the 3− 4 lt/min range. After insertion of
a mechanical circulatory device, the cardiac output and venous return will increase and
although this is beneficial for the systemic circulation, for the pulmonary circulation it
would prove challenging to deal with such increased load [190]. In general, flows of
about 4−6 lt/min are considered true assist devices that do not decompress the left ven-
tricle as much as true left ventricle replacement devices with flows as high as 7 lt/min or
greater [190]. Optimally, the central venous pressure should be less than 14 mmHg and
the mean arterial blood pressure range between 70−80 mmHg to keep adequate coronary,




The present experimental simulator of cardiovascular loops (SCVL) was developed in
collaboration with the research assistant Dr. Akbar Rahideh. In general, SCVLs can be
classified into three subdivisions according to the number of actuators used to emulate the
human heart as follows: single chamber; twin-chamber; and multi-chamber when more
than two actuators are implemented. Our experimental rig falls into the multi-chamber
category as we implemented four actuators to represent the human heart. In other avail-
able multi-chamber rigs [77, 191, 192], actuation of the heart chambers is achieved by
using pneumatic pumps and the circulation loops are opened to atmosphere to regulate
the pressure in the system. The present system utilises linear motors to accurately emu-
late the contraction and filling phases of the atria and ventricles of the human heart, and
is a closed-to-atmosphere system to allow for feedback control of the sensed pressures in
the systems. It also includes five mechanical heart valves to adequately achieved unidirec-
tional flow; five Hoffman clips used to induce resistance to the flow; and four air-spring
capacitors to account for the pressure-volume control in the blood vessels. Water was
selected as the working fluid with the purpose of preserving the good functioning of the
MCS device. It is worth mentioning that initially a glycol-water mixture was used as the
working fluid but it proved detrimental for the MCS device as it completely stop working.
The main goals of this SCVL are to simulate the aortic sinus pressure waveform, closer to
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patophysiological conditions as that found in the clinical setting, including steep rise of
the pulse pressure, dicrotic notch which is due to the closure of the aortic valve, and grad-
ual decline of pressure to the aortic diastolic pressure. Also, to mimic diseased conditions
with the intention of evaluating the system response while the MCS is placed at AAo and
DAo, as described in Chapter 4. These are achieved by using individual actuation for each
of the four chambers that constitute the heart by implementing linear motors. Each linear
motor consists of a stator and a slider accurately controlled by electromagnetic princi-
ples thus allowing accurate trace of the instantaneous location of the slider and therefore
precise emulation of contraction and filling phases as found in the native cardiac muscle.
6.1 The cardiovascular simulator
The multi-chamber SCVL can be classified into three main parts: (1) heart model; (2)
pulmonary and systemic circulations; and (3) control, measurement and monitoring sys-
tems. Fig. 6.1 shows the schematic representation of the multi-chamber SCVL system
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Figure 6.1. Diagrammatic representation of the SCVL. Ao: aorta artery; C: compliance; Ca: carotid artery; CT: celiac trunk; IVC: inferior vena cava; LA: left
































Figure 6.2. Schematic of the control system. AoP, aortic pressure; CAP, carotid artery pressure; DAQ,
data acquisition card; LA, left atrium; LV, left ventricle; PAP, pulmonary artery pressure; RA, right
atrium; RV, right ventricle.
6.1.1 Heart model
For modelling heart chambers, four rubber gaiters with proper sizes (left ventricle and
right ventricle with volume of 120 and 50 ml, respectively) are used to represent the
native heart chambers. Each chamber is connected to a separate linear motor. The well-
established time-varying elastance model introduced by Suga et al. [88] is used to indi-
vidually activate the four linear motors representing the ventricles and atria. Each linear
motor slider is displaced, according to the time-varying elastance model as described in
Eq. 2.5. The displacement of the linear motor representing the left ventricle function in a
single cardiac cycle is achieved according Eq. 2.6.
The model for the right ventricle is similar to that for the left ventricle, except the values of
parameters are different. The displacement of the linear motor representing the atrium in
a single cardiac cycle is achieved according to Eq. 2.7. The time parameters for the linear
motors are the same as previously implemented in the mathematical model described in
Chapter 2; see Table 2.2.
Four mechanical heart valves corresponding to mitral, pulmonary, tricuspid and aortic
are used in the vicinity of each chamber to control unidirectional flow. Additionally,
another mechanical valve is set at the end of vena cava before the right atrium to help
venous return and to prevent backflow of the working fluid. These five mechanical heart




6.1.2 Systemic and pulmonary circulation
Total systemic and pulmonary resistances are modelled by using adjustable resistors (Hoff-
man clips screw-type clamp). The level of resistance at various parts of the systemic and
pulmonary loops is manually set to mimic different physiological and pathological condi-
tions. The system compliance is modelled by using four air capacitors which consists of a
chamber partially filled with both water and compressed air, located one in the ascending
aorta, one in the pulmonary circulation, and two in the vena cava artery to control the
central venous pressure and venous return and consequently cardiac output (CO). These
compliance units are placed in parallel to their respective resistance units as seen in Fig.
6.1. The level of air pressure in each compliance chamber is adjusted via a sphygmo-
manometer for various physiological conditions. Any change in air pressure results in
changing the level of compliance in the system.
Systemic and pulmonary vasculatures are reproduced by using 24-mm diameter rubber
tubing. The aorta artery is made out of glass according to the anatomical features of
the average adult native system in a similar way to the study conducted by Pantalos et
al. [193], including: the ascending aorta; the aortic arch with the brachiocephalic trunk,
left common carotid artery, and left subclavian artery; thoracic aorta; abdominal aorta
with the celiac trunk and renal arteries; and common iliac arteries. This model of the
aorta artery was done with the intention of accurately distributing CO to the upper body,
heart, abdomen and lower body.
6.1.3 Control, measurement and monitoring systems
Four identical tubular permanent magnet linear motors (P01-37x120 LinMot, Spreiten-
bach, Switzerland) are used to drive the four chambers representing the heart. A con-
troller (E400 LinMot, Switzerland) with 4 channels is employed to accurately control
the position of the motors by independently controlling the displacement of each slider
according to a predefined time-varying elastance function. A high speed, high perfor-
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mance data acquisition card (DAQ) with four analogue outputs, 16 analogue inputs and
48 digital input/outputs (NI PXIe-6368 National Instrument, Budapest, Hungary) is used
to, firstly, send the desired displacement trajectories from the PC to the linear motor con-
troller and secondly to read the measurement signals from the pressure transducers and the
flow meter to the PC. The desired trajectory generation and monitoring tasks is achieved
via NI LabView software (National Instrument, Texas, USA). Four pressure transducers
(PMP1400 Druck General Electric Company Billerica, MA, USA) are used to simulta-
neously measure the pressures at aortic sinus, carotid, renal and pulmonary arteries. An
electromagnetic flowmeter (SITRANS F M MAG 1100 F Siemens, Munich, Germany) is
employed to measure the flowrate of the ascending aorta, carotid, renal and pulmonary
arteries. Fig. 6.2 shows the schematic of the control system.
6.2 Results
In this work, seven cases are studied: 1) control condition; 2) Class III HF; 3) Class IV
HF; 4) Class III HF with MCS at DAo; 5) Class IV HF with MCS at DAo; 6) Class III HF
with MCS at AAo; 7) Class IV HF with MCS at AAo. In each case, pressure and flow
time histories are simultaneously recorded at aortic sinus, carotid, renal and pulmonary ar-
teries together with CO measurement as these are the gold standards of cardiac condition
assessment [111]. In all seven cases, the experimental pressure waveforms are compared
to the numerical data. Peripheral resistance is measured at the aortic valve sinus as the
relationship between mean pressure and mean flow rate. All measured haemodynamic
variables are summarised in Table 6.1.
6.2.1 Statistical analyses
For each of the simulated cases, the system was run for 2 minutes prior to the recording of
the measured data. This was done with the purpose of allowing the system to settle down.
Next, the experimental data was recorded over a 3-minute period to allow for the data
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capture of at least 180 heart cycles per each simulated case. For the statistical analyses,
the first 150 heart cycles were processed. This strategy was implemented because the
system presents many systematic and random errors and so each cardiac cycle can be
considered as a new measurement. The sources of these errors were identified as follows:
1) the linear motors did not cope well with the early stages of the cardiac cycle given that
at these instances load is highest; 2) the rubber tubing used to model the blood vessels
were not fixed, hence, they continuously exhibited a jerky motion; 3) the glass material
used in the aorta model made the backward propagated waves travel faster generating
timing issues; 4) the prosthetic heart valves used to model the atrio-ventricular interface
never completely closed, this allowed for leakage to occur at the end of the systolic phase.
A moving-average filter was implemented to remove the spikes generated by the linear
motors at the beginning of the cardiac cycle and the random motion of the rubber tubing.
All processed data exhibited a normal distribution and was found to fall within the 95%
confidence limits. In all measured pressure waves the standard error is displayed with the
vertical bars. In Fig. 6.3-6.9, the mean pressure over 150 cycles is displayed. The mea-
sured waveforms are represented with solid lines, the numerical data with dashed-and-dot
lines and the filtered data with dotted lines. Frequency histograms are also provided for
all cases.
6.2.2 Simulated cases without MSC device
6.2.2.1 Case 1: Control condition
In this case the linear motors are operating at 66 bpm and the measured CO is 5.1 lt/min.
In Fig. 6.3a-h, it can be observed that the SCVL is able to capture the main physiological
features of the pressure waveforms as found in the native cardiovascular system, these
include: dicrotic notch due to valve closure, and a gradual decline of pressure to the
aortic diastolic pressure as seen in Fig. 6.3 (a); increased pulse pressure as the circulating
fluid moves away from the heart, as seen in Fig. 6.3 (e) and (g); diastolic pressure decay in
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all pressure waveforms, as seen in Fig. 6.3 (a), (c), (e) and (g). In general, the mean aortic
pressure (Pavs,mean) is 94 mmHg; mean carotid pressure (Pca,mean) is 94.41 mmHg, mean
renal pressure ((Pre,mean)) is 92.43 mmHg, mean pulmonary artery pressure (Ppvs,mean) is
18 mmHg.
6.2.2.2 Case 2: Class III HF
Class III HF, is considered as a mild to moderate HF condition and is commonly di-
vided into two further categories: left ventricular diastolic dysfunction (LVDD) and left
ventricular systolic dysfunction (LVSD). In this work LVVD was selected because in
most hypertensive patients there is co-existing impaired diastolic relaxation and therefore
impaired left ventricle diastolic filling [167, 194, 195]. In the clinical setting, hyperten-
sion is defined as a systolic blood pressure of 140 mmHg or greater and/or a diastolic
blood pressure of 90 mmHg or greater [196]. In most hypertensive patients there is co-
existing impaired diastolic relaxation and therefore impaired left ventricle diastolic filling
[167, 194, 195]. Zhou et al. [197], reported aortic stiffening as the main factor for devel-
oping increased left ventricle afterload and consequent left ventricle hypertrophy and left
ventricle dysfunction (LVD).
In order to mimic LVDD, aortic compliance is reduced, TPR is increased, left ventri-
cle elastance is reduced, and left ventricle resting volume is decreased. This is achieved
by decreasing displacement of the left ventricle actuator. The linear motors in this case
operate at 80 bpm.
In general, there is an increase in both the EDP and ESP at the aortic sinus and carotid
pressure waveforms, in comparison to the control condition, as seen in Fig. 6.4(a). Sim-
ilarly, Ppvs,mean has increased from the normal 18 mmHg to 28 mmHg; see Fig. 6.4(c).
Pavs is 140/100 mmHg and Pca is 142/96 mmHg; CO drops, from 5.1 lt/min in a control
condition, to 3.2 lt/min. The dicrotic notch due to valve closure can also be appreciated;
seen in Fig. 6.4(a).
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Figure 6.3. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during control condition. The standard error is displayed with the vertical bars. The time of
highest standard error is provided in the legend of each histogram.
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Figure 6.4. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during Class III HF.
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6.2.2.3 Case 3: Class IV HF
As previously introduced, a Class IV HF is an advanced form of HF; see Table 1.1; its
most common condition is congestive heart failure (CHF). This condition can be defined
as a heart that becomes severely weakened as a product of cardiovascular disease; mainly
myocardial infarction. As a consequence, the pumping action of the heart is severely
depressed resulting in two main effects: reduced CO and damming up of blood in the veins
leading to an increase in venous pressure and therefore increase in right atrial pressure
[6]. To reproduce a CHF condition, the circulating volume of water is increased; Elvmin
is increased in order to increase the resting left ventricle volume; Elvmax is decreased
by 50% of the normal value with the purpose of mimicking the reduced left ventricle
pumping ability. The linear motors in this case are operating at 60 bpm.
In general, CO is 2.6 lt/min while Pavs,mean is 85 mmHg. As it is evident in Fig. 6.5(a) and
(e), for both aortic sinus and carotid pressure waveforms there is a drop in EDP and ESP,
in comparison with the control condition. The pulmonary circulation by contrast, exhibits
hypertension where Ppvs,mean is 28.7 mmHg. Dicrotic notch due to valve closure can also
be appreciated; seen Fig. 6.5(a).
6.2.3 Simulated cases with MSC device
In the following cases the hydrodynamic impact of the MCS described in Chapter 5 is
investigated by measuring pressure, flow and resistance at the aortic sinus, carotid, re-
nal and pulmonary arteries. Implementing a MCS device in DAo produces pressure drop
upstream of the pump, that is in cerebral and upper limb circulations, and pressure rise
downstream of the pump, that is the splanchnic, renal and lower limb circulations. In par-
ticular, the pressure drop produced upstream of the MCS device unloads the left ventricle,
eventually improving cardiac output, whereas pressure rise produced downstream of the
MCS device results in increased blood perfusion rate in the abdominal organs, particu-
larly the liver and kidneys [198–200]. By contrast, the usage of a MSC device in AAo
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Figure 6.5. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during Class IV HF. The standard error is displayed with the vertical bars. The time of highest
standard error is provided in the legend of each histogram.
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generates pressure drop in the left ventricle and pressure rise in the cerebral, splanchnic,
renal and limbs vascular beds.
6.2.3.1 Case 4: Class III HF with MCS in DA
In Fig. 6.6 (a), it is observed that upon insertion of the MCS at DAo, the pathological
aortic sinus pressure waveform has returned to an acceptable level of 118/70 mmHg; and
the carotid pressure waveform, presented in Fig. 6.6 (e), has lowered to 120/66 mmHg. A
successful re-establishment in CO from 2.7 lt/min to 5.2 lt/min is also observed. Dicrotic
notch due to valve closure is less obvious than in the control condition due to the suction
generated upstream of the MCS device, as seen in Fig. 6.6 (a). As a general observation,
the pressure drop upstream of the MCS device alleviates the high arterial pressures in
aortic sinus and carotid artery. Similarly, in the pulmonary artery there is a decreased in
Ppvs,mean from 28 mmHg to 23 mmHg, as seen in Fig. 6.6(c). However, Pre,mean is elevated
from 114.3 mmHg to 137.8 mmHg indicating a potential risk for renal hypertension, as
seen in Fig. 6.6(g).
6.2.3.2 Case 5: Class IV HF with MCS in DA
In a similar fashion to Case 4, the MCS insertion at DAo unloaded the vascular beds
upstream of the pump and increased the perfusion in the renal loop as seen in Fig. 6.7(g).
Central pressure is within a normal-to-low value at 108/60 mmHg and CO is also within
a normal limit at 4.82 lt/min in comparison to 2.59 lt/min without MCS.
6.2.3.3 Case 6: Class III HF with MCS in AA
Upon insertion of the MCS in ascending aorta during Class III HF (see Fig. 6.8) it can be
observed an optimum LV unloading contrasted by an increased cerebral perfusion with
Pca,mean equal to 133.9 mmHg, hence, falling within the limits for adequately autoregu-
lated perfusion. In general, CO is 5.3 lt/min; Pavs,mean is 84.74 mmHg. As it is evident
from Fig. 6.5(a) and (e), for both the aortic sinus and carotid pressure waveforms there is
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Figure 6.6. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during CHF III upon insertion of MCS in the descending aorta. The standard error is displayed
with the vertical bars. The time of highest standard error is provided in the legend of each histogram.
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Figure 6.7. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during Class IV HF upon insertion of MCS in the descending aorta. The standard error is




a drop in EDP and ESP, in comparison with the control condition. The pulmonary circula-
tion, exhibits a decreased of mean pressure, Ppvs,mean, from 28.0 mmHg to 23.66 mmHg.
Dicrotic notch due to valve closure can not be well distinguished given that the aortic
valve remains partially opened during the diastolic phase; see Fig. 6.8(a).
6.2.3.4 Case 7: Class IV HF with MCS in AA
In a similar fashion to Case 6, the MCS insertion in AAo during Class IV HF unloaded
LV and increased perfusion to the remaining vascular beds, as seen in Fig. 6.9(a), (c),
(e) and (g). Central pressure is within a normal-to-low value at 108/62.4 mmHg and CO
is re-established to a normal value at 5.1 lt/min in comparison to the 2.59 lt/min without
MCS.
Table 6.1. Summary of hemodynamic variables for the all modelled cases.










HR 66.67 80.00 60.00 70.00 60.00 70.00 60.00 bmp
LVEDP 4.50 15.00 20.00 8.10 11.00 9.30 11.00 mmHg
LVESP 123.00 139.00 108.80 117.00 107.40 113.50 109.00 mmHg
Pavs,s 123.70 140.00 108.70 118.00 107.80 113.30 108.00 mmHg
Pavs,d 76.32 99.97 62.46 70.00 59.60 61.00 62.40 mmHg
AoPmean 94.00 119.40 84.49 89.44 81.74 84.74 84.32 mmHg
Central Pulse Pressure 47.38 40.03 46.24 48.00 48.20 52.30 45.60 mmHg
Pca,s 126.00 141.50 111.00 119.60 108.50 161.20 149.40 mmHg
Pca,d 74.16 95.02 60.72 65.90 55.80 114.70 102.80 mmHg
Pca,mean 94.41 116.50 82.05 85.42 78.94 133.90 122.70 mmHg
Pre,s 126.50 142.50 112.00 164.90 165.30 163.30 152.00 mmHg
Pre,d 71.53 93.87 56.56 123.30 118.40 112.00 99.00 mmHg
Pre,mean 92.43 114.30 79.79 137.80 136.40 131.20 118.30 mmHg
Ppvs,s 26.05 32.77 34.80 29.00 30.12 27.00 30.00 mmHg
Ppvs,d 10.82 24.12 24.32 17.65 15.67 17.79 16.00 mmHg
Ppvs,mean 18.00 28.08 28.60 22.96 23.15 23.66 23.15 mmHg
CO‡ 5.50 3.32 2.59 5.20 4.82 5.32 5.10 lt/min
TPR‡ 1.26 3.00 3.00 1.03 1.02 0.96 0.99 mmHg.s/ml
‡ Denotes a parameter calculated by using a correction factor of 0.22 given that water
is less viscous than blood.
6.3 Discussion
The results show the capability of the multi-chamber SCVL to reproduce the aortic sinus,
carotid, renal and pulmonary arteries pressure and flow waveforms in the control, Class
III HF and Class IV with and without MCS. Using four tubular permanent magnet linear
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Figure 6.8. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during Class III HF upon insertion of MCS in the ascending aorta. The standard error is






























































































































































































































Figure 6.9. Comparison of pressure and flow time histories in aortic, carotid, renal and pulmonary
arteries during Class IV HF upon insertion of MCS in the ascending aorta. The standard error is




motors, working according to prescribed elastance functions of the native ventricles and
atria shows the high success of this technique in emulating the contraction phase and
filling phases as found in the native cardiac muscle. A major downside in this work is the
implementation of water as the working fluid. Blood differs from water, amongst other
factors, by being more viscous, 4 mPa s in comparison with 0.89 mPa s, respectively.
Having such difference in viscosity implicated that higher resistances across the entire test
rig were necessary to achieve adequate pressure waveforms in all simulated conditions.
To compensate for this, a correction factor of 0.22 was implemented in the calculations of
TPR and CO; see Table 6.1.
From the statistical analyses, it can be can be observed that for the simulation cases with-
out the MCS device the greatest error occurs at the early stages of the cardiac cycle, that
is for T ranging between 0.08− 0.14 s; this coincides with the highest load or highest
systemic resistance encountered by the linear motor actuating the LV chamber. In the
cases with the MCS device, the uncertainties were attenuated at the early cardiac cycle
stages and the diastolic phase; this is because the MCS device relieves the load of the
linear motor actuating the LV chamber.
One important aspect captured by the SCVL is the augmented pressure at the late sys-
tolic phase of the AoPW for the HF simulations; this is due to the increased in systemic
resistance and the wave reflections from the periphery or arterial tree [168, 201]. The
augmented pulse pressure as the forward wave moves away from the heart is clearly cap-
tured by the system; this is, however, not captured by the mathematical model as it is only
a lumped parameter representation of the CV system where the arterial stiffness is not
accounted for. Finally, the delay between the feet of the aorta, carotid and renal arterial
pressures is also captured by the SCVL; see Fig. 6.10 for a schematic representation of
the progression of the pressure wave along the aortic tree. From this figure is it noticeable
that the onset of the systolic phase is delayed as the wave moves away from the heart.
Table 6.1 shows the haemodynamic variables as found with the multi-chamber SCVL.




Figure 6.10. Schematic representation of the progression of pressure wave along the aortic tree. A;
coronary arteries; B: Abdominal aorta at the level of the renal arteries; C: iliac artery. Adapted from
Safar et al. [201].
dangerous as it increases the perfusion of the cerebral vascular bed well above the control
values. In all simulated cases the dicrotic notch is captured in the aortic sinus and carotid
pressure waveforms although less notorious when the MCS device was inserted at DAo.
In comparison to the native pressure waveform, the dicrotic notch on the experimental
results seems slightly bigger, this is justified with the implementation of mechanical heart
valves as the pressure difference across these devices is higher than that found in the
native system [138]. The implementation of glass in the aorta section of the SCVL can be
accountable for the steeper rise of the pulse pressure as seen in all pressure waveforms;
this is because the stiffness of this material is far greater to what is found in the native
vasculature [168].
One of the crucial concerns of implanting a pump in descending aorta is that the per-
fusion pressure in the brain might be affected by the pressure drop generated upstream
the pump. Nevertheless, according to Guyton et al. [6] and different studies conducted
by Reitan et al. [198–200], in a native human cardiovascular system cerebral blood flow
is well autoregulated for a Pca,mean between 60-140 mmHg, that is, the local blood flow
feedback control provides enough blood perfusion within this limit. According to the ex-
perimental findings, upon insertion of MCS at DAo Pca,mean has a value of 85.42 mmHg
for Class III HF and 78.94 mmHg for Class IV HF, these values fit well within the range
of 60-140 mmHg therefore, the pressure drop in carotid artery will not impose perfusion
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disturbances in the brain. The pulmonary circulation also benefits from a MCS at DAo





The objectives set up in this work were well accomplished. As a result of the combination
of models and proper optimisation of the system parameters, predictions of pathophysi-
ological trends were successfully obtained; see Fig. 7.1 for diagrammatic representation
of the stages undertaken in this work. In the following sections the conclusion relevant to
the models implemented in this work are presented.
7.1.1 Mathematical model
Haemodynamic variables including pressures, flows and volumes were evaluated in the
four cardiovascular chambers. In general, the model followed physiological trends when
compared to cycle-averaged parameters but not so closely when compared to pressure
time histories along the aorta artery; however, the model is good enough for predicting
central artery pressures and flows which ultimately allowed the selection an adequate de-
sign point for the MCS device. Evaluation of central hemodynamic variables is essential
in the diagnosis and treatment of patients with suspected cardiovascular disease, such as
myocardial infarction and heart failure [111]. In clinical practice the conductance catheter
intervention continues to be the best technique for the evaluation of cardiac function, in-
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Figure 7.1. Flow chart representing the stages and processes undertaken during this work.
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cluding presure; volume and cardiac contractily [202]. However, this procedure has lim-
ited clinical applications due to its invasive nature and possible side effects [111, 202].
Imaging techniques such as MRI, although not invasive, tend to underestimate CO in non
physiological conditions [202]. Cardiovascular models have the potential to accurately
estimate patient specific cardiovascular function [112, 203].
Mathematical models of the human cardiovascular system continue to be relevant tools in
the estimation of haemodynamic properties that are almost impossible to measure in the
clinical settings. The implementation of GAs for tuning purposes increases the possibility
of creating more complex models. In the present model optimal values for the vessel
compliance of both systemic and pulmonary circulations were identified. These values
fit well a Gaussian distribution and can be used in future works as objective functions, or
geometric constraints, to implement a more sophisticated autoregulation system. In this
way, not only physiological conditions can be reproduced, but also diseased conditions,
and very importantly the use of cardiovascular supportive devices could be evaluated.
In the clinical setting, the gold standard of the cardiac condition assessment, mainly LV
contractility, is considered to be the dynamic PV loop analysis [202]. Unfortunately this
assessment is not routine in every day clinical practice due to its invasive nature and high
risk of complications. Clearly, a more dynamic non-invasive method is still missing in the
clinical setting and it will perhaps be through mathematical modelling that this could be
accomplished [111].
After several iterations, it was found that a pressure difference of 70 mmHg and a flow
rate of 5 lt/min produced the closest match to the imposed criteria of alleviating LV high
filling pressures, unloading LV and re-establishing a normal CO without compromising
cerebral perfusion. The inclusion of a volume reflex to the mathematical model, to ac-
count for the autoregulation of blood volume, played a crucial role in the adequate selec-
tion of the MCS device design point.
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7.1.2 In-vitro model
The multi-chamber SCVL implemented in this work successfully validated the numeri-
cal results. The present SCVL is a close-to-atmosphere system and includes models for
all four chambers as well as the systemic and pulmonary circulation loops. Using linear
motors for displacing individual heart chamber provides a satisfactory technique for em-
ulating different physiological and pathological conditions of the human cardiovascular
system. Although the system presented many random and systematic errors the mean
measurements predicted, closely enough, important haemodynamic variables.
The selected impeller provided effective circulatory support for Class III and IV HF con-
ditions displaying the capability of this approach for alleviating the high afterload pressure
in LV. In particular, it was found that placing the selected impeller at DAo can be more
beneficial for a Class III HF condition when compared to the AAo configuration, this is
because the mean carotid pressure was found to be elevated.
In general, the results show the capability of in-vitro model to replicate various physio-
logical and pathological conditions with and without an MCS device. Although in-vivo
testing is the ideal solution for investigating various MCS device performance, developing
more elaborate SCVL could be more cost effective and also could provide cardiologists
with reliable outcomes.
7.2 Further Work
Throughout the development of this work many limitations that could improve the accu-
racy of the results were identified. A summary of these items together with their suggested
pathway for improvement is provided below.
7.2.1 Mathematical model
The present mathematical model of CV system was developed with the intention of
mimicking several pathophysiological conditions and simulating short-term transient re-
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sponses to changes induced during the usage of MCS devices. The suggested pathway
would be to model cardiac and vascular functions at a molecular level so that more accu-
rate predictions of an MCS device performance in the short- and, most importantly, in the
long-term can be made. This should be coupled with a wave propagation model, for the
arterial tree mainly, with the intention of representing more adequately the early stages
of the systolic AoPW and the entirety of the diastolic portion of the AoPW. In this way,
patient-specific data can be input to the model with the main goal of optimising the MCS
device design and the surgical implantation site.
7.2.2 In-vitro model
In the present in-vitro model, the implementation of a glass made aorta meant that wave
propagations were occurring at a faster rate. One way to improve this difficulty would be
to implement a dynamic compliance unit. This system would be composed of a recipro-
cating piston mechanism and a silicone bellow; see Fig. 7.2. The piston would allow to
vary the compliance of the system while the silicone material, due to is elastic property,
would delay the fast propagating waves. The Dynamic Compliance model was built at
Queen Mary’s Workshop (see Fig.7.3) however, due to time constraints it was not possi-
ble to test it.
The tests performed with the MCS device were carried out in series with the heart and
although this proved beneficial it would be important to test a parallel configuration as
well. This is particularly important given that many of the commercial devices have a
LV-Apex-to-Aorta bypass configuration; see Table 1.3. The present model uses rubber
gaiters for heart chambers therefore, it is not possible to connect a MCS device to its non-
rigid walls. With this in mind, a diaphragm pump is recommended for further studies;
see Fig. 7.4. This system is composed of rigid walls and a rubber diaphragm. This
configuration would allow for the connection of MCS devices across the chamber’s rigid
walls. This model was built at Queen Mary’s Workshop (see Fig.7.5) however, due to
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7.2.3 The centrifugal pump
One of the main constraints of having selected an off-the-shelf centrifugal pump was
the inability to modify its volute; this in turn, limited the possibilities of investigating
many other impeller geometries. In future works, the impeller and the volute should
be purposely designed to fit the desirable operating condition. Similarly, the motor’s
angular speed was not controllable which in turn limited the geometry of the impeller.
It is therefore recommended to implement a motor controller that could also allow the
measurement of the current and voltage with the intention of calculating the efficiency of
the system.
Given that the wall shear stress should not exceed 150 Pa, greater attention should be
given to the design and testing of the impeller blades. In terms of testing, an optical
method for flow visualisation such as Particle Image Velocimetry coupled to a purposely
designed computer analysis program, for the compilation of the velocity data along a
boundary and its transformation into shear stress, should be implemented.
7.3 Published Work
The contents of Chapter 6 have been partially published in: In vitro cardiovascular sys-
tem emulator (bioreactor) for the simulation of normal and diseased conditions with and
without mechanical circulatory support. Paula Ruiz, Mohamand Amin Rezaienia, Ak-















Vcovb,0 100.000 110.000 110.000 120.000 115.000 115.000 115.000
Vcvb,0 450.000 605.000 605.000 660.000 632.500 632.500 632.500
Vsvb,0 1150.000 1320.000 1320.000 1440.000 1380.000 1380.000 1380.000
Vrvd,0 1000.000 1045.000 1045.000 1140.000 1092.500 1092.500 1092.500
Vp,0 550.000 605.000 605.000 660.000 632.500 632.500 632.500
Vulvb,0 400.000 440.000 440.000 480.000 460.000 460.000 460.000
Vllvb,0 500.000 550.000 550.000 600.000 575.000 575.000 575.000
Vsvc,0 100.000 110.000 110.000 120.000 115.000 115.000 115.000
Vivc,0 200.000 220.000 220.000 240.000 230.000 230.000 230.000
Vaorta,0 250.000 275.000 275.000 300.000 287.500 287.500 287.500
Vheart,0 380.000 330.000 330.000 360.000 345.000 345.000 345.000
Vlv0 152.000 132.000 132.000 144.000 138.000 138.000 138.000
Vla0 57.000 49.500 49.500 120.000 51.750 51.750 51.750
Vrv0 114.000 99.000 99.000 660.000 103.500 103.500 103.500
Vra0 57.000 49.500 49.500 49.500 51.750 51.750 51.750
T 0.830 0.750 0.750 1.00 0.660 0.750 0.750
HR 72.289 80.000 80.000 80.000 90.909 80.000 80.000
Ts1 0.273 0.260 0.260 0.260 0.244 0.260 0.260
Ts2 0.410 0.390 0.390 0.390 0.366 0.390 0.390
Tpwb 0.710 0.650 0.650 0.650 0.560 0.640 0.640
Tpww 0.830 0.750 0.750 0.750 0.660 0.750 0.750
Elvs 3.000 3.000 3.000 3.000 3.830 3.900 3.900
Elvd 0.100 1.500 1.500 1.500 2.000 1.900 1.900
Elamax 0.500 1.000 1.000 1.000 1.000 1.000 1.000
Elamin 0.250 0.500 0.500 0.500 0.500 0.500 0.500
Ervs 1.200 1.800 1.800 1.800 1.800 1.800 1.800
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Ervd 0.100 0.100 0.100 0.100 0.100 0.100 0.100
Eramax 0.500 1.000 1.000 1.000 1.000 1.000 1.000
Eramin 0.250 0.250 0.250 0.250 0.250 0.250 0.250
Plv,0 4.000 20.000 12.000 12.000 20.000 20.000 20.000
Pla,0 3.000 3.000 3.000 3.000 3.000 3.000 3.000
Prv,0 3.000 7.000 7.000 7.000 7.000 10.000 7.000
Pra,0 3.000 3.000 3.000 3.000 3.000 3.000 3.000
Pump AAo 0.000 0.000 70.000 0.000 0.000 70.000 0.000
Pump DAo 0.000 0.000 0.000 70.000 0.000 0.000 70.000
T_ref 0.830 0.750 0.750 1.000 0.660 0.750 0.750
Psyst_ref 90.000 90.000 90.000 90.00 90.000 90.000 90.000
Ppul_ref 8.000 8.000 8.000 8.000 8.000 8.000 4.000
G_co 0.035 0.035 0.035 0.035 0.035 0.035 0.035
CO_ref 5.000 5.000 5.000 0.250 5.000 5.000 5.000
G_gfr 1.000 2.000 2.000 2.000 2.000 2.000 2.000
Vra_ref 90.000 90.000 90.000 90.000 90.000 90.000 90.000
G_erv -0.005 -0.004 -0.004 -0.004 -0.004 -0.004 0.005
G_elv 0.010 0.010 0.010 0.010 0.010 0.010 0.010
G_eld 0.000 0.010 0.010 0.000 0.000 -0.010 0.010
G_r,sar 0.005 0.005 0.005 70.000 0.005 0.005 0.010
G_c,svn 0.050 0.050 0.050 0.750 0.050 0.100 0.100
G_r,par -0.005 -0.005 -0.005 -0.005 -0.005 -0.005 -0.005
G_c,pvn -0.050 -0.050 -0.050 -0.050 -0.050 -0.050 -0.050
Qsti 200.000 200.000 200.000 200.000 200.000 200.000 200.000
Qpti 0.180 0.180 0.180 0.180 0.180 0.180 0.180
Qdti 2.000 2.000 2.000 2.000 2.000 2.000 2.000
Qsmi 400.000 400.000 400.000 400.000 400.000 400.000 400.000
Qpmi 0.150 0.150 0.150 0.150 0.150 0.150 0.150
Qdmi 2.000 2.000 2.000 2.00 2.000 2.000 2.000
Qspo 800.000 800.000 800.000 800.000 800.000 800.000 800.000
Qppo 1.500 1.500 1.500 1.500 1.500 1.500 1.500
Qdpo 2.500 2.500 2.500 2.500 2.500 2.500 2.500
Qsao 900.000 900.000 900.000 900.000 900.000 900.000 900.000
Qpao 0.280 0.280 0.280 0.280 0.280 0.280 0.280
Qdao 1.000 1.000 1.000 1.000 1.000 1.000 1.000
Cavs 0.800 0.400 0.200 0.200 0.200 0.500 0.700
Carao 0.120 0.050 0.050 0.050 0.050 0.050 0.050
Ctao 0.120 0.025 0.025 0.025 0.025 0.025 0.025
Cuaao 0.120 0.025 0.025 0.025 0.025 0.025 0.025
Claao 0.120 0.025 0.025 0.025 0.025 0.025 0.025
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Ccoil 0.120 0.025 0.025 0.025 0.025 0.025 0.025
Lavs 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Larao 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Ltao 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Luaao 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Llaao 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Lcoil 0.000 0.000 0.000 1.000 0.000 0.000 0.000
Vavs,0 50.000 45.833 45.833 0.500 47.917 47.917 47.917
Varao,0 50.000 45.833 45.833 0.050 47.917 47.917 47.917
Vtao,0 50.000 45.833 45.833 0.025 47.917 47.917 47.917
Vuaao,0 50.000 45.833 45.833 0.025 47.917 47.917 47.917
Vlaao0 50.000 45.833 45.833 0.025 47.917 47.917 47.917
Vcoil0 50.000 45.833 45.833 0.025 47.917 47.917 47.917
Ravs 0.010 0.100 0.100 0.000 0.100 0.100 0.100
Rarao 0.000 0.010 0.010 0.000 0.010 0.010 0.003
Rtao 0.000 0.010 0.010 0.000 0.010 0.010 0.003
Ruaao 0.000 0.010 0.010 0.000 0.010 0.010 0.300
Rlaao 0.000 0.010 0.010 0.000 0.010 0.010 0.003
Rcoil 0.000 0.010 0.010 0.000 0.010 0.010 0.003
Qavs,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Qarao,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Qtao,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Quaao,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Qlaao,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Qcoil,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Csvc 31.820 31.820 31.820 31.820 31.820 31.820 31.820
Lsvc 0.000 0.000 0.000 0.000 0.000 0.000 0.000
Psvc,0 6.000 6.000 6.000 0.010 6.000 6.000 6.000
Rsvc 0.010 0.010 0.010 0.010 0.010 0.010 0.010
Qsvc,0 600.000 600.000 600.000 0.010 600.000 600.000 600.000
Civc 142.938 142.938 142.938 0.010 142.938 142.938 142.938
Livc 0.000 0.000 0.000 600.000 0.000 0.000 0.000
Pivc,0 6.000 6.000 6.000 600.000 6.000 6.000 6.000
Rivc 0.060 0.060 0.060 600.000 0.060 0.060 0.060
Qivc,0 600.000 600.000 600.000 600.000 600.000 600.000 600.000
Psat_covb,0 114.000 114.000 114.000 600.000 114.000 114.000 114.000
Psta_covb,0 108.000 108.000 108.000 600.000 108.000 108.000 108.000
Psar_covb,0 96.000 96.000 96.000 31.820 96.000 96.000 96.000
Pscp_covb,0 36.000 36.000 36.000 0.000 36.000 36.000 36.000
Psvl_covb,0 24.000 24.000 24.000 6.000 24.000 24.000 24.000
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Pssv_covb,0 18.000 18.000 18.000 0.010 18.000 18.000 18.000
Psvn_covb,0 12.000 12.000 12.000 600.000 12.000 12.000 12.000
Vsat_covb,0 10.530 11.583 11.583 142.938 12.110 12.110 12.110
Vsta_covb,0 4.680 5.148 5.148 0.000 5.382 5.382 5.382
Vsar_covb,0 4.680 5.148 5.148 6.000 5.382 5.382 5.382
Vscp_covb,0 3.510 3.861 3.861 0.060 4.037 4.037 4.037
Vsvl_covb,0 8.190 9.009 9.009 600.000 9.419 9.419 9.419
Vssv_covb,0 10.000 11.000 11.000 114.000 11.500 11.500 11.500
Vsvn_covb,0 48.400 53.240 53.240 108.000 55.660 55.660 55.660
Vcs,0 10.000 11.000 11.000 96.000 11.500 11.500 11.500
Csat_covb 0.012 0.007 0.007 36.000 0.007 0.007 0.007
Csta_covb 0.012 0.007 0.007 24.000 0.007 0.007 0.007
Csar_covb 0.012 0.007 0.007 18.000 0.007 0.007 0.007
Cscp_covb 0.012 0.007 0.007 12.000 0.007 0.007 0.007
Csvl_covb 0.019 0.011 0.011 12.636 0.011 0.011 0.011
Cssv_covb 1.640 0.957 0.957 5.616 0.957 0.957 0.957
Csvn_covb 6.012 3.507 3.507 5.616 3.507 3.507 3.507
Qsat_covb,0 577.751 577.751 577.751 4.212 577.751 577.751 577.751
Qsta_covb,0 200.277 200.277 200.277 9.828 200.277 200.277 200.277
Qsar_covb,0 100.000 100.000 100.000 12.000 100.000 100.000 100.000
Qscp_covb,0 200.277 200.277 200.277 58.080 200.277 200.277 200.277
Qsvl_covb,0 577.751 577.751 577.751 12.000 577.751 577.751 577.751
Qssv_covb,0 599.978 599.978 599.978 0.007 599.978 599.978 599.978
Qsvn_covb,0 600.000 600.000 600.000 0.007 600.000 600.000 600.000
Lsat_covb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsta_covb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsar_covb 0.000 0.000 0.000 0.011 0.000 0.000 0.000
Lscp_covb 0.000 0.000 0.000 0.957 0.000 0.000 0.000
Lsvl_covb 0.000 0.000 0.000 3.507 0.000 0.000 0.000
Lssv_covb 0.000 0.000 0.000 577.751 0.000 0.000 0.000
Lsvn_covb 0.000 0.000 0.000 200.277 0.000 0.000 0.000
Rsat_covb 1.392 3.555 3.087 100.000 3.227 3.227 3.423
Rsta_covb 4.100 10.474 9.096 200.277 9.509 9.509 10.085
Rsar_covb 6.000 15.327 13.310 577.751 13.915 13.915 14.758
Rscp_covb 4.100 10.474 9.096 599.978 9.509 9.509 10.085
Rsvl_covb 1.392 3.555 3.087 600.000 3.227 3.227 3.423
Rssv_covb 1.007 2.574 2.235 0.000 2.336 2.336 2.478
Rsvn_covb 1.000 2.555 2.218 0.000 2.319 2.319 2.460
Ccs 1.640 0.957 0.957 0.000 0.957 0.957 0.957
Lcs 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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Rcs 1.000 2.554 2.218 0.000 2.319 2.319 2.460
Pcs,0 12.000 12.000 12.000 0.000 12.000 12.000 12.000
Qcs,0 600.000 600.000 600.000 0.000 600.000 600.000 600.000
Psat_cvb,0 120.000 120.000 120.000 3.878 120.000 120.000 120.000
Psta_cvb,0 108.000 108.000 108.000 11.426 108.000 108.000 108.000
Psar_cvb,0 96.000 96.000 96.000 16.720 96.000 96.000 96.000
Pscp_cvb,0 36.000 36.000 36.000 11.426 36.000 36.000 36.000
Psvl_cvb,0 24.000 24.000 24.000 3.878 24.000 24.000 24.000
Pssv_cvb,0 18.000 18.000 18.000 2.807 18.000 18.000 18.000
Psvn_cvb,0 12.000 12.000 12.000 2.787 12.000 12.000 12.000
Vsat_cvb,0 47.385 63.707 63.707 0.957 66.602 66.602 66.602
Vsta_cvb,0 21.060 28.314 28.314 0.000 29.601 29.601 29.601
Vsar_cvb,0 21.060 28.314 28.314 2.787 29.601 29.601 29.601
Vscp_cvb,0 15.795 21.236 21.236 12.000 22.201 22.201 22.201
Vsvl_cvb,0 36.855 49.550 49.550 600.000 51.802 51.802 51.802
Vssv_cvb,0 92.160 123.904 123.904 120.000 129.536 129.536 129.536
Vsvn_cvb,0 215.685 289.977 289.977 108.000 303.157 303.157 303.157
Csat_cvb 0.012 0.007 0.007 36.000 0.007 0.007 0.007
Csta_cvb 0.012 0.007 0.007 24.000 0.007 0.007 0.007
Csar_cvb 0.012 0.007 0.007 18.000 0.007 0.007 0.007
Cscp_cvb 0.012 0.007 0.007 12.000 0.007 0.007 0.007
Csvl_cvb 0.067 0.039 0.049 69.498 0.049 0.049 0.049
Cssv_cvb 12.221 7.129 9.503 30.888 9.503 9.503 9.503
Csvn_cvb 45.012 26.257 35.007 30.888 35.007 35.007 35.007
Qsat_cvb,0 389.988 577.751 577.751 23.166 577.751 577.751 577.751
Qsta_cvb,0 171.632 200.277 200.277 54.054 200.277 200.277 200.277
Qsar_cvb,0 92.308 100.000 100.000 135.168 100.000 100.000 100.000
Qscp_cvb,0 171.632 200.277 200.277 316.338 200.277 200.277 200.277
Qsvl_cvb,0 389.988 577.751 577.751 12.000 577.751 577.751 577.751
Qssv_cvb,0 399.990 599.978 599.978 0.007 599.978 599.978 599.978
Qsvn_cvb,0 400.000 600.000 600.000 0.007 600.000 600.000 600.000
Lsat_cvb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsta_cvb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsar_cvb 0.000 0.000 0.000 0.049 0.000 0.000 0.000
Lscp_cvb 0.000 0.000 0.000 9.503 0.000 0.000 0.000
Lsvl_cvb 0.000 0.000 0.000 35.007 0.000 0.000 0.000
Lssv_cvb 0.000 0.000 0.000 577.751 0.000 0.000 0.000
Lsvn_cvb 0.000 0.000 0.000 200.277 0.000 0.000 0.000
Rsat_cvb 0.374 0.781 0.633 100.000 0.656 0.656 0.752
Rsta_cvb 1.036 2.164 1.527 200.277 1.550 1.550 2.084
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Rsar_cvb 1.500 3.135 2.154 577.751 2.177 2.177 3.019
Rscp_cvb 1.036 2.164 1.527 599.978 1.550 1.550 2.084
Rsvl_cvb 0.374 0.781 0.633 600.000 0.656 0.656 0.752
Rssv_cvb 0.280 0.584 0.507 0.000 0.530 0.530 0.563
Rsvn_cvb 0.278 0.581 0.504 0.000 0.527 0.527 0.559
Psat_ulvb,0 114.000 114.000 114.000 0.000 114.000 114.000 114.000
Psta_ulvb,0 108.000 108.000 108.000 0.000 108.000 108.000 108.000
Psar_ulvb,0 96.000 96.000 96.000 0.000 96.000 96.000 96.000
Pscp_ulvb,0 36.000 36.000 36.000 0.000 36.000 36.000 36.000
Psvl_ulvb,0 24.000 24.000 24.000 0.000 24.000 24.000 24.000
Pssv_ulvb,0 18.000 18.000 18.000 0.852 18.000 18.000 18.000
Psvn_ulvb,0 12.000 12.000 12.000 2.361 12.000 12.000 12.000
Vsat_ulvb,0 42.120 46.332 46.332 3.420 48.438 48.438 48.438
Vsta_ulvb,0 18.720 20.592 20.592 2.361 21.528 21.528 21.528
Vsar_ulvb,0 18.720 20.592 20.592 0.852 21.528 21.528 21.528
Vscp_ulvb,0 14.040 15.444 15.444 0.637 16.146 16.146 16.146
Vsvl_ulvb,0 32.760 36.036 36.036 0.633 37.674 37.674 37.674
Vssv_ulvb,0 81.920 90.112 90.112 114.000 94.208 94.208 94.208
Vsvn_ulvb,0 191.720 210.892 210.892 108.000 220.478 220.478 220.478
Csat_ulvb 0.012 0.007 0.007 36.000 0.007 0.007 0.007
Csta_ulvb 0.012 0.007 0.007 24.000 0.007 0.007 0.007
Csar_ulvb 0.012 0.007 0.007 18.000 0.007 0.007 0.007
Cscp_ulvb 0.012 0.007 0.007 12.000 0.007 0.007 0.007
Csvl_ulvb 0.041 0.024 0.024 50.544 0.024 0.024 0.024
Cssv_ulvb 6.523 3.805 3.805 22.464 3.805 3.805 3.805
Csvn_ulvb 24.012 14.007 14.007 22.464 14.007 14.007 14.007
Qsat_ulvb,0 577.751 577.751 577.751 16.848 577.751 577.751 577.751
Qsta_ulvb,0 200.277 200.277 200.277 39.312 200.277 200.277 200.277
Qsar_ulvb,0 100.000 100.000 100.000 98.304 100.000 100.000 100.000
Qscp_ulvb,0 200.277 200.277 200.277 230.064 200.277 200.277 200.277
Qsvl_ulvb,0 577.751 577.751 577.751 12.000 577.751 577.751 577.751
Qssv_ulvb,0 599.978 599.978 599.978 0.007 599.978 599.978 599.978
Qsvn_ulvb,0 600.000 600.000 600.000 0.007 600.000 600.000 600.000
Lsat_ulvb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsta_ulvb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsar_ulvb 0.000 0.000 0.000 0.024 0.000 0.000 0.000
Lscp_ulvb 0.000 0.000 0.000 3.805 0.000 0.000 0.000
Lsvl_ulvb 0.000 0.000 0.000 14.007 0.000 0.000 0.000
Lssv_ulvb 0.000 0.000 0.000 577.751 0.000 0.000 0.000
Lsvn_ulvb 0.000 0.000 0.000 200.277 0.000 0.000 0.000
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Rsat_ulvb 1.237 2.585 2.245 100.000 2.347 2.347 2.490
Rsta_ulvb 3.645 7.617 6.615 200.277 6.916 6.916 7.335
Rsar_ulvb 5.333 11.147 9.680 577.751 10.120 10.120 10.733
Rscp_ulvb 3.645 7.617 6.615 599.978 6.916 6.916 7.335
Rsvl_ulvb 1.237 2.585 2.245 600.000 2.347 2.347 2.490
Rssv_ulvb 0.896 1.872 1.625 0.000 1.699 1.699 1.802
Rsvn_ulvb 0.889 1.858 1.613 0.000 1.687 1.687 1.789
Psat_svb,0 114.000 114.000 114.000 0.000 114.000 114.000 114.000
Psta_svb,0 108.000 108.000 108.000 0.000 108.000 108.000 108.000
Psar_svb,0 96.000 96.000 96.000 0.000 96.000 96.000 96.000
Pscp_svb,0 36.000 36.000 36.000 0.000 36.000 36.000 36.000
Psvl_svb,0 24.000 24.000 24.000 0.000 24.000 24.000 24.000
Pssv_svb,0 18.000 18.000 18.000 2.820 18.000 18.000 18.000
Psvn_svb,0 12.000 12.000 12.000 8.310 12.000 12.000 12.000
Vsat_svb,0 121.095 138.996 138.996 12.160 145.314 145.314 145.314
Vsta_svb,0 53.820 61.776 61.776 8.310 64.584 64.584 64.584
Vsar_svb,0 53.820 61.776 61.776 2.820 64.584 64.584 64.584
Vscp_svb,0 40.365 46.332 46.332 2.042 48.438 48.438 48.438
Vsvl_svb,0 94.185 108.108 108.108 2.027 113.022 113.022 113.022
Vssv_svb,0 235.520 270.336 270.336 114.000 282.624 282.624 282.624
Vsvn_svb,0 551.195 632.676 632.676 108.000 661.434 661.434 661.434
Csat_svb 0.012 0.007 0.007 36.000 0.007 0.007 0.007
Csta_svb 0.012 0.007 0.007 24.000 0.007 0.007 0.007
Csar_svb 0.012 0.007 0.007 18.000 0.007 0.007 0.007
Cscp_svb 0.012 0.007 0.007 12.000 0.007 0.007 0.007
Csvl_svb 0.121 0.071 0.071 151.632 0.071 0.071 0.071
Cssv_svb 24.430 14.251 14.251 67.392 14.251 14.251 14.251
Csvn_svb 90.012 52.507 52.507 67.392 52.507 52.507 52.507
Qsat_svb,0 577.751 577.751 577.751 50.544 577.751 577.751 577.751
Qsta_svb,0 200.277 200.277 200.277 117.936 200.277 200.277 200.277
Qsar_svb,0 100.000 100.000 100.000 294.912 100.000 100.000 100.000
Qscp_svb,0 200.277 200.277 200.277 690.192 200.277 200.277 200.277
Qsvl_svb,0 577.751 577.751 577.751 12.000 577.751 577.751 577.751
Qssv_svb,0 599.978 599.978 599.978 0.007 599.978 599.978 599.978
Qsvn_svb,0 600.000 600.000 600.000 0.007 600.000 600.000 600.000
Lsat_svb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsta_svb 0.000 0.000 0.000 0.007 0.000 0.000 0.000
Lsar_svb 0.000 0.000 0.000 0.071 0.000 0.000 0.000
Lscp_svb 0.000 0.000 0.000 14.251 0.000 0.000 0.000
Lsvl_svb 0.000 0.000 0.000 52.507 0.000 0.000 0.000
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Lssv_svb 0.000 0.000 0.000 577.751 0.000 0.000 0.000
Lsvn_svb 0.000 0.000 0.000 200.277 0.000 0.000 0.000
Rsat_svb 0.285 0.584 0.507 100.000 0.525 0.525 0.557
Rsta_svb 0.718 1.407 1.222 200.277 1.240 1.240 1.315
Rsar_svb 1.022 1.984 1.723 577.751 1.742 1.742 1.847
Rscp_svb 0.718 1.407 1.222 599.978 1.240 1.240 1.315
Rsvl_svb 0.285 0.584 0.507 600.000 0.525 0.525 0.557
Rssv_svb 0.223 0.467 0.405 0.000 0.424 0.424 0.449
Rsvn_svb 0.222 0.464 0.403 0.000 0.422 0.422 0.447
Psat_rvd,0 114.000 114.000 114.000 0.000 114.000 114.000 114.000
Psta_rvd,0 108.000 108.000 108.000 0.000 108.000 108.000 108.000
Psar_rvd,0 96.000 96.000 96.000 0.000 96.000 96.000 96.000
Pscp_rvd,0 36.000 36.000 36.000 0.000 36.000 36.000 36.000
Psvl_rvd,0 24.000 24.000 24.000 0.000 24.000 24.000 24.000
Pssv_rvd,0 18.000 18.000 18.000 0.626 18.000 18.000 18.000
Psvn_rvd,0 12.000 12.000 12.000 1.449 12.000 12.000 12.000
Vsat_rvd,0 105.300 110.039 110.039 2.027 115.040 115.040 115.040
Vsta_rvd,0 46.800 48.906 48.906 1.449 51.129 51.129 51.129
Vsar_rvd,0 46.800 48.906 48.906 0.626 51.129 51.129 51.129
Vscp_rvd,0 35.100 36.680 36.680 0.509 38.347 38.347 38.347
Vsvl_rvd,0 81.900 85.586 85.586 0.507 89.476 89.476 89.476
Vssv_rvd,0 204.800 214.016 214.016 114.000 223.744 223.744 223.744
Vsvn_rvd,0 479.300 500.869 500.869 108.000 523.635 523.635 523.635
Csat_rvd 0.003 0.002 0.002 36.000 0.002 0.002 0.002
Csta_rvd 0.003 0.002 0.002 24.000 0.002 0.002 0.002
Csar_rvd 0.003 0.002 0.002 18.000 0.002 0.002 0.002
Cscp_rvd 0.003 0.002 0.002 12.000 0.002 0.002 0.002
Csvl_rvd 0.090 0.053 0.053 120.042 0.053 0.053 0.053
Cssv_rvd 19.537 11.397 11.397 53.352 11.397 11.397 11.397
Csvn_rvd 72.003 42.002 42.002 53.352 42.002 42.002 42.002
Qsat_rvd,0 577.751 577.751 577.751 40.014 577.751 577.751 577.751
Qsta_rvd,0 200.277 200.277 200.277 93.366 200.277 200.277 200.277
Qsar_rvd,0 100.000 100.000 100.000 233.472 100.000 100.000 100.000
Qscp_rvd,0 200.277 200.277 200.277 546.402 200.277 200.277 200.277
Qsvl_rvd,0 577.751 577.751 577.751 12.000 577.751 577.751 577.751
Qssv_rvd,0 599.978 599.978 599.978 0.002 599.978 599.978 599.978
Qsvn_rvd,0 600.000 600.000 600.000 0.002 600.000 600.000 600.000
Lsat_rvd 0.000 0.000 0.000 0.002 0.000 0.000 0.000
Lsta_rvd 0.000 0.000 0.000 0.002 0.000 0.000 0.000
Lsar_rvd 0.000 0.000 0.000 0.053 0.000 0.000 0.000
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Lscp_rvd 0.000 0.000 0.000 11.397 0.000 0.000 0.000
Lsvl_rvd 0.000 0.000 0.000 42.002 0.000 0.000 0.000
Lssv_rvd 0.000 0.000 0.000 577.751 0.000 0.000 0.000
Lsvn_rvd 0.000 0.000 0.000 200.277 0.000 0.000 0.000
Rsat_rvd 0.356 0.729 0.561 100.000 0.587 0.587 0.696
Rsta_rvd 0.898 1.759 1.654 200.277 1.729 1.729 1.644
Rsar_rvd 1.278 2.481 2.420 577.751 2.530 2.530 2.309
Rscp_rvd 0.898 1.759 1.654 599.978 1.729 1.729 1.644
Rsvl_rvd 0.356 0.729 0.561 600.000 0.587 0.587 0.696
Rssv_rvd 0.279 0.583 0.406 0.000 0.425 0.425 0.562
Rsvn_rvd 0.278 0.581 0.403 0.000 0.422 0.422 0.559
Psat_llvb,0 114.000 114.000 114.000 0.000 114.000 114.000 114.000
Psta_llvb,0 108.000 108.000 108.000 0.000 108.000 108.000 108.000
Psar_llvb,0 96.000 96.000 96.000 0.000 96.000 96.000 96.000
Pscp_llvb,0 36.000 36.000 36.000 0.000 36.000 36.000 36.000
Psvl_llvb,0 24.000 24.000 24.000 0.000 24.000 24.000 24.000
Pssv_llvb,0 18.000 18.000 18.000 0.782 18.000 18.000 18.000
Psvn_llvb,0 12.000 12.000 12.000 1.811 12.000 12.000 12.000
Vsat_llvb,0 52.650 57.915 57.915 2.533 60.548 60.548 60.548
Vsta_llvb,0 23.400 25.740 25.740 1.811 26.910 26.910 26.910
Vsar_llvb,0 23.400 25.740 25.740 0.782 26.910 26.910 26.910
Vscp_llvb,0 17.550 19.305 19.305 0.636 20.183 20.183 20.183
Vsvl_llvb,0 40.950 45.045 45.045 0.633 47.093 47.093 47.093
Vssv_llvb,0 102.400 112.640 112.640 114.000 117.760 117.760 117.760
Vsvn_llvb,0 239.650 263.615 263.615 108.000 275.598 275.598 275.598
Csat_llvb 0.001 0.001 0.001 36.000 0.001 0.001 0.001
Csta_llvb 0.001 0.001 0.001 24.000 0.001 0.001 0.001
Csar_llvb 0.001 0.001 0.001 18.000 0.001 0.001 0.001
Cscp_llvb 0.001 0.001 0.001 12.000 0.001 0.001 0.001
Csvl_llvb 0.038 0.022 0.022 63.180 0.022 0.022 0.022
Cssv_llvb 8.141 4.749 4.749 28.080 4.749 4.749 4.749
Csvn_llvb 30.001 17.501 17.501 28.080 17.501 17.501 17.501
Qsat_llvb,0 577.751 577.751 577.751 21.060 577.751 577.751 577.751
Qsta_llvb,0 200.277 200.277 200.277 49.140 200.277 200.277 200.277
Qsar_llvb,0 100.000 100.000 100.000 122.880 100.000 100.000 100.000
Qscp_llvb,0 200.277 200.277 200.277 287.580 200.277 200.277 200.277
Qsvl_llvb,0 577.751 577.751 577.751 12.000 577.751 577.751 577.751
Qssv_llvb,0 599.978 599.978 599.978 0.001 599.978 599.978 599.978
Qsvn_llvb,0 600.000 600.000 600.000 0.001 600.000 600.000 600.000
Lsat_llvb 0.000 0.000 0.000 0.001 0.000 0.000 0.000
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Lsta_llvb 0.000 0.000 0.000 0.001 0.000 0.000 0.000
Lsar_llvb 0.000 0.000 0.000 0.022 0.000 0.000 0.000
Lscp_llvb 0.000 0.000 0.000 4.749 0.000 0.000 0.000
Lsvl_llvb 0.000 0.000 0.000 17.501 0.000 0.000 0.000
Lssv_llvb 0.000 0.000 0.000 577.751 0.000 0.000 0.000
Lsvn_llvb 0.000 0.000 0.000 200.277 0.000 0.000 0.000
Rsat_llvb 1.546 3.232 2.807 100.000 2.934 2.934 3.112
Rsta_llvb 4.556 9.522 8.269 200.277 8.645 8.645 9.169
Rsar_llvb 6.667 13.933 12.100 577.751 12.650 12.650 13.417
Rscp_llvb 4.556 9.522 8.269 599.978 8.645 8.645 9.169
Rsvl_llvb 1.546 3.232 2.807 600.000 2.934 2.934 3.112
Rssv_llvb 1.119 2.340 2.032 0.000 2.124 2.124 2.253
Rsvn_llvb 1.111 2.322 2.017 0.000 2.108 2.108 2.236
Cpvs 1.200 1.200 1.200 0.000 1.200 1.200 1.200
Cpat 1.200 1.200 1.200 0.000 1.200 1.200 1.200
Cpta 1.200 1.200 1.200 0.000 1.200 1.200 1.200
Cpar 1.200 1.200 1.200 0.000 1.200 1.200 1.200
Cpcp 1.200 1.200 1.200 0.000 1.200 1.200 1.200
Cpvl 1.546 1.546 1.546 3.526 1.546 1.546 1.546
Cpsv 25.276 25.276 25.276 10.387 25.276 25.276 25.276
Cpvn 66.200 66.200 66.200 15.200 66.200 66.200 66.200
Cpvn 25.276 25.276 25.276 10.387 25.276 25.276 25.276
Lpvs 0.000 0.000 0.000 3.526 0.000 0.000 0.000
Lpat 0.000 0.000 0.000 2.552 0.000 0.000 0.000
Lpta 0.000 0.000 0.000 2.533 0.000 0.000 0.000
Lpar 0.001 0.001 0.001 1.200 0.001 0.001 0.001
Lpcp 0.005 0.005 0.005 1.200 0.005 0.005 0.005
Lpvl 0.001 0.001 0.001 1.200 0.001 0.001 0.001
Lpsv 0.000 0.000 0.000 1.200 0.000 0.000 0.000
Lpvn 0.000 0.000 0.000 1.200 0.000 0.000 0.000
Lpvn 0.000 0.000 0.000 1.546 0.000 0.000 0.000
Rpvs 0.002 0.002 0.002 25.276 0.002 0.002 0.002
Rpat 0.002 0.002 0.002 66.200 0.002 0.002 0.002
Rpta 0.032 0.032 0.032 25.276 0.032 0.032 0.032
Rpar 0.127 0.127 0.127 0.000 0.127 0.127 0.127
Rpcp 0.032 0.032 0.032 0.000 0.032 0.032 0.032
Rpvl 0.002 0.002 0.002 0.000 0.002 0.002 0.002
Rpsv 0.002 0.002 0.002 0.001 0.002 0.002 0.002
Rpvn 0.002 0.002 0.002 0.005 0.002 0.002 0.002
Rpvn 0.002 0.002 0.002 0.001 0.002 0.002 0.002
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Ppvs,0 25.000 25.000 25.000 0.000 25.000 25.000 25.000
Ppat,0 22.915 22.915 22.915 0.000 22.915 22.915 22.915
Ppta,0 16.665 16.665 16.665 0.000 16.665 16.665 16.665
Ppar,0 8.333 8.333 8.333 0.002 8.333 8.333 8.333
Ppcp,0 5.208 5.208 5.208 0.002 5.208 5.208 5.208
Ppvl,0 2.083 2.083 2.083 0.032 2.083 2.083 2.083
Ppsv,0 1.043 1.043 1.043 0.127 1.043 1.043 1.043
Ppvn,0 0.625 0.625 0.625 0.032 0.625 0.625 0.625
Ppvn,0 0.415 0.415 0.415 0.002 0.415 0.415 0.415
Qpvs,0 600.000 600.000 600.000 0.002 600.000 600.000 600.000
Qpat,0 550.000 550.000 550.000 0.002 550.000 550.000 550.000
Qpta,0 400.000 400.000 400.000 0.002 400.000 400.000 400.000
Qpar,0 200.000 200.000 200.000 25.000 200.000 200.000 200.000
Qpcp,0 125.000 125.000 125.000 22.915 125.000 125.000 125.000
Qpvl,0 50.000 50.000 50.000 16.665 50.000 50.000 50.000
Qpsv,0 25.000 25.000 25.000 8.333 25.000 25.000 25.000
Qpvn,0 15.000 15.000 15.000 5.208 15.000 15.000 15.000
Qpvn,0 10.000 10.000 10.000 2.083 10.000 10.000 10.000
Vpvs,0 9.680 10.648 10.648 1.043 11.132 11.132 11.132
Vpat,0 57.915 63.707 63.707 0.625 66.602 66.602 66.602
Vpta,0 25.740 28.314 28.314 0.415 29.601 29.601 29.601
Vpar,0 25.740 28.314 28.314 600.000 29.601 29.601 29.601
Vpcp,0 19.305 21.236 21.236 550.000 22.201 22.201 22.201
Vpvl,0 45.045 49.550 49.550 400.000 51.802 51.802 51.802
Vpsv,0 77.220 84.942 84.942 200.000 88.803 88.803 88.803
Vpvn,0 263.615 289.977 289.977 125.000 303.157 303.157 303.157
Vpvn,0 25.740 28.314 28.314 50.000 29.601 29.601 29.601
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%% ************ Plot Meridional Profile created with ellipses and ...
bezier curves *******



















































% title('Blade Meridional Profile')
print('−depsc','−r600','Mprofile')




































































print('−deps','−r600','bladeloft')%Use for black and white figure
% print('−depsc','−r600','bladeloft')

















surf(x_fpshaft,y_fpshaft,z_fpshaft,'FaceColor',[1 1 1]);%flow passage
surf(x_tdiff,y_tdiff,z_tdiff,'FaceColor',[1 1 1]);%flow passage
surf(x_tout,y_tout,z_tout,'FaceColor',[1 1 1]);%flow passage
surf(x_bout,y_bout,z_bout,'FaceColor',[1 1 1]);%flow passage
surf(x_bdiff,y_bdiff,z_bdiff,'FaceColor',[1 1 1]);%flow passage
surf(x_hub,y_hub,z_hub,'FaceColor',[1 1 1]);%flow passage
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% print('−deps','−r600','flowpath')%Use for black and white figure
% print('−depsc','−r600','flowpath')%Use for color figure




% ********************** Results **********************************
fprintf(' ______________________________Table. Summary of ...
calculated pump parameters _________________________________\n')
fprintf(' ...
______________________________________________________________________________








fprintf(' Rotational speed rpm ...
%0.2f rev/min\n',N)
fprintf(' Pressure difference DP ...
%0.2f Pa\n',DP)
fprintf(' Static head H ...
%0.2f m\n',H)
fprintf(' Hub diameter D,h ...
%0.2f mm\n',R_span(1,1)*2)
fprintf(' Tip diameter D,t ...
%0.2f mm\n',R_span(1,5)*2)
fprintf(' Exit diameter D2 ...
%0.2f mm\n',R2*2000)
fprintf(' Inlet blade angle at hub B1,h ...
%0.2f degree\n',−beta1(1))
fprintf(' Inlet blade angle at span 2 B1,s02 ...
%0.2f degree\n',−beta1(2))
fprintf(' Inlet blade angle at span 3 B1,s03 ...
%0.2f degree\n',−beta1(3))
fprintf(' Inlet blade angle at span 4 B1,s04 ...
%0.2f degree\n',−beta1(4))
fprintf(' Inlet blade angle at tip B1,t ...
%0.2f degree\n',−beta1(5))
fprintf(' Mean inlet blade angle B1,mean ...
%0.2f degree\n',mean(beta1)*−1)
fprintf(' Exit blade angle B2 ...
%0.2f degree\n',−beta2)
fprintf(' Inlet area A1 ...
%32f m^2\n',iarea)
fprintf(' Exit area A2 ...
%3f m^2\n',oarea)
fprintf(' Inlet width b1 ...
%0.2f mm\n',b1*1000)













dp=60; % Pressure difference in mmHg
DP=dp*1.01325e5/760; % Pressure difference in Pascal [kg/m.s^2]
rho=1060; % water density [kg/m^3]
g=9.81; % [m/s^2]
H=DP/(rho*g); % Head [m]
q=5; % Volume flow rate in lt/min
Q=q/(1000*60); % Volume flow rate in m^3/s
mdot=Q*rho; % mass flow rate in kg/s
N=1500; % Rotational speed in rpm
w=N*2*pi/60; % Rotational speed in rad/s
z=5; % Number of blade sets. Note: value...
% obtained heuristically using CFX
D2=30e−3; % Exit diameter in meter
U2=w*D2/2; % exit speed in m/s





eta=0.8; % Target efficiency
psi=(g*H)/(eta*U2^2); % Head coefficient
phi=psi/tand(85.24); % flow coefficient
% phi=0.042; % flow coefficient
bb2=(Q/(pi*D2*U2*phi)); % exit blade width
%% ************ Impeller dimensions *****************
sftrad=3.5e−3; % shaft radius
shrad=9.5e−3; % shroud radius
b1=shrad−sftrad; % blade width at LE
R2=D2/2; % impeller exit radius
IH=12.6e−3; % impeller height
b2=−bb2; % blade width at TE
b3=−3.5e−3; % flow passage exit height
LEsw=b1/4; % LE span width
TEsw=b2/4; % TE span width
%% ************ Calculate Meridional profile of the Blade with ...
ellipse ************



























































































%% Inlet Angle: 1. Calculate individual flow channels' width, where ...
the number of flow
% channels is Nspan−1.
















% If the leading edge (LE) is oblique D1 varies in different flow lines






















%% ****** Blade meridional profile in meridional coordinate ...
definiton *********












% Cubic bezier curve with 4 control points P0,P1,P2,P3
t=linspace(0,1,100); % linearly space parameterization
profile=zeros(length(t),2); % Size preallocation
for k=1:length(t)%120 points
profile(k,:)=(−P0 + 3*(P1−P2) + P3)*t(k).^3 + ...


















%% ***** Coordinate transformation (Cartesian definition):
%**************** Construction of LE ellipse ************
NpLE=10; %Length ratio of LE's ellipse
%size allocation


















































































































































%% FP: Flow Path construction from span 01 and 05 based on Z=11 ...
blades FPOA=360/Z




















%% **************** Construction of Flow Path Inlet and Outlet ...
diffusers ************
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179
BIBLIOGRAPHY
D. A. Cooley, “Improved survival after extended bridge to cardiac transplantation,”
The Annals of thoracic surgery, vol. 57, pp. 1416 – 1422, 1994. 15
[42] S. A. Hunt, O. H. Frazier, and T. J. Myers, “Mechanical circulatory support and
cardiac transplantation,” Circulation, vol. 97, no. 20, pp. 2079–2090, 1998. x, 15,
18, 19, 20, 27, 28
[43] M. E. DeBakey, “Development of mechanical heart devices,” The Annals of Tho-
racic Surgery, vol. 79, no. 6, pp. S2228 – S2231, 2005. 15, 16
[44] S. D. Moulopoulos, “Intra-aortic balloon counterpulsation 50 years later: Initial
conception and consequent ideas,” Artificial Organs, vol. 35, no. 9, pp. 843–848,
2011. 16
[45] D. A. Cooley, D. Liotta, G. L. Hallman, R. D. Bloodwell, R. D. Leachman, and
J. D. Milam, “Orthotopic cardiac prosthesis for two-staged cardiac replacement,”
The American Journal of Cardiology, vol. 24, no. 5, pp. 723 – 730, 1969. 16
[46] J. Norman, D. Cooley, B. Kahan, A. Keats, E. Massin, R. Solis, W. Luper,
M. Brook, T. Klima, O. Frazier, J. Hacker, J. Duncan, C. Dacso, D. Winston, and
G. Reul, “Total support of the circulation of a patient with post-cardiotomy stone-
heart syndrome by a partial artificial heart (ALVAD) for 5 days followed by heart
and kidney transplantation,” The Lancet, vol. 311, no. 8074, pp. 1125 – 1127, 1978.
16
[47] J. Norman, J. Fuqua, R. Trono, C. Hibbs, C. Edmonds, S. Igo, M. Brewer,
D. Holub, and D. Cooley, “An intracorporeal (abdominal) left ventricular assist
device: Initial clinical trials (LX),” in Assisted Circulation (F. Unger, ed.), pp. 107–
126, Springer Berlin Heidelberg, 1979. 16
[48] Y. Nosé, M. Yoshikawa, S. Murabayashi, and T. Takano, “Development of rotary
blood pump technology: Past, present, and future,” Artificial Organs, vol. 24, no. 6,
pp. 412–420, 2000. 16
180
BIBLIOGRAPHY
[49] K. E. Johnson, M. B. Liska, L. D. Joyce, and R. W. Emery, “Registry report. use of
total artificial hearts: summary of world experience, 1969-1991,” ASAIO journal
(American Society for Artificial Internal Organs : 1992), vol. 38, no. 3, pp. M486–
92, 1992. 16
[50] A. M. Feldman, ed., Heart Failure: Device Management, ch. Left Ventricular As-
sist Devices for Acute and Chronic Heart Failure, p. 141. West Sussex, UK: John
Wiley & Sons, Ltd., 2010. 17
[51] O. H. Frazier, T. J. Myers, I. D. Gregoric, T. Khan, R. Delgado, M. Croitoru,
K. Miller, R. Jarvik, and S. Westaby, “Initial clinical experience with the jarvik
2000 implantable axial-flow left ventricular assist system,” Circulation, vol. 105,
no. 24, pp. 2855–2860, 2002. 17
[52] J. W. Long, A. G. Kfoury, M. S. Slaughter, M. Silver, C. Milano, J. Rogers, R. Del-
gado, and O. Frazier, “Long-term destination therapy with the heartmate xve left
ventricular assist device: improved outcomes since the rematch study,” Congestive
Heart Failure, vol. 11, no. 3, pp. 133–138, 2005. x, 17, 18, 27
[53] D. Gagnon, M. Petty, and J. R. Lahpor, “HeartMate® family of left ventricular
assist systems,” Perfusion, vol. 15, no. 4, pp. 345–354, 2000. 17, 18, 27
[54] A. Pavie, N. Reiss, and S. Aubert, “Implantation technique of the novacor left ven-
tricular assist device,” Multimedia Manual of Cardio-Thoracic Surgery, vol. 2007,
no. 0219, 2007. 18, 27
[55] M. C. Deng, M. Loebe, A. El-Banayosy, E. Gronda, P. G. Jansen, M. Vigano, G. M.
Wieselthaler, B. Reichart, E. Vitali, A. Pavie, et al., “Mechanical circulatory sup-
port for advanced heart failure effect of patient selection on outcome,” Circulation,
vol. 103, no. 2, pp. 231–237, 2001. x, 18
[56] D. J. Farrar and J. D. Hill, “Univentricular and biventricular thoratec VAD support
181
BIBLIOGRAPHY
as a bridge to transplantation,” The Annals of Thoracic Surgery, vol. 55, no. 1,
pp. 276–282, 1993. x, 19, 27
[57] W. Konertz, H. Hotz, M. Schneider, M. Redlin, and H. Reul, “Clinical experience
with the MEDOSHIA-VAD System in Infants and Children: A Preliminary Re-
port,” The Annals of Thoracic Surgery, vol. 63, no. 4, pp. 1138 – 1143, 1997. x,
19, 20, 27
[58] J. G. Copeland, R. G. Smith, F. A. Arabia, P. E. Nolan, G. K. Sethi, P. H. Tsau,
D. McClellan, and M. J. Slepian, “Cardiac replacement with a total artificial heart
as a bridge to transplantation,” New England Journal of Medicine, vol. 351, no. 9,
pp. 859–867, 2004. xi, 20, 27
[59] B. P. Griffith, R. L. Kormos, H. S. Borovetz, K. Litwak, J. F. Antaki, V. L. Poirier,
and K. C. Butler, “HeartMate II left ventricular assist system: from concept to
first clinical use,” The Annals of Thoracic Surgery, vol. 71, no. 3, Supplement 1,
pp. S116 – S120, 2001. xi, 21, 28
[60] D. J. Goldstein, “Worldwide Experience With the MicroMed DeBakey Ventricular
Assist Device™ as a Bridge to Transplantation,” Circulation, vol. 108, no. 10 suppl
1, pp. II–272–II–277, 2003. 21, 28
[61] G. P. Noon and M. Loebe, “Current status of the micromed debakey noon ventric-
ular assist device,” Texas Heart Institute Journal, vol. 37, no. 6, p. 652, 2010. 21,
28
[62] M. E. DeBakey, “A miniature implantable axial flow ventricular assist device,” The
Annals of Thoracic Surgery, vol. 68, no. 2, pp. 637 – 640, 1999. xi, 22, 28
[63] O. H. Frazier, T. J. Myers, S. Westaby, and I. D. Gregoric, “Use of the jarvik 2000
left ventricular assist system as a bridge to heart transplantation or as destination
therapy for patients with chronic heart failure,” Annals of Surgery, vol. 237, no. 5,
pp. 631–636, 2003. xi, 22, 28
182
BIBLIOGRAPHY
[64] S. Westaby, M. Siegenthaler, F. Beyersdorf, M. Massetti, J. Pepper, A. Khayat,
R. Hetzer, and O. H. Frazier, “Destination therapy with a rotary blood pump and
novel power delivery,” European Journal of Cardio-Thoracic Surgery, vol. 37,
no. 2, pp. 350–356, 2010. 22, 28
[65] C. Schmid, T. D. Tjan, C. Etz, C. Schmidt, F. Wenzelburger, M. Wilhelm,
M. Rothenburger, G. Drees, and H. H. Scheld, “First clinical experience with the
incor left ventricular assist device,” The Journal of Heart and Lung Transplanta-
tion, vol. 24, no. 9, pp. 1188 – 1194, 2005. xi, 23, 28
[66] R. Hetzer, Y. Weng, E. V. Potapov, M. Pasic, T. Drews, M. Jurmann, E. Hennig,
and M. J, “First experiences with a novel magnetically suspended axial flow left
ventricular assist device,” European Journal of Cardio-thoracic Surgery, vol. 25,
no. 6, pp. 964–970, 2004. xi, 23
[67] M. Strueber, G. O’Driscoll, P. Jansz, A. Khaghani, W. C. Levy, and G. M.
Wieselthaler, “Multicenter evaluation of an intrapericardial left ventricular assist
system,” Journal of the American College of Cardiology, vol. 57, no. 12, pp. 1375
– 1382, 2011. 24, 29, 78
[68] HeartWare Inc., USA, HeartWare® Ventricular Assist System Instructions for Use,
November 2012. xi, 24, 29
[69] M. Morshuis, A. El-Banayosy, L. Arusoglu, R. Koerfer, R. Hetzer, G. Wieselthaler,
A. Pavie, and C. Nojiri, “European experience of duraheart™ magnetically levitated
centrifugal left ventricular assist system,” European Journal of Cardio-Thoracic
Surgery, vol. 35, no. 6, pp. 1020–1028, 2009. xi, 25, 29
[70] P. Ayre, S. Vidakovic, G. Tansley, P. Watterson, and N. Lovell, “Sensorless flow and
head estimation in the ventrassist rotary blood pump,” Artificial Organs, vol. 24,
no. 8, pp. 585 – 588, 2000. 25, 30
183
BIBLIOGRAPHY
[71] D. Esmore, P. Spratt, R. Larbalestier, S. Tsui, A. Fiane, P. Ruygrok, D. Meyers, and
J. Woodard, “VentrAssist™ left ventricular assist device: clinical trial results and
clinical development plan update,” European Journal of Cardio-Thoracic Surgery,
vol. 32, no. 5, pp. 735–744, 2007. xi, 25, 30
[72] D. Timms, “A review of clinical ventricular assist devices,” Medical Engineering
& Physics, vol. 33, no. 9, pp. 1041 – 1047, 2011. 25, 29
[73] K. Yamazaki, S. Kihara, T. Akimoto, O. Tagusari, A. Kawai, M. Umezu,
J. Tomioka, R. Kormos, B. Griffith, and H. Kurosawa, “EVAHEART™: An im-
plantable centrifugal blood pump for long-term circulatory support,” The Japanese
Journal of Thoracic and Cardiovascular Surgery, vol. 50, no. 11, pp. 461–465,
2002. 26, 29
[74] S. Agarwal and K. M. High, “Newer-generation ventricular assist devices,” Best
Practice & Research Clinical Anaesthesiology, vol. 26, no. 2, pp. 117 – 130, 2012.
Mechanical Circulatory Support. 26, 29, 78
[75] B. Meyns, S. Klotz, A. Simon, W. Droogne, F. Rega, B. Griffith, R. Dowling, M. J.
Zucker, and D. Burkhoff, “Proof of concept: Hemodynamic response to long-term
partial ventricular support with the synergy pocket micro-pump,” Journal of the
American College of Cardiology, vol. 54, no. 1, pp. 79 – 86, 2009. 26, 30
[76] HeartWare™ International, Inc., USA, CircuLite™ Overview, December 2013. xi,
26, 30
[77] D. L. Timms, S. D. Gregory, N. A. Greatrex, M. J. Pearcy, J. F. Fraser, and U. Stein-
seifer, “A compact mock circulation loop for the in vitro testing of cardiovascular
devices,” Artificial Organs, vol. 35, pp. 384–391, 2011. xi, 26, 107
[78] M. S. Slaughter, J. G. Rogers, C. A. Milano, S. D. Russell, J. V. Conte, D. Feldman,
B. Sun, A. J. Tatooles, R. M. Delgado, J. W. Long, T. C. Wozniak, W. Ghumman,
184
BIBLIOGRAPHY
D. J. Farrar, and O. H. Frazier, “Advanced heart failure treated with continuous-
flow left ventricular assist device,” New England Journal of Medicine, vol. 361,
no. 23, pp. 2241–2251, 2009. 27, 28
[79] J. Copeland, A. Pavie, D. Duveau, W. Keon, R. Masters, R. Pifarre, R. Smith, and
F. Arabia, “Bridge to transplantation with the CardioWest total artificial heart: the
international experience 1993 to 1995,” Journal of Heart and Lung Transplantion,
vol. 15, pp. 94 – 99, 1996. 27
[80] L. W. Miller, F. D. Pagani, S. D. Russell, R. John, A. J. Boyle, K. D. Aaronson,
J. V. Conte, Y. Naka, D. Mancini, R. M. Delgado, T. E. MacGillivray, D. J. Farrar,
and O. Frazier, “Use of a continuous-flow device in patients awaiting heart trans-
plantation,” New England Journal of Medicine, vol. 357, no. 9, pp. 885–896, 2007.
28
[81] K. A. Pennings, J. R. Martina, B. F. Rodermans, J. R. Lahpor, F. N. van de Vosse,
B. A. de Mol, and M. C. Rutten, “Pump Flow Estimation From Pressure Head and
Power Uptake for the HeartAssist5, HeartMate II, and HeartWare VADs,” ASAIO
Journal, vol. 59, pp. 420 – 426, 2013. 28
[82] O. Frazier, T. J. Myers, S. Westaby, and I. D. Gregoric, “Clinical experience with an
implantable, intracardiac, continuous flow circulatory support device: physiologic
implications and their relationship to patient selection,” The Annals of Thoracic
Surgery, vol. 77, no. 1, pp. 133 – 142, 2004. 28
[83] T. Yagdi, E. Oguz, F. Ayik, S. Ertugay, S. Nalbantgil, C. Engin, and M. Ozbaran,
“Ventricular assist system applications in end-stage heart failure,” Transplantation
Proceedings, vol. 43, no. 3, pp. 923 – 926, 2011. 28
[84] T. Akimoto, K. Yamazaki, P. Litwak, K. N. Litwak, O. Tagusari, T. Mori, J. F.
Antaki, M. V. Kameneva, M. J. Watach, M. Umezu, J. Tomioka, R. L. Kormos,
H. Koyanagi, and B. P. Griffith, “Continuously maintaining positive flow avoids
185
BIBLIOGRAPHY
endocardial suction of a rotary blood pump with left ventricular bypass,” Artificial
Organs, vol. 24, no. 8, pp. 606–610, 2000. 29, 78
[85] T. Akimoto, K. N. Litwak, K. Yamazaki, P. Litwak, S.-i. Kihara, O. Tagusari, S.-i.
Yamazaki, M. V. Kameneva, M. J. Watach, M. Umezu, J. Tomioka, R. L. Kormos,
H. Koyanagi, and B. P. Griffith, “The role of diastolic pump flow in centrifugal
blood pump hemodynamics,” Artificial Organs, vol. 25, no. 9, pp. 724 – 727, 2001.
29, 78
[86] R. M. Lazar, P. A. Shapiro, B. E. Jaski, M. K. Parides, R. C. Bourge, J. T. Watson,
L. Damme, W. Dembitsky, J. D. Hosenpud, L. Gupta, A. Tierney, T. Kraus, and
Y. Naka, “Neurological events during long-term mechanical circulatory support for
heart failure - the randomized evaluation of mechanical assistance for the treatment
of congestive heart failure (REMATCH) experience,” Circulation, vol. 109, no. 20,
2004. 31
[87] G. S. Murphy, E. A. Hessel, and R. C. Groom, “Optimal perfusion during car-
diopulmonary bypass: An evidence-based approach,” Anesthesia and Analgesia,
vol. 108, no. 5, pp. 1394–1417, 2009. 31
[88] H. Suga, K. Sagawa, and A. Shoukas, “Load independence of the instantaneous
pressure-volume ratio of the canine left ventricle and effects of epinephrine and
heart rate on the ratio,” Circulation Research, vol. 32, pp. 314–322, 1973. 33, 34,
110
[89] G. Pennati, M. Bellotti, and R. Fumero, “Mathematical modelling of the human
foetal cardiovascular system based on doppler ultrasound data,” Medical Engineer-
ing & Physics, vol. 19, no. 4, pp. 327 – 335, 1997.
[90] F. Y. Chen, D. B. Lautz, B. J. deGuzman, L. Aklog, R. M. Ahmad, R. G. Laurence,
G. S. Couper, L. H. Cohn, and T. A. McMahon, “An Engineering Model of Dy-
186
BIBLIOGRAPHY
namic Cardiomyoplasty. I.,” Annals of Biomedical Engineering, vol. 26, pp. 441–
453, 1998.
[91] X. Xiao, E. Ozawa, Y. Huang, and R. Kamm, “Model-based assessment of cardio-
vascular health from noninvasive measurements,” Annals of Biomedical Engineer-
ing, vol. 30, pp. 612–623, 2002. 33
[92] B. W. Smith, J. G. Chase, R. I. Nokes, G. M. Shaw, and G. Wake, “Minimal
haemodynamic system model including ventricular interaction and valve dynam-
ics,” Medical Engineering & Physics, vol. 26, no. 2, pp. 131 – 139, 2004. 33, 34,
35, 70
[93] R. Fogliardi, R. Burattini, S. G. Shroff, and K. B. Campbell, “Fit to diastolic ar-
terial pressure by third-order lumped model yields unreliable estimates of arterial
compliance,” Medical Engineering & Physics, vol. 18, no. 3, pp. 225 – 233, 1996.
33
[94] R. Pietrabissa, S. Mantero, T. Marotta, and L. Menicanti, “A lumped parameter
model to evaluate the fluid dynamics of different coronary bypasses,” Medical En-
gineering & Physics, vol. 18, no. 6, pp. 477 – 484, 1996.
[95] R. Cole, C. Lucas, W. Cascio, and T. Johnson, “A labview™ model incorporating
an open-loop arterial impedance and a closed-loop circulatory system,” Annals of
Biomedical Engineering, vol. 33, pp. 1555–1573, 2005.
[96] P. Segers, E. R. Rietzschel, M. L. De Buyzere, N. Stergiopulos, N. Westerhof, L. M.
Van Bortel, T. Gillebert, and P. R. Verdonck, “Three- and four-element windkessel
models: assessment of their fitting performance in a large cohort of healthy middle-
aged individuals,” Proceedings of the Institution of Mechanical Engineers Part H-
Journal of Engineering in Medicine, vol. 222, no. H4, pp. 417–428, 2008. 33
[97] G. Pennati and R. Fumero, “Scaling approach to study the changes through the
187
BIBLIOGRAPHY
gestation of human fetal cardiac and circulatory behaviors,” Annals of Biomedical
Engineering, vol. 28, pp. 442–452, 2000. 33
[98] K. Peterson, E. T. Ozawa, G. M. Pantalos, and M. K. Sharp, “Numerical simu-
lation of the influence of gravity and posture on cardiac performance,” Annals of
Biomedical Engineering, vol. 30, pp. 247–259, 2002.
[99] T. Korakianitis and Y. Shi, “A concentrated parameter model for the human cardio-
vascular system including heart valve dynamics and atrioventricular interaction,”
Medical Engineering & Physics, vol. 28, pp. 613–628, 2006.
[100] T. Korakianitis and Y. Shi, “Effects of atrial contraction, atrioventricular interac-
tion and heart valve dynamics on human cardiovascular system response,” Medical
Engineering & Physics, vol. 28, no. 8, pp. 762–779, 2006. 34, 35, 49, 66
[101] T. Korakianitis and Y. Shi, “Numerical simulation of cardiovascular dynamics
with healthy and diseased heart valves,” Journal of Biomechanics, vol. 39, no. 11,
pp. 1964–1982, 2006. 33, 35
[102] Y. Shi and T. Korakianitis, “Numerical simulation of cardiovascular dynamics with
left heart failure and in-series pulsatile ventricular assist device,” Artificial Organs,
vol. 30, no. 12, pp. 929–948, 2006. 33
[103] Y. Shi, T. Korakianitis, and C. Bowles, “Numerical simulation of cardiovascu-
lar dynamics with different types of VAD assistance,” Journal of Biomechanics,
vol. 40, no. 13, pp. 2919 – 2933, 2007.
[104] T. Korakianitis and Y. Shi, “Numerical comparison of hemodynamics with atrium
to aorta and ventricular apex to aorta VAD support,” ASAIO Journal, vol. 53, no. 5,
pp. 537–548, 2007.
[105] E. Lim, S. Dokos, S. L. Cloherty, R. F. Salamonsen, D. G. Mason, J. A. Reizes, and
N. H. Lovell, “Parameter-optimized model of cardiovascular-rotary blood pump
188
BIBLIOGRAPHY
interactions,” IEEE Transactions on Biomedical Engineering, vol. 57, pp. 254–
266, FEB 2010. 33
[106] M. S. Olufsen, C. S. Peskin, W. Y. Kim, E. M. Pedersen, A. Nadim, and J. Larsen,
“Numerical simulation and experimental validation of blood flow in arteries with
structured-tree outflow conditions,” Annals of Biomedical Engineering, vol. 28,
pp. 1281–1299, 2000. 33
[107] H. Kim, K. Jansen, and C. Taylor, “Incorporating autoregulatory mechanisms of
the cardiovascular system in three-dimensional finite element models of arterial
blood flow,” Annals of Biomedical Engineering, vol. 38, pp. 2314–2330, 2010. 45
[108] R. L. Spilker and C. A. Taylor, “Tuning multidomain hemodynamic simulations to
match physiological measurements,” Annals of Biomedical Engineering, vol. 38,
no. 8, pp. 2635–2648, 2010.
[109] P. Blanco, J. Leiva, R. Feijóo, and G. Buscaglia, “Black-box decomposition ap-
proach for computational hemodynamics: One-dimensional models,” Computer
Methods in Applied Mechanics and Engineering, vol. 200, no. 13-16, pp. 1389 –
1405, 2011.
[110] M. Willemet, V. Lacroix, and E. Marchandise, “Inlet boundary conditions for blood
flow simulations in truncated arterial networks,” Journal of Biomechanics, vol. 44,
no. 5, pp. 897 – 903, 2011. 33
[111] R. Mukkamala and D. Xu, “Continuous and less invasive central hemody-
namic monitoring by blood pressure waveform analysis,” American Journal of
Physiology-Heart and Circulatory Physiology, vol. 299, no. 3, pp. H584–H599,
2010. 33, 59, 112, 128, 130
[112] A. Tsanas, J. Y. Goulermas, V. Vartela, D. Tsiapras, G. Theodorakis, A. C. Fisher,
and P. Sfirakis, “The windkessel model revisited: A qualitative analysis of the cir-
189
BIBLIOGRAPHY
culatory system,” Medical Engineering & Physics, vol. 31, no. 5, pp. 581 – 588,
2009. 33, 35, 130
[113] M. D. Feldman, P. H. Pak, C. C. Wu, H. L. Haber, C. M. Heesch, J. D. Bergin, E. R.
Powers, T. D. Cowart, W. Johnson, A. M. Feldman, and D. A. Kass, “Acute car-
diovascular effects of OPC-18790 in patients with congestive heart failure : Time-
and dose-dependence analysis based on pressure-volume relations,” Circulation,
vol. 93, no. 3, pp. 474–483, 1996. 34
[114] G. J. Langewouters, K. H. Wesseling, and W. J. A. Goedrd, “The static elastic prop-
erties of 45 human thoracic and 20 abdominal aortas in vitro and the parameters of
a new model,” Journal of Biomechanics, vol. 17, no. 6, pp. 425 – 435, 1984. 34
[115] S. G. Shroff, J. S. Janicki, and K. T. Weber, “Evidence and quantitation of left
ventricular systolic resistance,” American Journal of Physiology —Heart and Cir-
culation Physiology, vol. 249, no. 2, pp. H358–370, 1985. 34
[116] T. E. Claessens, D. Georgakopoulos, M. Afanasyeva, S. J. Vermeersch, H. D. Mil-
lar, N. Stergiopulos, N. Westerhof, P. R. Verdonck, and P. Segers, “Nonlinear
isochrones in murine left ventricular pressure-volume loops: how well does the
time-varying elastance concept hold?,” American Journal of Physiology —Heart
and Circulation Physiology, vol. 290, no. 4, pp. H1474–1483, 2006. 34
[117] K. B. Campbell, A. M. Simpson, S. G. Campbell, H. L. Granzier, and B. K. Slinker,
“Dynamic left ventricular elastance: a model for integrating cardiac muscle con-
traction into ventricular pressure-volume relationships,” Journal of Applied Physi-
ology, vol. 104, no. 4, pp. 958–975, 2008. 34
[118] J.-W. Lankhaar, F. A. Rövekamp, P. Steendijk, B. E. Westerhof, T. Kind, A. Vonk-
Noordegraaf, and N. Westerhof, “Modeling the instantaneous pressure-volume re-
lation of the left ventricle: A comparison of six models,” Annals of Biomedical
Engineering, vol. 37, pp. 1710–1726, 2009. 34, 70
190
BIBLIOGRAPHY
[119] H. Senzaki, C.-H. Chen, and D. A. Kass, “Single-beat estimation of end-systolic
pressure-volume relation in humans: A new method with the potential for nonin-
vasive application,” Circulation, vol. 94, no. 10, pp. 2497–2506, 1996. 34
[120] S. Patrick, S. Paul, S. Nikos, and W. Nico, “Predicting systolic and diastolic aortic
blood pressure and stroke volume in the intact sheep,” Journal of Biomechanics,
vol. 34, no. 1, pp. 41 – 50, 2001.
[121] N. Westerhof, N. Stergiopulos, and M. Noble, Snapshots of Hemodynamics: An
Aid for Clinical Research and Graduate Education, vol. 18. Springer US, 2005. 34
[122] T. Cochrane, “Simple model of circulatory system dynamics including heart valve
mechanics,” Journal of Biomedical Engineering, vol. 13, no. 4, pp. 335 – 340,
1991. 35
[123] T. Cochrane, C. J. Kenyon, P. V. Lawford, M. M. Black, J. B. Chambers, and D. C.
Sprigings, “Validation of the orifice formula for estimating effective heart-valve
opening area,” Clinical Physics and Physiological Measurement, vol. 12, no. 1,
pp. 21–37, 1991. 35
[124] D. Garcia, P. J. C. Barenbrug, P. Pibarot, A. L. A. J. Dekker, F. H. van der Veen,
J. G. Maessen, J. G. Dumesnil, and L. G. Durand, “A ventricular-vascular coupling
model in presence of aortic stenosis,” American Journal of Physiology - Heart and
Circulation Physiology, vol. 288, no. 4, pp. H1874–1884, 2005. 35
[125] J. Palladino and A. Noordergraaf, “Defining muscle elastance as a parameter,” in
Engineering in Medicine and Biology Society, 2007. EMBS 2007. 29th Annual In-
ternational Conference of the IEEE, pp. 5315 –5318, 22-26 2007. 35
[126] P. Segers, N. Stergiopulos, P. Verdonck, and N. Westerhof, “Mathematical model
analysis of heart-arterial interaction in hypertension,” Proceedings of the 23rd An-
nual International Conference of the IEEE Engineering in Medicine and Biology
Society, Vols 1-4, vol. 23, pp. 192–195, 2001. 35
191
BIBLIOGRAPHY
[127] F. Bauer, M. Jones, T. Shiota, M. Firstenberg, X. Jian, H. Tsujino, J. Yong, M. Sit-
ges, L. Cardon, A. Zetts, and J. Thomas, “Left ventricular outflow tract mean sys-
tolic acceleration as a surrogatefor the slope of the left ventricular end-systolic
pressure-volume relationship,” Journal of the American College of Cardiology,
vol. 40, no. 7, pp. 1320 – 1327, 2002. 35, 49
[128] J. Werner, D. Böhringer, and M. Hexamer, “Simulation and Prediction of Car-
diotherapeutical Phenomena from a Pulsatile Model Coupled to the Guyton Cir-
culation Model,” IEEE Transaction on Biomedical Engineering, vol. 49, no. 5,
pp. 430–439, 2002. 35
[129] E. Lanzarone, P. Liani, G. Baselli, and M. Costantino, “Model of arterial tree and
peripheral control for the study of physiological and assisted circulation,” Medical
Engineering & Physics, vol. 29, no. 5, pp. 542 – 555, 2007. 35
[130] E. Lim, S. Dokos, S. L. Cloherty, R. F. Salamonsen, D. G. Mason, J. A. Reizes, and
N. H. Lovell, “Parameter-optimized model of cardiovascular-rotary blood pump in-
teractions,” IEEE Transactions on Biomedical Engineering, vol. 57, no. 2, pp. 254–
266, 2010.
[131] E. Lim, A.-H. H. Alomari, A. V. Savkin, S. Dokos, J. F. Fraser, D. L. Timms,
D. G. Mason, and N. H. Lovell, “A method for control of an implantable rotary
blood pump for heart failure patients using noninvasive measurements,” Artificial
Organs, vol. 35, no. 8, 2011. 35
[132] T. Korakianitis and Y. Shi, “A concentrated parameter model for the human cardio-
vascular system including heart valve dynamics and atrioventricular interaction,”
Medical Engineering & Physics, vol. 28, pp. 613–628, July 2006. 36, 37, 39
[133] T. Korakianitis and Y. Shi, “Effects of atrial contraction, atrioventricular interac-
tion, and heart valve dynamics on human cardiovascular system response,” Medical
Engineering & Physics, vol. 28, pp. 762–779, August 2006.
192
BIBLIOGRAPHY
[134] T. Korakianitis and Y. Shi, “Numerical simulation of cardiovascular dynamics with
healthy and diseased heart valves,” Journal of Biomechanics, vol. 39, pp. 1964–
1982, August 2006.
[135] Y. Shi and T. Korakianitis, “Numerical simulation of cardiovascular dynamics with
left heart failure and in-series pulsatile ventricular assist device,” Artificial Organs,
vol. 30, pp. 929–948, December 2006.
[136] T. Korakianitis and Y. Shi, “Numerical comparison of hemodynamics with atrium
to aorta and ventricular apex to aorta VAD support,” ASAIO Journal, vol. 53,
pp. 537–548, September/October 2007.
[137] Y. Shi, T. Korakianitis, and C. Bowles, “Numerical simulation of cardiovascu-
lar dynamics with different types of VAD assistance,” Journal of Biomechanics,
vol. 40, pp. 2919–2933, October 2007. 36, 37, 39
[138] J. She, M. Li, L. Huan, and Y. Yu, “Dynamic characteristics of prosthetic heart
valves,” Medical Engineering & Physics, vol. 17, no. 4, pp. 273 – 281, 1995. 38,
39, 126
[139] F. Luca, A. Quarteroni, and A. Veneziani, Cardiovascular Mathematics: Modeling
and simulation of the circulatory system. Springer, 2009. 39
[140] E. Sandblom and M. Axelsson, “The venous circulation: A piscine perspective,”
Comparative Biochemistry and Physiology a-Molecular & Integrative Physiology,
vol. 148, no. 4, pp. 785–801, 2007. xii, 43
[141] T. Heldt, E. Shim, R. Kamm, and R. Mark, “Computational modeling of cardio-
vascular response to orthostatic stress,” Journal of Applied Physiology, vol. 92,
pp. 1239–1254, 2002. xii, 43, 45, 46, 49
[142] E. B. Shim, H. M. Jun, C. H. Leem, S. Matusuoka, and A. Noma, “A new
integrated method for analyzing heart mechanics using a cell-hemodynamics-
193
BIBLIOGRAPHY
autonomic nerve control coupled model of the cardiovascular system,” Progress
in Biophysics & Molecular Biology, vol. 96, no. 1-3, pp. 44–59, 2008. xii, 43, 45
[143] T. Heldt, Computational Models of Cardiovascular Response to Orthostatic Stress.
PhD thesis, Massachusetts Institute of Technology, 2004. 43, 60, 70
[144] A. C. Guyton, “Determination of cardiac output by equating venous return curves
with cardiac response curves,” Physiological reviews, vol. 35, no. 1, pp. 123–9,
1955. xii, 44
[145] M. J. Davis and M. A. Hill, “Signaling mechanisms underlying the vascular myo-
genic response,” Physiological Reviews, vol. 79, no. 2, pp. 387–423, 1999. 45
[146] D. M. Bers, “Cardiac excitation-contraction coupling,” Nature, vol. 415, no. 6868,
pp. 198–205, 2002. 45
[147] K. Lu, J. Clark, Jr, F. GhorBel, D. Ware, and A. Bidani, “A human cardiopulmonary
system model applied to the analysis of the valsalva maneuver,” American Journal
of Physiology —Heart and Circulation Physiology, vol. 281, pp. H2661–H2679,
2001. 45, 49
[148] P. Ataee, G. A. Dumont, W. T. Boyce, and IEEE, “Baroreflex modeling in the
genesis of stress reactivity using sigmoidal characteristic,” in American Control
Conference, pp. 3566–3571, 2010. 45
[149] A. C. Guyton, H. J. Granger, and T. G. Coleman, “Circulation —overall regula-
tion,” Annual Review of Physiology, vol. 34, pp. 13–44, 1972. 45
[150] T. E. Jackson, A. C. Guyton, and J. E. Hall, “Transient response of glomerular-
filtration rate and renal blood flow to step changes in arterial pressure,” American
Journal of Physiology, vol. 233, no. 5, pp. F396–F402, 1977.
[151] J. P. Gilmore, K. G. Cornish, S. D. Rogers, and W. L. Joyner, “Direct evidence for
194
BIBLIOGRAPHY
myogenic auto-regulation of the renal micro-circulation in the hamster,” Circula-
tion Research, vol. 47, no. 2, pp. 226–230, 1980.
[152] M. Shahin and S. Maka, “A transfer function method for the assessment of nervous
system modulation of long term dynamics of blood pressure,” in Communication
Control and Computing Technologies (ICCCT), 2010 IEEE International Confer-
ence on, pp. 560 –564, oct. 2010. 45
[153] R. Bailon, G. Laouini, C. Grao, M. Orini, P. Laguna, and O. Meste, “The integral
pulse frequency modulation model with time-varying threshold: Application to
heart rate variability analysis during exercise stress testing,” IEEE Transactions on
Biomedical Engineering, vol. 58, no. 3, pp. 642–652, 2011. 47
[154] M. Takeuchi, Y. Igarashi, S. Tomimoto, M. Odake, T. Hayashi, T. Tsukamoto,
K. Hata, H. Takaoka, and H. Fukuzaki, “Single-beat estimation of the slope of
the end-systolic pressure volume relation in the human left-ventricle,” Circulation,
vol. 83, no. 1, pp. 202–212, 1991. 49
[155] S. Nakatani, M. Garcia, M. Firstenberg, L. Rodriguez, R. Grimm, N. Greenberg,
P. McCarthy, P. Vandervoort, and J. Thomas, “Noninvasive assessment of left atrial
maximum dP/dt by a combination of transmitral and pulmonary venous flow,”
Journal of the American College of Cardiology, vol. 34, no. 3, pp. 795 – 801,
1999.
[156] J. Thomas, J. Zhou, N. Greenberg, G. Bibawy, P. McCarthy, and P. VanDervoort,
“Physical and physiological determinants of pulmonary venous flow: Numerical
analysis,” American Journal of Physiology —Heart and Circulation Physiology,
vol. 272, no. 41, pp. H2453–H2465, 1997.
[157] D. R. Hose, A. J. Narracott, J. M. T. Penrose, D. Baguley, I. P. Jones, and P. V. Law-
ford, “Fundamental mechanics of aortic heart valve closure,” Journal of Biome-
chanics, vol. 39, no. 5, pp. 958–967, 2006. 52
195
BIBLIOGRAPHY
[158] F. Liang, S. Takagi, R. Himeno, and H. Liu, “Biomechanical characterization of
ventricular-arterial coupling during aging: A multi-scale model study,” Journal of
Biomechanics, vol. 42, no. 6, pp. 692 – 704, 2009. 49, 82
[159] A. Rahideh, T. Korakianitis, P. Ruiz, T. Keeble, and M. T. Rothman, “Optimal
brushless DC motor design using genetic algorithms,” Journal of Magnetism and
Magnetic Materials, vol. 322, pp. 3680–3687, Nov 2010. xiii, 51, 52, 53
[160] D. A. Coley, An Introduction to Genetic Algorithms for Scientists and Engineers.
Covent Garden, London: World Scientific, 2003. 52, 53
[161] P. Segers, P. Verdonck, Y. Deryck, S. Brimioulle, R. Naeije, S. Carlier, and N. Ster-
giopulos, “Pulse pressure method and the area method for the estimation of total
arterial compliance in dogs: Sensitivity to wave reflection intensity,” Annals of
Biomedical Engineering, vol. 27, pp. 480–485, 1999. 52
[162] C. Quick, D. Berger, D. Hettrick, and A. Noordergraaf, “True arterial system com-
pliance estimated from apparent arterial compliance,” Annals of Biomedical Engi-
neering, vol. 28, pp. 291–301, 2000.
[163] E. Kung, A. Les, C. Figueroa, F. Medina, K. Arcaute, R. Wicker, M. McConnell,
and C. Taylor, “In vitro validation of finite element analysis of blood flow in de-
formable models,” Annals of Biomedical Engineering, vol. 39, pp. 1947–1960,
2011. 52
[164] M. Westwood, L. Anderson, D. Firmin, P. Gatehouse, C. Charrier, B. Wonke, and
D. Pennell, “A single breath-hold multiecho T2* cardiovascular magnetic reso-
nance technique for diagnosis of myocardial iron overload,” Journal of Magnetic
Resonance Imaging, vol. 18, no. 1, pp. 33–39, 2003. 52
[165] G. F. Uler, O. A. Mohammed, and C. S. Koh, “Utilizing genetic algorithms for
the optimal-design of electromagnetic devices,” IEEE Transactions on Magnetics,
vol. 30, no. 6, pp. 4296–4298, 1994. 53
196
BIBLIOGRAPHY
[166] M. Longmore, I. Wilkinson, and E. Török, Oxford Handbook of Clinical Medicine,
fifth edition. Oxford University Press, 2001. 70
[167] G. Schillaci, L. Pasqualini, P. Verdecchia, G. Vaudo, S. Marchesi, C. Porcellati,
G. de Simone, and E. Mannarino, “Prognostic significance of left ventricular di-
astolic dysfunction in essential hypertension,” Journal of the American College of
Cardiology, vol. 39, no. 12, pp. 2005 – 2011, 2002. 70, 114
[168] S. J. Denardo, R. Nandyala, G. L. Freeman, G. L. Pierce, and W. W. Nichols, “Pulse
wave analysis of the aortic pressure waveform in severe left ventricular systolic
dysfunction,” Circulation-Heart Failure, vol. 3, no. 1, pp. 149–156, 2010. xiv, 71,
72, 73, 125, 126
[169] K. Berenji, M. H. Drazner, B. A. Rothermel, and J. A. Hill, “Does load-induced
ventricular hypertrophy progress to systolic heart failure?,” American Journal of
Physiology —Heart and Circulatory Physiology, vol. 289, no. 1, pp. H8–H16,
2005. 71
[170] N. Moorjani, S. Westaby, J. Narula, P. A. Catarino, R. Brittin, T. J. Kemp,
N. Narula, and P. H. Sugden, “Effects of left ventricular volume overload on mito-
chondrial and death-receptor mediated apoptotic pathways in the transition to heart
failure,” The American Journal of Cardiology, vol. 103, no. 9, pp. 1261 – 1268,
2009. 71
[171] S. R. Houser, V. P. III, and J. Weisser, “Abnormalities of calcium cycling in the
hypertrophied and failing heart,” Journal of Molecular and Cellular Cardiology,
vol. 32, no. 9, pp. 1595 – 1607, 2000. 71
[172] P. Ruiz, M. A. Rezaienia, A. Rahideh, T. R. Keeble, M. T. Rothman, and T. Ko-
rakianitis, “In vitro cardiovascular system emulator (bioreactor) for the simulation
of normal and diseased conditions with and without mechanical circulatory sup-
port,” Artificial Organs, vol. 37, no. 6, pp. 549–560, 2013. 71
197
BIBLIOGRAPHY
[173] L. Leverett, J. Hellums, C. Alfrey, and E. Lynch, “Red blood cell damage by shear
stress,” Biophysical Journal, vol. 12, no. 3, pp. 257 – 273, 1972. 79, 105
[174] A. J. Stepanoff, Centrifugal and Axial Flow Pumps: Theory, Design, and Applica-
tion. New York: John Wiley & Sons, Inc., second edition ed., 1962. xiv, 80, 81,
90
[175] A. Kovaáts, Design and Performance of Centrifugal and Axial Flow Pumps and
Compressors. Pergamon Press, 1964. 80, 81
[176] J. Tuzson, Centrifugal Pump Design. Wiley-Interscience, 2000. xiv, 80, 84, 85, 96
[177] K. Srinivasan, Rotodynamic Pumps (Centrifugal and Axial). New Delhi: New Age
International Publishers, 2008. 81, 86, 87, 88
[178] A. R. Curtas, H. G. Wood, P. E. Allaire, J. C. McDaniel, S. W. Day, and D. B. Olsen,
“Computational fluid dynamics modeling of impeller designs for the HeartQuest
left ventricular assist device,” ASAIO Journal, vol. 48, no. 5, pp. 552–561, 2002.
84
[179] W.-G. Li, “Effects of viscosity of fluids on centrifugal pump performance and flow
pattern in the impeller,” International Journal of Heat and Fluid Flow, vol. 21,
no. 2, pp. 207 – 212, 2000. 84
[180] D. Timms, Design, development and evaluation of centrifugal ventricular assist
devices. PhD thesis, Queensland University of Technology, Brisbane, Queensland,
Australia, 2005. 84
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